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Psoriasis is a chronic inflammatory skin disorder that affects around two percent 
of the population.  There are many treatments available for the management of 
psoriasis including topical therapy, systemic agents and phototherapy.  Despite 
the number of treatments available, however, there are still problems in the 
management of psoriasis. 
It is suggested here that the thioredoxin enzyme system may play a role in the 
pathology of psoriasis.  Using specific molecular modelling techniques, a lead 
compound, RDP00060, was identified as a potential inhibitor of thioredoxin 
reductase, a key enzyme in the thioredoxin system.  In vitro RDP00060 showed 
moderate inhibitory activity against the thioredoxin enzyme system with an IC50 
value of 1.4 mM.  RDP00060 also showed powerful activity in an MTT assay 
using a human papilloma virus immortalized keratinocyte (HPV-16) cell line. 
To increase the inhibitory activity towards thioredoxin reductase, molecular 
modelling techniques were used to identify analogues of RDP00060 with a high 
binding affinity for thioredoxin reductase.  Several novel compounds were then 
synthesized, characterized and evaluated for inhibitory activity towards the 
thioredoxin system.  One of the compounds, N-(3,4-bis-(toluene-4-
sulfonylamino)phenyl)-2-furamide (33f) showed good inhibitory activity against 
the thioredoxin enzyme with an IC50 value of 37 μM.  It is anticipated that N-(3,4-
bis-(toluene-4-sulfonylamino)phenyl)-2-furamide (33f) binds to thioredoxin 
reductase irreversibly through a 1,4-conjugate addition mechanism. This 
compound also showed powerful activity in the MTT assay using an HPV-16 
immortalized keratinocyte cell line.   
Further testing revealed that N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-
furamide (33f) also showed apoptotic and antiproliferative properties in human T-
cells.  As a result of this work, N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-
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1. Introduction 
1.1. History 
The word psora comes from the Greeks, who helped pioneer the development of 
ancient medicine.  Psora literally means ‘to itch’ and the term psoriasis is derived 
from it. 
Psoriasis, a term that has been around since circa 133 A.D., was used 
synonymously with the term ‘lepra’ until 1863, when Wilson encouraged the 
dermatological community to replace the term lepra with psoriasis [1863MIS7].  
A paper published by Thin in 1881 describes psoriasis as ‘a disease of the skin, 
in which white masses of epidemic scales are attached, more or less firmly to a 
reddish vascular base.  When the scales are removed by the finger nails, small 
drops of blood ooze from the vascular surface’.  The condition described by Thin 
is clearly the disease recognised today as psoriasis vulgaris, or plaque psoriasis, 
the most common form of psoriasis.  The author also recognised that 
inflammation of the epithelium is a key characteristic of psoriasis [1881BMJ146]. 
Indeed, there was a great deal of confusion regarding this condition in the Middle 
Ages.  It has been suggested that biblical leprosy was, in fact, the disorder 
known today as psoriasis [1986JAAD863]. 
 
1.2. Epidemiology 
There have been only a few population based studies used to estimate the 
prevalence of psoriasis.  These studies generally estimate that psoriasis affects 
around two percent of the population, with ethnic factors playing a role in the 
prevalence [2005NEJM1899].  For example, in the United States, the percentage 
of blacks suffering from psoriasis is between 0.45 and 0.7 percent, whereas the 
percentage of the rest of the population with psoriasis is a lot higher at around 
1.4 percent [2001MI314].  Gender does not seem to affect the prevalence of 
psoriasis with similar rates reported in men and woman [2003L1197]. 
The prevalence is also increased in certain disease states.   Patients affected by 
Crohn’s disease, another chronic inflammatory disorder, are more than three 
times as likely to suffer from psoriasis [2005JAAD94].
     - 3 -
1.3. Pathogenesis 
1.3.1.  The concept of a T-cell mediated disease 
The pathogenesis of psoriasis is extremely complex and for many years it was 
considered to be mainly an epidermal disease.  However, recent evidence 
supports the idea that psoriasis is a T-cell mediated disease [2000MI275].  This 
was first suggested when ciclosporin, a drug used to suppress T-cell activity, was 
active against psoriasis.  Indeed, ciclosporin is very effective in treating psoriasis; 
its efficacy was first demonstrated in patients who were taking it as an 
immunosuppressant to prevent transplant rejection [1979NEJM555].
 
Another interesting observation which supports this idea is that bone marrow 
transplantation can lead to the ‘transfer’ of psoriasis [1990BMJ908].
  For example, 
a bone marrow donor with psoriasis can transfer the condition to a patient who 
has never suffered from it before.  Similarly, an improvement in the condition is 
observed when a psoriatic patient receives bone marrow from a non-psoriatic 
patient.  Other evidence supporting this concept is that Denileukin diftitox, a 
compound which is toxic to T-cells, can improve or alleviate the plaques 
associated with psoriasis [1998JAAD938]. 
 
1.3.2. Immunopathogenesis 
The pathogenesis of psoriasis can be described in terms of two major events: T-
cell activation and release of cytokines.  
The first event, T-cell activation (Figure 1), is initiated by antigen-presenting-cells 
(also known as Langerhans cells) taking up unidentified antigens in the epidermis.  
It has been suggested that keratinocyte proteins, such as keratin-17 can act as 
auto-antigens in psoriasis [2005NEJM1899].  After this series of events, the 
antigens are processed, causing migration of the antigen-presenting-cells (APC) 
to the lymph nodes.  Here, the APCs interact with naive (resting) T-cells through 
an ‘immunological synapse’ which results in T-cell activation.  The major 
interaction within the synapse is between the processed antigen, bound to the 
major-histocompatability complex, and the T-cell receptor.  Other interactions are 
required for T-cell activation and include coupling between intracellular adhesion   - 4 -
molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1), 
CD58 and CD28 with either CD80 or CD86.  These interactions are known as co-
stimulatory signals and T-cell activation will not occur without them.   
Once the T-cells have been activated, they proliferate and differentiate into 
memory cells, which then migrate to the site of cutaneous inflammation.  A key 
step in this process is the T-cell expression of lymphocyte associated antigen, 
which promotes the attachment of T-cells to the dermal endothelium.  This 
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Figure 1.  T-cell activation in psoriasis.  This diagram also illustrates the ‘immunological synapse’ 
and the specific interactions between the T-cell and the antigen presenting cell [2005NEJM1899]. 
Reproduced with permission from the author, Dr. M. Schön; 2008.   - 6 -
1.3.3.  The Cytokine Pool 
Once in the dermis, the T-cells encounter the unidentified antigen and release 
pro-inflammatory cytokines (Figure 2).  These cytokines are predominately type 1 
(Th1) and include tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), interferon-
γ (IFN-γ), and transforming growth factor-α (TGF-α).  It is the release of these 
pro-inflammatory cytokines that accounts for many of the histopathological 
features of psoriasis.   
Each cytokine has a pivotal role to play in psoriasis; TNF-α, an important primary 
cytokine, has many effects on the dermal vasculature.  TNF-α increases 
keratinocyte proliferation, promotes angiogenesis and stimulates the expression 
of ICAM-1 [2005JAAD94].
  TNF-α also promotes the production of other pro-
inflammatory cytokines from T-cells and macrophages using a positive feedback 
mechanism. 
TGF-α, another primary cytokine targets keratinocytes, causing them to produce 
vascular endothelial growth factor (VEGF), which indirectly causes dilation of 
blood vessels and stimulates angiogenesis.  TGF-α also promotes keratinocyte 
proliferation [2005JAAD94].  
IFN-γ stimulates the expression of ICAM-1 in vascular cells, which facilitates the 
trafficking of T-cells to sites of inflammation.  IFN-γ can also induce the 
expression of monokine induced by interferon-γ (MIG) [2005JAAD94].
  MIG is 
directly expressed by endothelial cells and macrophages; it acts as a T-cell 
chemoattractant. 
Other cytokines and chemokines associated within this network include RANTES 
(regulated on activation, normal T-cell expressed and secreted) and monocyte 
chemotactic protein-1 (MCP-1), both of which attract mast cells to the inflamed 
psoriatic area.   
Cutaneous T-cell attracting chemokine (CTACK), macrophage inflammatory 
protein-3α (MIP-3α), thymus and activation-regulated chemokine (TARC), and 
macrophage-derived chemokine (MDC) are all implicated in attracting T-cells to 
the psoriatic area.       - 7 -
Interleukin-8 (IL-8) and growth related cytokine-α (GRO-α) act as neutrophil 
chemo-attractants.  These chemokines may also have an effect on the 
proliferation of keratinocytes. 
These Th1 cytokines predominantly target the keratinocytes within the dermis, 
causing an increase in cellular proliferation, with production up to 28 times 
greater in psoriasis [1985MI579].
  The transit time of keratinocytes also 
decreases in psoriasis.  In a non-psoriatic patient, it takes around 13 days for the 
keratinocytes to move from the basal layer to the granular layer.  In psoriasis, this 
process is significantly reduced, taking around 2 days [2005CD491]. 
It has been suggested that oxidative stress induced by reactive oxygen species 
(ROS) may have a role in the pathology of psoriasis.  Oxidative stress results 
from an imbalance between the production and regulation of ROS.  As discussed 
previously, the pathogenesis of psoriasis can be described in terms of two major 
events: T cell activation and the release of cytokines.  The latter event, 
sometimes known as ‘the cytokine pool’ is of interest in this case.  Generally, 
ROS are produced in small amounts by epidermal keratinocytes through aerobic 
respiration.  In the case of psoriasis and the cytokine pool, ROS can be induced 
by cytokines, for example, by TNF-α and IL-1.  The link between cytokines and 
ROS is illustrated by the transcription factor, NFκB.  NFκB is a transcription factor 
involved in amplifying inflammation.  The activity of NFκB is tightly regulated by 
predominantly existing as the inactive pre-cursor protein, IκB.  NFκB regulation is 
very sensitive to the cellular redox state.  Oxidative stress, caused by increased 
levels of ROS, can activate NFκB from its inactive form, IκB.  This allows the 
complex to translocate to the nucleus, where it activates many inflammatory 
genes (e.g. the gene for TNF-α).  Furthermore, some of the cytokine genes 
upregulated by NFκB, are themselves activators of NFκB.  This results in the 
generation of a positive feedback cytokine loop [2008BBA1368].  This illustrates 
why the regulation and control of ROS is essential to maintain redox homeostasis.  
This is achieved through a series of complex enzyme and antioxidant systems.  
These systems will be discussed in detail in the next section.  
   - 8 -
  
 
Figure 2.  The complex cytokine network implicated in the pathogenesis of psoriasis 
[2005NEJM1899].  Reproduced with permission from the author, Dr. M. Schön; 2008. 
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1.4. Clinical  Features of Psoriasis 
Plaque psoriasis is the most common form of psoriasis.  It is estimated that 
around 80 percent of cases of psoriasis are plaque psoriasis.  The classical 
features of this disorder are chronic erythematous plaques covered with silvery 
scales (Figures 3A and 3B).  
Sites most commonly affected are the scalp, elbows, lumbar region of the back 
and the knees.  All of these sites have a high epidermal turnover. 
Inverse psoriasis has also been described.  Here, the plaques present on the 
intertiginous areas, such as, under the breasts, the groin, and behind the knees 
(Figure 3C). 
Other forms of psoriasis are less common and include guttate psoriasis, pustular 
psoriasis and erythrodermic psoriasis. 
Around 10 percent of cases of psoriasis are guttate psoriasis.  Guttate is derived 
from the term gutta, meaning a drop [B1996MI].
  This type of psoriasis presents 
as though the patient has been splashed by small erythematous papules, hence 
the name of the condition (Figure 3D). 
Pustular psoriasis is a rare form of psoriasis.  It is characterised by reddening of 
the skin and formation of pustules.  The major cause of this condition is the 
abrupt withdrawal of systemic corticosteroids.  In severe cases the pustules can 
be widespread affecting the trunk and extremities.  In minor cases, however, only 
the palms and soles are affected.  In this case, the condition is still quite 
distressing, as the patient often has problems using their hands and feet.    
Erythrodermic psoriasis, although rare, is a serious condition.  It is characterised 
by widespread erythema and scaling of the skin (Figure 3E).  The condition can 
compromise the normal functions of the skin, with bacteraemia common.  Other 
complications include hyperthermia, hypothermia, loss of water precipitating 
renal failure, sepsis and death [1996JAAD911].   - 10 -
 
Figure 3.  The different types of psoriasis. A and B: Plaque psoriasis., C: Inverse psoriasis., D: 
Guttate psoriasis., E: Erythrodermic psoriasis; 
www.dermnet.com/moduleIndex.cfm?moduleID=15 ;
 accessed September 2006. 
A  B
C
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The most debilitating part of psoriasis is its appearance.  The impact psoriasis 
can have on peoples lives should not be dismissed, and part of the clinician’s 
role in treating psoriasis is to reassure the patient.  Indeed, psoriasis is said to 
have as great an impact on patients’ lives as more serious disorders, such as 
diabetes, rheumatoid arthritis and cancer [1999JAAD401].
   
Once a diagnosis has been made, it is important to identify a treatment regimen 
and also establish the patient’s goals and expectations from their treatment.   
When choosing a regimen, it is often a fine balance between efficacy and 





Dithranol (1)  
 
Dithranol (1) has been used to treat psoriasis for many years.  It is particularly 
effective if the psoriatic plaques are stable, well defined and few in number.  It is 
believed to up-regulate the IL-10 receptor on keratinocytes, which may account 
for its therapeutic action.  A major disadvantage of dithranol (1) is that it is very 
irritating to the skin.  There have been a number of reported cases where 
dithranol  (1) has caused severe skin burns.  As a result of this, it is 
recommended that maximum contact time with the skin should be one hour.   
After this time, the treatment should be carefully washed off. 
Dithranol (1) stains skin and clothing, and consequently this treatment is often 
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1.5.2. Vitamin  D  Analogues 
The name vitamin D is given to a group of compounds which can be used to 
prevent or treat rickets.  They include ergocalciferol (2a) (calciferol; vitamin D2), 








Calcitriol (2c)  
 
Vitamin D affects keratinocyte proliferation and differentiation by binding to a 
vitamin D receptor.  It also tips the balance of cytokine production from Th1 to 
Th2 by increasing IL-10 expression and decreasing IL-8 expression which may 
contribute to the efficacy of vitamin D in psoriasis.  The main limitation of using 
vitamin D is the possibility of developing hypercalcaemia due to the effects it has 
on calcium metabolism.  
In an attempt to solve this problem, the vitamin D analogues, calcipitriol (2d) and 
tacalcitol  (2e), were developed.  These analogues still bind to the vitamin D 
receptor, but have a less marked effect upon calcium metabolism.  Vitamin D 
analogues are effective, cosmetically acceptable and are generally well tolerated. 





Tacalcitol (2e)  
 
1.5.3. Corticosteroids 
Corticosteroids have powerful anti-inflammatory and immunosuppressive activity.  
For this reason, they are often used in the management of many disease states, 
including psoriasis.   
Corticosteroids act by binding to, and activating an intracellular receptor.  Once 
activated, the corticosteroid – receptor complex dimerises and interacts with DNA, 
which then modifies gene transcription.  This, in turn, induces the synthesis of 
some proteins and inhibits the synthesis of others.     
Corticosteroids are often combined with other topical treatments, such as the 
vitamin D analogues.  This type of combined preparation has been used 
successfully in the management of stable chronic plaque psoriasis.   
Corticosteroids used alone are not regarded as suitable treatments for 
widespread chronic plaque psoriasis.  One risk of using corticosteroids in 
psoriasis is that the condition may 
deteriorate into a more serious form of psoriasis, such as generalised pustular 
psoriasis or erythrodermic psoriasis.  This phenomenon generally occurs when 
systemic corticosteroids are withdrawn abruptly and, for this reason, 
corticosteroids should always be used with caution in psoriasis. 














Betamethasone (3b)  
 
Generally, a mild topical corticosteroid, such as hydrocortisone (3a), can be used 
on the face and flexural areas, while a potent corticosteroid, such as 
betamethasone (3b), can be used on the hands, feet and scalp. 
Side effects are more common from the potent corticosteroids and include 
thinning of the skin, spread and worsening of an untreated infection, irreversible 
striae atrophicae and telangiectasia.  Indeed, systemic absorption of potent 
corticosteroids is possible, and there have been incidences where the absorption 




Tar has been known to be effective in treating psoriasis for over 50 years.  Tar 
has anti-inflammatory and anti-scaling properties, which make it a useful 
preparation for chronic plaque psoriasis. 
A follow up of patients who used tar preparations between 1917 and 1937 
concluded that tar does not increase the risk of skin cancer [B1996MI].  However, 
tar can cause skin irritation, contact allergic dermatitis and sterile folliculitis. 
Crude coal tar is the most effective preparation, but few patients can tolerate its 
pungent smell and the mess it makes.  Usually crude coal tar is used in a 
hospital setting while cleaner extracts, used in proprietary preparations, are used 
at home.  Proprietary preparations are not as effective as crude coal tar, but they 
are cosmetically more acceptable.   
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1.5.5. Retinoids 
Retinoids are a group of compounds that are chemically related to vitamin A.  
They all have marked effects on epidermal differentiation and act by binding to 
two types of receptor, the retinoic acid receptor (RAR) and the retinoid X receptor 
(RXR).  The main disadvantage of using retinoids systemically is that they are 
highly teratogenic and often cause a high proportion of serious abnormalities 









Tazarotene (4a)  
 
Tazarotene (4a) is a member of the acetylenic retinoids.  It has been shown to be 
effective in treating psoriasis and also appears to lack the toxicity problems 
associated with oral retinoid therapy.  Furthermore, topical tazarotene is clean 
and odourless, which makes it a useful alternative to dithranol (1) and coal tar. 
Tazarotene  (4a), like all retinoids, modulate keratinocyte proliferation and 
differentiation, which may account for the antipsoriatic action. 
A major drawback of tazarotene (4a) is that it commonly causes skin irritation 
[1998JAAD705].
  This is minimised in practice by applying tazarotene (4a) 
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Acitretin (4b) is a retinoid that is used systemically for the treatment of psoriasis.  
As with all systemic therapies for psoriasis, it should only be initiated by 
specialists in a hospital setting.  Acitretin (4b) is indicated for severe extensive 
psoriasis resistant to other forms of therapy.  It is also sometimes used in other 
disorders of keratinisation such as Darier’s disease.  The disadvantage with 
acitretin (4b) is that it is teratogenic.  In females, before treatment is commenced, 
the possibility of pregnancy should be excluded.  It is also recommended that 
pregnancy should be avoided for at least two years after treatment.  Acitretin (4b) 
is a metabolite of the prodrug etretinate (4c) and is a second generation aromatic 
retinoid.  It has a shorter half life than etretinate (4c)
 (2 days vs 120 days) 
because it is less lipophilic [2003MI133].  It was expected that the development 
of acitretin (4b) would alleviate the drastic contraceptive measures required after 
etretinate (4c) treatment.  However, this was not the case, as it was found that 
acitretin (4b) is back-esterified to etretinate (4c), so post-treatment contraception 
of two years is still recommended. 
Other side effects of systemic retinoid therapy include dry and cracked lips, dry 
skin, hair thinning, liver toxicity and abnormalities in blood lipids.  As a result of   - 17 -
these side effects, it is recommended that liver function and blood lipids should 















Methotrexate (5)  
 
Methotrexate (5) was discovered in 1947 by a group of scientists who were trying 
to develop folic acid antagonists [B2005MI].  The scientists demonstrated that 
methotrexate  (5) was effective in treating acute leukaemia.  Methotrexate (5) 
inhibits dihydrofolate reductase, which consequently inhibits the conversion of 
dihydrofolate to tetrahydrofolate.  This in turn, depletes the body of one-carbon 
donors, which are essential for DNA and RNA synthesis, and, as a result of this, 
methotrexate (5) affects the proliferation of rapidly dividing cells. 
Methotrexate  (5) is considered by many clinicians as the ‘gold standard’ 
treatment for severe recalcitrant psoriasis, although, despite its efficacy, 
methotrexate (5) is not without its problems.  There have been reports of blood 
dyscrasias (including fatalities) and hepatotoxicity with low dose methotrexate (5).  
In view of this, the committee of the safety of medicines has advised that full 
blood count, renal and liver function tests be done prior to and during treatment, 
until the therapy is stabilised. 
Other side effects include mucosal ulceration, stomatitis, nausea, intestinal 
ulceration and bleeding.  In patients who experience mucosal or gastrointestinal 
side effects, folic acid is given once weekly in an attempt to alleviate such side 
effects.   
 





Ciclosporin  (6) was discovered in Basle, Switzerland, where a group of 
researchers were working on fungal metabolites [B2005MIa].  It was found that 
an extract from the fungus, Tolypocladium inflatum, had strong 
immunosuppressive activity.  This extract was purified and characterised – the 
structure responsible for the activity was elucidated in 1971 and given the name 
ciclosporin (6) [B2005MIa].
  It was not until 1979, however, that the therapeutic 
effect of ciclosporin (6) in psoriasis was discovered [1979NEJM555]. 
Ciclosporin  (6) binds to a cytosolic immunophilin, which is an 
immunosuppressant binding protein.  The ciclosporin-immunophilin complex then 
binds and inhibits the enzyme calcineurin.  This results in the inhibition of nuclear 
factor of activated T-cells (NFAT), which leads to the inhibition of cytokine 
production. 
Ciclosporin  (6) is licensed for the management of severe psoriasis where 
conventional therapy is ineffective or inappropriate.  It is also effective in pustular 
Ciclosporin (6)   - 19 -
and erythrodermic psoriasis.  The major drawback of using ciclosporin (6) is that 
it is markedly nephrotoxic.  Other side effects include hyperkalaemia, 










Hydroxyurea (7) is an antineoplastic drug that is primarily used to treat chronic 
myeloid leukaemia.  It inhibits the enzyme ribonucleotide diphosphate reductase, 
which converts ribonucleotides to deoxyribonucleotide – a key step in DNA 
synthesis.  In psoriasis, hydroxyurea reduces cellular replication and proliferation 
in the epidermis, but unfortunately, is in not licensed for the treatment of psoriasis 















Trimethylpsoralen (8c)  
 
Phototherapy is often used to treat moderate to severe psoriasis.  There are two 
kinds of phototherapy: treatment with UV-B, or a combination with UV-A and a 
psoralen (PUVA).  The mechanism of action of both UV-B and PUVA is thought 
to be due to the effects on T-cell apoptosis. 
UV-B is effective in the management of chronic stable psoriasis and guttate 
psoriasis, but it may irritate inflammatory psoriasis.  It is recommended that a   - 20 -
specific wavelength of 311 nm be used to manage the condition.  This is called 
narrow-band UV-B and it is less likely to burn than conventional broad-band 
therapy. 
UV-A alone has limited efficacy in psoriasis, but when combined with a psoralen 
(5-methoxypsoralen  (8a), 8-methoxypsoralen (8b) or trimethylpsoralen (8c)) it 
greatly enhances the anti-psoriatic activity.  The psoralen is usually administered 
either orally or topically shortly before UV-A irradiation.  PUVA is effective in 
unstable forms of psoriasis and pustular psoriasis.  The risk of long term 
phototherapy is the development of neoplastic skin lesions, most notably 
squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and malignant 
melanoma. 
 
1.5.10.  The Biologically Active Agents 
Over the past few years, an understanding of the immunopathological 
mechanisms that occur in psoriasis has been elucidated.  Indeed, few disorders 
show the complex interactions between cytokines and chemokines in the 
initiation and maintenance of chronic inflammation as clearly as psoriasis.  This 
has enabled the development of more selective therapies which specifically 
target the pathogenic T-cells, or block the cytokines they secrete.   
Recently, three agents which target the underlying immunopathogenesis of 
psoriasis have been released on market.  The first of these agents Infliximab, is a 
humanised monoclonal antibody that inhibits the actions of TNF-α.  The next 
biological agent, Etanercept, was a fused protein combining two extracellular 
binding domains; p75 TNF-α fused to the Fc portion of human IgG1.   This fused 
protein competively binds to TNF-α, preventing it from binding to TNF-α 
receptors on the cell surface.  Although both Infiximab and Etanercept have 
different mechanisms of action, they produce the same pharmacological outcome, 
i.e. they inhibit the action of TNF-α. 
Efalizumab is a recombinant humanised monoclonal antibody that targets the 
LFA-1/ICAM-1 interaction involved in T-cell activation [2008N866].  Efalizumab 
has been approved for the treatment of severe plaque psoriasis, but is   - 21 -
considered second line to Etanercept [www.nice.org.uk/TA103#documents; 
accessed June 2008]. 
The new biological agents appear safe, although the theoretical risk of infection 
cannot be discounted. 
These agents offer great promise in the management of psoriasis and have also 
been evaluated against other chronic inflammatory conditions, such as Crohn’s 
disease and rheumatoid arthritis.  There are currently more than 30 new 
biological agents under evaluation that target the different biological mechanisms 
behind psoriasis [2003MI133]. 
It has been many years since a new chemical entity (NCE) has been discovered 
for the treatment of psoriasis.  The majority of the topical products available have 
a role in the management of mild to moderate plaque psoriasis, but remain 
ineffective for severe plaque psoriasis.  The systemic products available for 
psoriasis are generally quite toxic and are associated with serious side effects, 
for example, methotrexate (5) and ciclosporin (6) cause blood dyscrasias and 
nephrotoxicity respectively.  The newer biological agents have been successful in 
managing severe forms of this disease.  However, a major disadvantage of the 
biological agents is that because of their large molecular weight they have to be 
administered via the parenteral route.  This is carried out in a hospital setting 
where it takes around two hours for a dose to be administered.  This is done at 
the beginning of treatment, and again after two and six weeks. After this, the 
biological agent is then administered every eight weeks which is a major 
inconvenience for the patient.  In view of the problems with the biologicals and 
the toxicity associated with the systemic products, there still remains a place on 
the market for a NCE with the ability to treat severe forms of psoriasis. 
The ability to develop novel treatments for psoriasis by rational design is 
dependent on our understanding of the immunopathological mechanisms behind 
psoriasis.  Clearly, a great deal of progress has been made since Thin’s paper in 
1881 which has resulted in more effective therapies being discovered.  Perhaps 
the most noteworthy are the biologically active agents which are designed 
specifically to target the underlying mechanisms of psoriasis.  However, further   - 22 -
work is needed to exploit new therapeutic targets to continue the progress 
against this debilitating disease. 
 
1.6.  Reactive Oxygen Species and the Thioredoxin System 
Reactive oxygen species (ROS) are a group of reactive molecules formed from 
oxygen.  The term oxidative stress is used when the level of ROS disrupts the 
redox homeostasis of the cell.  The most common ROS are the superoxide anion 
(O2
. –), hydrogen peroxide (H2O2), hydroxyl radical (
.OH) and nitric oxide (NO). 
Accumulation of ROS can compromise and threaten the cell integrity, with 
proteins, lipids and DNA affected.  ROS can react with biomolecules, forming 
free radicals, which then react with other components of the cell, starting a chain 
reaction.  In order to stop this sequence of events, a free radical must react with 
another radical, or react with a free radical scavenger (or an antioxidant). 
In order to maintain the intracellular redox homeostasis, there are many defence 
mechanisms in place, including free radical scavengers (e.g. glutathione) and 
enzyme systems (e.g. superoxide dismutase). 
 
1.6.1. Superoxide  (O2
. –) 
This anion is formed from molecular oxygen, and despite being a free radical, is 
not very reactive.  The main source of production of superoxide is caused by 
‘leakage’ of electrons from the electron transport chain in the mitochondria.   
Since this radical is charged, it doesn’t readily cross cell membranes, keeping it 
enclosed in the compartment in which it was produced.  It is destroyed by 
dismutation; two molecules of superoxide dismutate to molecular oxygen and 
hydrogen peroxide catalysed by the enzyme superoxide dismutase (SOD), as 
illustrated by Equation 1.  
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1.6.2. Hydrogen  peroxide  (H2O2) 
The main source of hydrogen peroxide comes from the superoxide anion via the 
enzyme, SOD.  Hydrogen peroxide has the ability to cross cell membranes, so its 
regulation must be tightly controlled.  Hydrogen peroxide plays a role in forming 
more reactive ROS, for example, hypochlorous acid, HOCl (Equation 2). 
 
H + Cl + H2O2 HOCl + H2O
Equation 2 
 
Hydrogen peroxide is removed via several enzyme systems, including catalases, 
peroxiredoxins and glutathione peroxidases. 
 
1.6.3.  Hydroxyl radical (
.OH) 
This radical is highly reactive and has the ability to react with biomolecules.  It is 
formed from hydrogen peroxide in a reaction catalysed by the transition metal 
ions, Cu
+ or Fe
2+, by a process known as the Fenton reaction, as illustrated by 
Equation 3. 
H2O2 +C u   /   F e
2 OH + OH + Cu




Superoxide regenerates the metal ions required for the Fenton reaction as shown 
by Equation 4. 
 
Cu   /   Fe
2 Cu
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1.6.4. Nitric  Oxide  (NO) 
Nitric oxide is rather an unusual ROS because it does not react readily with other 
biomolecules.  Indeed, nitric oxide reacts with other free radicals forming less 
reactive molecules, thereby functioning as a free radical scavenger.  However, 
nitric oxide can combine with the superoxide anion to form the peroxynitrite anion 
(ONOO 
-), which is highly toxic.   
The main source of nitric oxide is derived from the enzyme NO synthase (NOS) 
used in the oxidation of L-arginine (Equation 5). 
 
L-arginine
+ O2 NADPH +
L-citrulline


















NOS is found in three different isoforms; neuronal NOS (nNOS), inducible NOS 
(iNOS) and endothelial (eNOS).  When NO is produced in excess it is detoxified 
by conjugation to glutathione to form an S-nitrosoglutathione adduct (GSNO).  
 
1.6.5.  The Mammalian Thioredoxin System 
The cellular redox homeostasis needs to be tightly regulated and controlled.  This 
is achieved through a complex network of enzyme and antioxidant systems.  Two 
of the major enzyme systems responsible for the maintenance of the cellular 
redox homeostasis are the thioredoxin system and the glutathione system. 
Glutathione (GSH) and glutathione reductase (GR) are collectively known as the 
glutathione enzyme system.  GSH is the most abundant thiol-based antioxidant, 
found in millimolar concentrations within the cell – the oxidized form, GSSG, is 
reduced by the NADPH-dependent flavoenzyme GR.  
The classic mammalian thioredoxin system consists of two oxidoreductase 
proteins; thioredoxin (Trx) and thioredoxin reductase (TrxR) [2004MI40].
  There 
are three different thioredoxin isoenzymes encoded by separate genes; cytosolic 
thioredoxin (Trx1), thioredoxin located in the mitochondria (Trx2), and thioredoxin 
highly expressed in spermatozoa (SpTrx).  The most studied thioredoxin is the   - 25 -
classic Trx1, which is a ubiquitous 12 kDa cytosolic redox active protein (Figure 
4). 
All mammalian thioredoxins contain a conserved –Cys-Gly-Pro-Cys- active site.  
The cysteine residues at positions 32 and 35 are key to the redox activity of Trx.  
Trx also contains 3 other cysteine residues at positions 62, 69 and 73.  Although 
these cysteine residues do not form part of the active site, they are still essential 
for activity [2005TIPS398].  It is thought that these three cysteine residues 
contribute to essential protein conformation, possibly through hydrogen bonding 
of the thiol group rather than through disulfide bond formation. 
Thioredoxin has many different physiological functions, but its main role appears 
to be maintaining cellular proteins in their dormant state [2000EJB6102].  For 
example, Trx inhibits the production of the transcription factor, NFκB, by 
stabilizing the inactive pre-cursor protein, IκB.   
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Figure 4.  The Crystal Structure of Thioredoxin.  The two catalytic cysteines at positions 32 and 
35 are coloured according to atom type.  Crystal structure obtained from protein databank: 
www.rcsb.org/pdb. code; 1ERT, accessed September 2005 [1996MI735]. 
 
Trx can act as a direct antioxidant, reducing hydrogen peroxide to water and 
oxygen.  Peroxiredoxins also catalyse the reduction of hydrogen peroxide. Here, 
Trx reduces the oxidized peroxiredoxins and reactivates them.  Trx also plays a 
part in regulating cellular apoptosis.  This is achieved by Trx binding to apoptosis 
signaling kinase-1 (ASK-1) and maintaining it in its dormant state.  Interestingly, 
this binding is lost when Trx is oxidized [1998EMBOJ2596].
  Extracellularly, Trx 
induces the chemotaxis of neutrophilic granulocytes, monocytes and T-cells.   - 27 -
Trx also has a role in DNA synthesis [1989JBC13963].
  Here, reduced Trx acts 
as a hydrogen donor for the enzyme ribonucleotide reductase, which is involved 
in the conversion of ribonucleoside 5’-diphosphates (NDP) to 2’-
deoxyribonucleoside 5’-diphosphates (dNDP), an essential step in DNA 
synthesis. 
Recently, a truncated form of Trx was discovered [2001FRBM1287].
  The 
truncated form, given the name Trx80, was found to be secreted from monocytes 
and T-cells.  Surprisingly, Trx80 is not a substrate for TrxR and is not capable of 
reducing protein disulfides.  It does, however appear, to have remarkable 
immunostimulatory properties, for example, stimulating the proliferation of 
monocytes and T-cells [2000JBC37474]. 
 
1.6.6. Thioredoxin  Reductase 
The other major component in the Trx system is thioredoxin reductase (TrxR), a 
NADPH-dependent enzyme that is responsible for reducing oxidized Trx via 
electron transfer through FAD (Figure 5).  TrxR exists as a homodimer with one 











Figure 5. The Thioredoxin Enzyme system  
 
In 1996, Thressa Stadtman and coworkers showed that the active site of TrxR 
contained an unusual selenocysteine (SeCys) motif [1996PNAS6146].
  Although 














FAD NADPH + H
NADP
TrxR  - 28 -
 
 
Figure 6.  The Crystal Structure of Thioredoxin Reductase.  Each subunit of the enzyme contains 
FAD (red), and NADPH (yellow) Crystal structure obtained from protein databank; 
www.rcsb.org/pdb. code; 1H6V, accessed September 2005 [2001PNAS9533]. 
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[1996MI83].  In mammalian TrxR, the selenocysteine is located at the C-terminus, 
within the tetrapeptide Gly-Cys-SeCys-Gly-COOH.  The selenocysteine residue 
is critical, as replacement of SeCys with cysteine (Cys) severely impairs TrxR 
activity [2000JBC18121].  The crystal structure of TrxR is closely related to other 
mammalian flavoprotein oxidoreductases, such as glutathione reductase (GR).  
The first step of the catalytic mechanism of TrxR is similar to GR.  This step 
consists of the transport of electrons from NADPH via FAD to a disulfide, formed 
between cysteines at postions 59 and 64.  This first step occurs in both TrxR and 
GR because selenocysteine is not essential for this part of catalysis.  The second 
part of catalysis involves the Cys497 and SeCys498 motif.  Addition of NADPH 
can reduce the selenylsulfide bond between Cys497 and SeCys498, which 
generates a nucleophilic selenolate anion, capable of reducing many substrates, 
including oxidized Trx [2001PNAS9533].  
This proposed mechanism of catalysis is consistent with the observed 3D 
structure of TrxR.  The conformation of TrxR can be modelled to show that the C-
terminal tetrapeptide, Gly-Cys-SeCys-Gly-COOH can move close enough to the 
disulfide Cys59-Cys64 for electron transfer to take place.  In this model, the 
distance between Cys59 and Cys497 decreases from 12 Å to 3 Å. Once the 
electron transfer has taken place, the C-terminal ‘arm’ can move away from the 
residues Cys59-Cys64 to the surface of the enzyme and reduce bound 
substrates, such as Trx [2001PNAS9533] (Figure 7).
    This conformational 
change mainly involves residues Ser495 and Cys497.  Another key residue 
involved in catalysis is the histidine residue located at position 472.  It has been 
suggested that the imidazole side chain of His472 can transfer a proton to 





















































Figure 7.  A Suggested Mechanism for Mammalian TrxR [2001PNAS9533]. 
 
TrxR has a wide substrate specificity, most likely explained by the unique SeCys 
residue.  Direct substrates for TrxR include dehydroascorbic acid, α-lipoic acid 
and hydrogen peroxide.  
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1.6.7. Thioredoxin-Interacting Protein 
Thioredoxin-interacting protein (TrxIP) is another protein that has a role in the 
thioredoxin enzyme system.  As its name suggests, TrxIP binds to and 
inactivates Trx.  Interestingly, TrxIP only binds to reduced Trx by interacting with 
the catalytic cysteine residues at positions 32 and 35.  It has been suggested that 
TrxIP acts as an endogeneous inhibitor of Trx, as once TrxIP is bound to reduced 
Trx, the activity of Trx is inhibited. 
Mounting evidence suggests that TrxIP may also have a role to play in various 
disease states [2008BBA1368];  for example, transfection of tumour cells with 
TrxIP has been shown to reduce cell growth dramatically [2003MI4035]. 
 
1.6.8.  The Thioredoxin system and Psoriasis 
There is increasing evidence to support the role of ROS in the pathology of 
inflammatory diseases, such as psoriasis [2001FRBM337].
  It is suggested here 
that the thioredoxin enzyme system may play a role in psoriasis.  This concept is 
based on the emerging evidence that Trx has two distinct roles; one in the 
cytoplasm and one in the nucleus [1999JBC27891]. 
Thioredoxin primarily acts as an antioxidant in the cytoplasm when the cells 
redox homeostasis is intact, as previously discussed.  When intracellular levels of 
ROS rise, Trx is translocated from the cytoplasm to the nucleus where it 
promotes the DNA binding of several transcription factors, including NFκB, AP-1 
via Ref1, and p53 [2001FRBM1287].   
Trx appears to play opposing roles in the regulation of NFκB, depending on the 
level of oxidative stress.  At low levels of oxidative stress, Trx is predominantly 
found in the cytoplasm, where it blocks the degradation of the inactive IκB by 
interfering with the signals to IκB kinases.   Under high levels of oxidative stress, 
Trx is predominantly found in the nucleus, where it enhances the ability of NFκB 
to bind to DNA.  This is achieved by reduction of a critical cysteine residue 
identified as cysteine 62 of NFκB [1999FRBM936].
  Once this residue is reduced, 
Trx is oxidized, which is then recycled by TrxR, to reduced Trx, allowing the 














Figure 8.  Activation of NFκB by ROS.  The DNA binding of NFκB is promoted by reduced Trx 
which leads to the expression of various cytokines, chemokines and cell adhesion molecules.      
 
NFκB regulates a wide variety of genes, particularly those involved in 
inflammatory and immune responses; for example, NFκB regulates the 
production of TNF-α, a primary cytokine implicated in the pathogenesis of several 
inflammatory disorders, including psoriasis.   
If reduced Trx was inhibited either directly, or indirectly by inhibition of TrxR, this 
process would be disrupted, as only reduced Trx is able to reduce key residues 
in the transcription factors.  It is the aim of this work to develop a novel 
thioredoxin enzyme inhibitor (either directly by inhibiting Trx or indirectly by 
inhibiting TrxR).  It is anticipated that Trx inhibition will disrupt the DNA binding of 
NFκB and, consequently, reduce the activation of a number of pro-inflammatory 
genes.   
Trx and TrxR are accepted as realistic and rational targets for drug design 
[2000EJB6118, 2006CL164].
  Indeed, there are many organic compounds known 
to inhibit the thioredoxin system (Figure 9).  To date, the majority of these 
compounds have been proposed as potential anticancer agents.  For example, 
PX-12 has entered phase 2 clinical trials for people suffering from advanced 
pancreatic cancer [www.oncothyreon.com/clinical/px-12.htm; accessed   - 33 -
December, 2008].  Furthermore, the group of Malcolm Stevens has shown that 



































Figure 9.  Organic inhibitors of the thioredoxin system. 
 
Recently, curcumin, a natural product from the plant Curcuma longa (commonly 
known as turmeric)  has been shown to inhibit proliferation, invasion, 
angiogenesis and metastasis of many different cancers [2008CL199].  More 
specifically, curcumin has also been shown to inhibit NFκB signaling, a target for 
the current research and of potential in the treatment of psoriasis. 
The thioredoxin enzyme system has been shown to be involved in a number of 
diseases such as cataract formation, ischemic heart disease, cancer, AIDS, 
rheumatoid arthritis, and diabetes. To date, no literature has been published 
linking Trx with psoriasis [2008BBA1368].   - 34 -
1.7.  Molecular  Modelling and Drug Discovery 
Drug discovery is an extraordinarily complicated process.  On average, it takes 
around 10 - 15 years and 200 - 300 million dollars to get a drug from concept to 
market.  Generally, the rational development of a new drug follows a three step 
process. 
Firstly, a target has to be identified, such as a receptor or an enzyme.  Secondly, 
the target has to be characterised.  Finally, a molecule must be designed that fits 
the target.  This last process can take years alone, as, even with good structural 
information, it is very difficult to design a drug that will bind specifically to a given 
target. 
The development of rational drug design using molecular modelling has 
revolutionized the development of new drugs.  Software aiding structure based 
drug design has been around since the early eighties, and, considering it takes 
around 10 to 15 years to get a drug to market, the results are just starting to 
appear.  For example, donepezil, an anticholinesterase inhibitor, used in the 
treatment of Alzheimer’s disease, was developed using quantitative structure 
activity relationship (QSAR) studies [1996BMC1429].  Similarly, indinavir and 
nelfinavir, both HIV1 protease inhibitors, were developed by structure based 
design [1997JMC3979]. 
For a ligand to fit into an active site, it must have specific characteristics, as not 
all molecules can bind to a given active site.  For example, the shape of the 
ligand is crucial if it is to bind to an active site.  This would be quite easy to 
predict and calculate assuming the enzyme or receptor is rigid, however, this is 
not the case, because most systems are, in fact, dynamic and not static.   
Furthermore, ligands can bind to an active site by displacing water, or by 
changing the conformation of the system; features that may have not been 
predicted by the original crystal structure. 
Once the problem of shape has been overcome, it is important to establish the 
forces that are in place to hold the molecule into the active site.  These forces 
may be for example, hydrogen bonding or electrostatic attraction between ligand 
and receptor.  The electrostatics of a molecule is vitally important when   - 35 -
considering how a molecule binds to an active site, as illustrated by examining 
the structures of methotrexate and dihydrofolate.  Methotrexate is an 
antimetabolite drug that acts by mimicking the structure of dihydrofolate, thereby 
inhibiting the enzyme dihydrofolate reductase.  The shapes of methotrexate and 
dihydrofolate are rather similar, so it would be reasonable to expect that these 
molecules bind in a similar way.  In fact, methotrexate binds to dihydrofolate 
reductase upside down relative to dihydrofolate.  This can be explained by 
examining the electrostatics of each molecule (Figure 10).  It can be seen that 
when methotrexate is inverted the electrostatics are very similar to dihydrofolate.  
The red regions of both molecules correspond to negatively charged areas that 
are most likely to interact with a positively charged area of dihydrofolate 
reductase.  This interaction is only possible when methotrexate binds upside 
down relative to dihydrofolate.  If methotrexate is in the same orientation as 
dihydrofolate, the electrostatics of the two systems are different, such that 




Figure 10a.  The electrostatic properties of dihydrofolate; red areas indicate negative charges; 
blue areas indicate positive charges. 
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Figure 10b.  The electrostatic properties of methotrexate; red areas indicate negative charges; 
blue areas indicate positive charges. 
 
The hydrophobic interactions between a ligand and a receptor are also important.  
Non-polar groups, such as alkyl chains or aromatic groups interact more 
favourably with other non-polar groups.  For example, the active site may contain 
a hydrophobic pocket which neatly fits a methyl group, or an aromatic ring 
present in the active site could interact with an aromatic ring on the ligand by 
aromatic stacking.  This type of lipophilic interaction can significantly increase the 
binding between ligand and receptor.  
 
Generally, there are 4 possible scenarios when using specialist structure based 
drug design software:   
1.  Ligand and receptor structures are unknown. 
2.  Ligand and receptor structures are known. 
3.  Ligand structure known, receptor structure unknown.   
4.  Ligand structure unknown, receptor structure known.   
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The data available on the system determines what kind of approach will be used. 
In the case where the ligand and receptor structures are unknown, a 
combinatorial chemistry approach can be employed.  If, however, both ligand and 
receptor structures are known, a structure based design approach can be used.  
If the ligand structure is known but the receptor structure is unknown, a QSAR 
approach may be adopted.  In the case where the receptor structure is known, 
but the ligand structure is unknown, de novo design techniques may be used.  All 
of these techniques use molecular modelling to accelerate the drug discovery 
process.     
 
The aim of the current work was to design rationally novel agents that inhibit the 
thioredoxin system using molecular modelling.   Since the crystal structures of 
Trx and TrxR are known, and are available from the protein databank, a structure 
based design approach was adopted.  Structure based design involves the 
rational design of a ligand which interacts with the 3D structure of the target 
receptor.  There are generally two methods used in structure based design to 
identify a lead compound; de novo design or database searching.  The latter 
method was used, together with a structure based focussing (SBF) programme, 
to identify lead compounds.  SBF is a technique used to identify key 
pharmacophores within an active site, which can then be screened against 
various databases for potential hits.   
The rational design of a drug can be a daunting process, even with the help of 
molecular modelling.  For a drug to be effective, it is vital that the shape and 
electrostatics of the ligand complement its given target.  Hopefully the further 
development of specialist structure based drug design software will assist and 
inspire medicinal chemists in the design of future drugs. 
 
1.8. Biological  Evaluation 
Once hit compounds had been identified by structure based design, they were 
evaluated for biological activity towards the thioredoxin enzyme system.  This 
was achieved using the insulin reduction assay, as described by Stevens and   - 38 -
colleagues [2003MI1695].  This assay was crucial to this work, as it allowed the 
specific evaluation if the hit compounds were acting directly on the thioredoxin 
system, as suggested by the molecular modelling.  The results of the assay also 
allowed the refinement of the SBF model which could result in the discovery of 
more active hit compounds.   
Another biological assay used to evaluate the hit compounds was the MTT cell 
viability assay, which is a cellular based assay and is often used as a crude 
measure of antiproliferation.  A key feature of psoriasis is that the keratinocytes 
within the dermis hyperproliferate, which gives arise to the characteristic psoriatic 
plaque.  Clearly, any compound showing antiproliferative properties may have a 
role to play in the treatment of psoriasis.  It was anticipated that any compound 
exhibiting activity against the thioredoxin system, may also exhibit 
antiproliferative properties, determined crudely by the MTT assay.   
The key to the successful use of molecular modelling in drug design is the 
relevant biological assay that quantifies the interaction used in the in silico screen.  
It gives a direct measure of the relevance of the model to the biological system 
under scrutiny.  In the case of the current work, the insulin reduction assay is 
crucial as it allows the direct measurement of activity towards the thioredoxin 
system. 
 
1.8.1.  Thioredoxin/Thioredoxin Reductase Insulin Assay 
Thioredoxin/thioredoxin reductase inhibition was measured using the insulin 
reduction assay [2003MI1695].  This assay is based on the key fact that insulin is 
an excellent substrate for Trx [1979JBC9113].  The first part of the assay 
involves TrxR reducing oxidized Trx via NADPH. The reduced Trx then reduces 
disulphide bonds in the insulin, leaving exposed thiol groups, as summarized by 
Figure 11.  Unfortunately the Trx/TrxR insulin reduction assay does not 
distinguish whether a compound is active against Trx or TrxR, but considering 
the compounds were specifically designed to inhibit TrxR, it was assumed that 
any activity in the insulin reduction assay was a consequence of TrxR inhibition. 
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Figure 11.  The Trx/TrxR insulin reduction assay.   
 
The addition of dithionitrobenzoic acid (DTNB) to the free thiol groups of the 
insulin cleaves the disulfide bond in the DTNB which gives arise to a yellow 
colour (Figure 12).  The yellow colour is observed under basic conditions due to 
the conjugation of electrons between the thiolate anion and the nitro group of 
thionitrobenzoic acid (TNB).  The level of thioredoxin/thioredoxin reductase 





















Figure 12.  Addition of DTNB to reduced insulin produces thionitrobenzoic acid (TNB) and a 
mixed insulin disulfide.  DTNB has very little absorbance, but under mild basic conditions the TNB 
anion gives an intense yellow colour at 412nm.  
 
1.8.2. MTT  assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
was first described in 1983 by Mosmann [1983MI55].  The assay is based on the 
ability of a mitochondrial dehydrogenase enzyme to cleave the tetrazolium rings   - 40 -
of the yellow MTT to form dark blue formazan crystals (Figure 13).  These 
crystals are mostly impermeable to cell membranes and, consequently, they 
accumulate in healthy viable cells.  The addition of detergent solubilizes the cells, 
which results in the liberation of purple formazan crystals.  The number of viable 
cells is directly proportional to the level of purple formazan produced.  This colour 
change can be measured by a spectrophotometer enabling quantification of 
























Figure 13.  MTT is cleaved by mitochondrial dehydrogenase enzymes to yield formazan. 
 
The human papilloma virus-16 (HPV-16) immortalized keratinocyte cell line was 
used in the MTT cell viability assay.  This cell line is well characterized and was 
originally used to assess the role HPV-16 plays in carcinogenesis [1987MI1061].  
The outstanding characteristic of keratinocytes transfected with HPV-16 DNA is 
that they exhibit an extended lifespan when compared to normal keratinocytes.  
The cell line also has similar characteristics to normal human keratinocytes, for 
example, both cell lines undergo differentiation by prolonged confluency, or lack 
of growth factors in the medium [1987MI1061].  These attributes make this cell 
line an ideal candidate to mimic the hyperproliferation of the dermis, a key 
feature of psoriasis. 
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2. Molecular  Modelling 
 
2.1. General 
All molecular modelling simulations were carried out on a HP XW8200 
workstation using Redhat Linux Enterprise 4 as the operating system.  The 
crystal structures of reduced thioredoxin (1ERT) and thioredoxin reductase 
(1H6V) were obtained from the RCSB protein databank [www.rcsb.org/pdb]; both 
were determined by X-ray diffraction [2001PNAS9533, 1996MI735]. 
InsightII, Cerius
2 and Catalyst (Accelrys, San Diego) were the molecular 
modelling programmes used. 




Hydrogen atoms were added to the crystal structure of TrxR (1H6V) using the 
Builder module of InsightII.  Potentials were fixed using the forcefield, CFF91.  
Both FAD and NADPH were manually inspected to ensure each atom type and 
bonding order was correct.  After this, the crystal structure was minimised using 
the Discover 3 module of InsightII.  The structure was firstly minimised using the 
steepest descent algorithm and then using a conjugate gradient algorithm.  The 
system was fixed in a series of subsets; each subset was minimised sequentially 
as follows: 
1.  Backbone and heavy atoms fixed; hydrogens minimised; 
2.  Backbone fixed; hydrogens and heavy atoms minimised; 
3. Everything  minimised. 
 
This is a typical minimisation cascade employed to find the local minimum of a 
system.  Steepest descent algorithms provide the answer to the question ‘Which 
way should we go?’ but not to the question ‘How far should we go?’  In other 
words, they are effective at minimising the energy of a system, but not effective 
at finding the local energy minimum.  This is achieved using a conjugate gradient   - 43 -
algorithm, which stores information about the minimised structure and helps to 
shape the rest of the minimisation by rejecting structures that are higher in 
energy than the previous.  In this study, the Polak-Ribiere conjugate gradient 
algorithm was used.  
 
2.3.  Structure Based Focusing 
Structure based focusing (SBF) is a method that uses a known protein structure 
to generate compounds which are likely to bind within a defined active site. 
For SBF to be successful, the protein must have an active site for the ligand to 
bind into.  From the crystal structure of Trx, it was apparent that there was no 
active site.  The two catalytic cysteines at positions 32 and 35 are on the surface 
of the protein (Figure 4), so drug design using SBF would be difficult with this 
approach.  TrxR does, however, have an active site which could be exploited by 
SBF (Figure 6). 
Isolated TrxR is unstable and denatures to an inactive form.  It can be stabilised 
by replacement of the selenocysteine residue (SeCys498) by cysteine (Cys498); 
hence, the structure of TrxR obtained from the protein databank had 
selenocysteine (SeCys498) replaced by cysteine [2001PNAS9533].  In view of 
the fact that sulphur has similar chemical properties to selenium, it was decided 
to use this crystal structure for SBF. 
The first step of SBF is to define the active site.  The residue Cys498 was 
defined as the centre, with a radius of 12 Å.  The radius used included the four 
essential residues required for activity: Cys498, Cys497, Cys59 and Cys64.  The 
latter two residues are crucial for in the first step of catalysis, while the former two 
residues are vital in the second step of catalysis. 
Once the active site had been defined, the next step was to generate an 
interaction site.  SBF uses Ludi, another programme used in Cerius
2, to model 
potential protein – ligand interaction sites.  This is based on the theory that 
interactions between a protein and a ligand are usually formed through non-
bonded contacts, such as hydrogen bonding or lipophilic interactions.  For each 
functional group in the active site, a set of non-bonded interactions were   - 44 -





Figure 14a.  Illustration of the interaction map in the active site of thioredoxin reductase.  The 
interactions are hydrogen bond acceptors (pink, blue and yellow cylinders), hydrogen bond 
donors (red, green, brown and purple cylinders), and lipophilic regions (spheres). 
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1. Hydrogen  bond  donor; 
2. Hydrogen  bond  acceptor; 
3.  Lipophilic – aliphatic; 
4.  Lipophilic – aromatic. 
 
To generate these sites, a set of rules that cover the range of theoretically 
energetically favourable orientations for hydrogen bonds and lipophilic 
interactions are used.  These rules predict where non-bonding interactions are 
most likely to take place using a set of 3D vectors.  It is essential that the 
interactions are accurate and representative of the system; therefore, time was 
taken to manually inspect each interaction and ensure that each interaction 
belonged to the correct residue. 
Once the interaction map was completed, the next step was to generate 
exclusion volumes (Figure 14b).   
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Figure 14b. The interaction map with volume exclusions added.    
 
Exclusion volumes represent the sites of the protein’s heavy atoms (e.g. C, N, O, 
and S) and are essential because a ligand cannot bind over an existing atom.  
The next step in SBF is to generate 3D queries of the system using Catalyst.  
The number of features used in each query (or pharmacophore) is user defined.    - 47 -
In this case, a random subset of 6 feature queries was generated.  The more 
features the query has, the more specific it is to the system.  The major drawback 
of using a high featured query is that it could decrease the number of hits 
obtained from the 3D database screen.  For example, for a 3 feature query, the 
percentage of queries producing hits is around 57 %, while for a 6 feature query 
the percentage queries producing hits is around 3 %.  The 3D search must be 
specific to the system, but not so specific that no hits are generated from the 
screen.  Ultimately, the choice of number of features is a compromise between 
specificity and practicality. 
Once the queries were constructed, they were viewed in Catalyst to ensure all of 
the features were in close proximity and were not separated by exclusion 
volumes (Figure 15).  If, for example, two features were separated by exclusion 
volumes, that particular query would not be used in the screen, as it would be 
unlikely to generate any hits. 
Ten 6 feature queries were identified and used for the 3D database screen.   
Each query was screened against Maybridge’s screening collection, which 
contains around 60,000 molecules.  The results are summarised in Table 1. 
These hits were then filtered according to Lipinski’s rule of 5 [2001ADDR3]: 
1.  Fewer than 5 hydrogen bond donors; 
2.  Less than 10 hydrogen bond acceptors; 
3.  A molecular weight below 500; 
4.  A logP of less than 5. 
 
If any hit compound fell outside of the filtering criteria outlined by the rule of 5, 









































































































































































































































































































Table 1.  The number of hits each query generated when screened against Maybridge’s 
screening collection, before and after filtering. 
 
Other filters applied to the screen were as follows; 
1.  No chiral centres 
2.  Rotatable bonds > 10 were removed 
 
2.4. LigandFit 
These hits were then further examined using LigandFit, which is a programme 
incorporated into Cerius
2 that is designed to dock a series of ligands into a 
protein binding site [2003JMGM289].  During the docking process, the protein is 
kept rigid, while the ligand remains flexible.  This allows different conformations 
of the ligand to be generated and docked within the defined binding site. 
The first step when using LigandFit is finding an active site in the protein.   
LigandFit uses a flood filling algorithm to achieve this (Figure 16).  The site 




Number of hits prior 
to filtering 
Number of hits after 
filtering 
1 647  97 
2 230  189 
3 518  303 
4 1008  246 
5 67  0 
6 1222  582 
7 346  220 
8 205  46 
9 182  80 
10 960  460   50
 
 
Figure 16.  The active site of TrxR found using the flood filling algorithm of LigandFit.  Yellow 
spheres are representative of the active site.  The site search was based on the shape of TrxR.  
 
Sometimes, crystal structures are available with a ligand bound in the active site.  
This is very useful, because it allows the model to be validated and to compare 
where other potential ligands bind.    In the case of TrxR, the site search was 
based on shape, because there was no docked ligand in the original crystal 
structure.   
When the binding site has been defined, LigandFit uses a Monte Carlo algorithm 
to generate different ligand conformers for docking.  A shape matching method is 
then used to select conformers which are similar to the shape of the binding site.    51
Once this is achieved, the ligand pose is optimized and, depending on the 
calculated energy, the ligand pose is either removed or saved.  If the calculated 
energy between the ligand and the protein is higher than the previous pose, this 
particular conformation will be discarded.       
The number of saved poses is user defined; for this study, the number of poses 
saved for each ligand was set to one.  When the top pose for each ligand was 
saved, it was then necessary to prioritize the hits.  This was accomplished using 




2.5. Ligand  Scoring 
The ligands were scored using the scoring functions Ludi [1994JCAMD243], Jain 
[1996JCAMD427], PLP1 (piecewise linear potential), PLP2 [1995CB317], PMF 
(potential of mean force) [1999JMC791], LigScore1 and LigScore2 
[2005JMGM395].  Scoring functions estimate interaction energies between small 
ligands and proteins.  They play an essential role in structure based drug design 
and are used to select probable binding modes.  They are also used to help 
discriminate binding ligands from non-binding ligands. 
 
2.5.1. Ludi  Score 
Ludi score is a simple empirical scoring function, which uses individual 
descriptors to calculate the free energy of binding, ∆G. Empirical scoring 
functions are generally derived from fitting experimentally determined Ki values 
for protein – ligand complexes whose crystal structures have been previously 
solved.  Although empirical scoring functions are fairly simplistic, they have been 
surprisingly successful in view of the fact that they often model complex 
molecular interactions. 
A function for expressing ∆G was described by Böhm in 1994 [1994JCAMD243], 
as described below.  This function and its descriptors went on to contribute to the 
Ludi-1 scoring function. 
   52
∆G = ∆G0 + ∆Ghb ∑h-bonds f(∆R)f(∆α) + ∆Gion ∑ionic f(∆R)f(∆α) + ∆GlipoAlipo + 
∆GrotNR 
 
f(∆R) = 1      ∆R ≤ 0.2 Å 
f(∆R) = 1 – (∆R – 0.2)/0.4  ∆R ≤ 0.6 Å 
f(∆R) = 0       ∆R > 0.6 Å 
f(∆α) = 1      ∆α ≤ 30° 
f(∆α) = 1 – (∆α – 30)/50  ∆α ≤ 80° 
f(∆α) = 0       ∆α > 80° 
 
In this equation, ∆G0 represents the contribution to the binding energy due to the 
entropy loss of the ligand.  ∆Ghb represents the contributions from an ideal 
hydrogen bond, whilst ∆Gion describes the contributions from an unperturbed 
ionic interaction.  ∆Glipo represents the contribution from lipophilic interactions, 
which is assumed to be directly proportional to the lipophilic contact area, Alipo.   
The final parameter in the equation is ∆GrotNR,  where  ∆Grot  represents the 
contribution due to freezing of internal degrees of freedom, and NR represents 
the number of rotatable bond in the ligand.  ∆Grot effectively acts as a penalty 
function, which is proportional to the number of rotatable bonds in the ligand.  





2 bonds, where terminal CH3 or NH3 groups are not considered. 
f(∆R)f(∆α) is another penalty function which penalises hydrogen bonds and ionic 
interactions that differ from ideal geometry.  If the interactions differ by more than 
0.2 Å, from the ideal bond length, 1.9 Å, the interaction is penalised.  If, however, 
the interaction differs by more than 0.6 Å, the interaction is penalised to such an 
extent that it will not be taken into account when calculating the score.  Similarly, 
a deviation in bond angle of 30°, from the ideal bond angle of 180°, will result in a 
penalty [1994JCAMD243]   
Although Ludi is a fast, simple empirical function that enables ligands to be 
scored and prioritised, it does have several limitations.  Firstly, Ludi does not 
distinguish between aliphatic and aromatic lipophilic interactions.  Secondly,   53
although Ludi penalises ionic/hydrogen bond interactions that differ from ideal 
geometry, it does not distinguish between the strength of these interactions.  For 
example, an interaction in a protein binding pocket will tend to be stronger than 
an interaction on a protein’s outer surface.  Thirdly, Ludi does not take into 
account any solvent effects.  In some protein-ligand complexes, water forms 
important hydrogen bonds between the ligand and the protein.  The present 
function does not account for this.   
In view of these limitations, Böhm developed another scoring function, based on 
his earlier work [1998JCAMD309].  This function accounts for aromatic lipophilic 
interactions, different strengths of ionic/hydrogen bond interaction, and solvent 
effects.  Although this model has more parameters, it is not without its limitations. 
The first model Böhm described is incorporated into the Structure Based 
Focusing module in Cerius
2, whereas the second model is incorporated into the 
LigScore module in Cerius
2.  Both of these models, called Ludi-1 and Ludi-2 
respectively, were used to score the ligands in this study. 
 
2.5.2. LigScore 
LigScore is an empirical scoring function developed ‘in house’ at Accelrys, San 
Diego [2005JMGM395].  LigScore1 was developed against a set of 50 protein-
ligand complexes with known binding constants.  The functional form of 
LigScore1 is fairly simple and only contains three descriptors, as shown below: 
 
LigScore1 = C – β1[EvdW] + β2Cpos_tot – β3TotPol
2 
 
Where C, β1, β2 and β3 are constants obtained by a linear regression analysis.  
EvdW is the van der Waal energy between the ligand and protein atoms calculated 
using a Leonard-Jones Potential.  Cpos_tot is the total surface area of the ligand 
involved in attractive polar interactions with the protein.  The last descriptor, 
TotPol
2, is equal to Cpos_tot
2 + Cneg_tot
2, where Cneg is the total surface of the 
ligand involved in repulsive polar interactions with the protein.  Despite  the   54
success of LigScore1, it still failed to predict the binding of lysozyme protein – 
ligand complexes.  This led to the development of LigScore2 as illustrated below: 
 





The first two descriptors were the same in both scoring functions, but the last 
descriptor of LigScore1 was replaced by a new function.  SolvPlty_lig
2 represents 
the overall polar ligand surface that is buried inside the protein binding site, while 
SolvPlty_prot
2 accounts for the polar protein surface in contact with the docked 
ligand. 
The new LigScore2 function is able to predict the binding affinity of the 
troublesome lysozyme – ligand complex with which LigScore1 struggled.   
 
2.5.3. Jain 
The Jain scoring function is an empirical scoring function developed from 34 
known protein – ligand complexes [1996JCAMD427].  A. N. Jain used five 
different descriptors to evaluate each protein – ligand complex.  The descriptors 
are: 
1. Lipophilic  interactions; 
2.  Polar attractive interactions; 
3.  Polar repulsive interactions; 
4.  Solvation of the protein and ligand; 
5.  An entropy term for the ligand. 
 
The sum of these terms gives rise to the Jain score.  The scoring function also 
assesses if the ligand and protein overlap. Any overlap between ligand and 
protein will result in a high energy complex and, consequently, will be penalised 
by Jain.   
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2.5.4.  PMF (Potential of Mean Force) 
This scoring function is based on a statistical analysis using 3D structure 
databases to give a prediction of protein – ligand binding energy [1999JMC791].  
It is defined as the sum of the interaction energies of all of the protein – ligand 
atom pairs in the complex.  The PMF scoring function uses a potential based 
approach, rather than an empirical one.  
 
2.5.5.  PLP (Piecewise Linear Potential) 
PLP is a simple empirical scoring function that appears to produce results which 
correlate well with protein – ligand binding affinities [1995CB317].  There are two 
versions of the PLP scoring function, PLP1 and PLP2.  The first function, PLP1, 
assigns each atom a PLP type.  There are four atom types in PLP1: 
1.  Hydrogen bond donor (e.g. primary or secondary amines); 
2.  Hydrogen bond acceptor (e.g. oxygen or nitrogen atoms with no hydrogen 
atoms attached); 
3. Both hydrogen bond acceptor and donor (e.g. hydroxyl groups or 
crystallographic water); 
4. Non-polar  (e.g. carbon or sulfur atoms). 
 
Once each atom has been assigned a PLP type, the next step is to assign the 
interaction type.  There are two interaction types – hydrogen bond and steric, as 
shown in Table 2.  The PLP1 score is the sum of all of the pairwise interactions 
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Steric H-bond  H-bond Steric 
Acceptor 
(Protein) 
H-bond Steric  H-bond Steric 
Both 
(Protein) 
H-bond H-bond  H-bond  Steric 
Non-Polar 
(Protein) 
Steric Steric  Steric Steric 
 
Table 2.  Interaction types of PLP1 [1995CB317]. 
 
The second function, PLP2, is similar to PLP1, but, in addition, a PLP atomic 
radius is given to each atom set (except for hydrogen).  There are three classes 
of atomic radii: 
1. Small  (e.g. F); 
2. Medium  (e.g. C, O and N); 
3. Large  (e.g. S, Cl and Br). 
 
There are three types of PLP interaction in the PLP2 scoring function, as shown 
in Table 3.  The PLP2 score is the sum of all of the pairwise interactions between 
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Repulsion H-bond  H-bond  Dispersion 
Acceptor 
(Protein) 
H-bond Repulsion H-bond  Dispersion 
Both 
(Protein) 
H-bond H-bond H-bond  Dispersion 
Non-Polar 
(Protein) 
Dispersion Dispersion Dispersion Dispersion 
 
Table 3.  Interaction types of PLP2 [1999AMC292]. 
  
2.5.6.  Limitations of Scoring Functions 
The high-throughput screening of ligands in an active site can be divided into two 
major steps: docking and scoring.  Evaluating how well a ligand fits into an active 
site is known as the scoring problem.  While much significant progress has been 
made in the process of docking ligands, no scoring function is available that 
accurately predicts the binding affinity of a wide range of protein targets 
[2003JMC2287]. 
In a study by Krovat and Langer, a database of 1000 diverse drug-like 
compounds were docked into the active site of the aspartic protease renin, using 
the docking programme LigandFit [2004MI1123]. The database used in this study 
contained 10 known active renin inhibitors, all with IC50 values in the nano-molar 
range, and 990 randomly generated molecules with no known activity against 
renin.  All seven scoring functions used (LigScore 1, LigScore 2, Ludi, PMF, Jain, 
PLP1 and PLP2) were able to prioritize at least 50 % of the active compounds 
within the first 20 % (200 compounds) of the rest of the database [2004MI1123].  
The hit rate significantly increased when the scoring functions were used 
together. 
This study demonstrates that, while scoring functions are useful tools used to 
prioritize potential ligands, they cannot be used to predict accurately binding 
affinities of protein – ligand interactions.  Nevertheless, if these functions can   58
minimize the number of compounds submitted for biological testing, they 
potentially have an important role to play in the future of drug discovery. 
 
2.6. Filters   
The remainder of the compounds were filtered by the following criteria: 
Ludi Score 1  < 300 
Ludi Score 2  < 300 
LigScore 1  < 0 
LigScore 2  < 0 
Jain   <  0 
-PMF   <  20 
-PLP1   < 20 
-PLP2   < 20 
 
If a hit compound scored less than the above criteria in any of the scoring 
functions, they were rejected. There were a total of 60 compounds that passed 
the strict filtering criteria.  After this, 10 compounds were chosen to purchase for 
biological testing (Table 4).  These compounds were chosen from the final 60 












   59
Code LigScore1  Ligscore2  -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
NRB00073 3.790  2.790  39.560  31.200  4.370  36.420  510  600 
HTS05503 1.570  0.410 20.290  23.050  0.03  46.700  830 716 
RDP00060 3.320  5.610  84.120  77.490  2.180  87.740  539  440 
S05636 4.320  4.200  47.880  51.040  0.180  27.760  399  412 
BTB07615 2.410  0.660 27.260  21.940  3.170  41.630  611 608 
KM08040 4.530  4.750 52.640  41.820  2.180  33.530  601 722 
HTS02422 2.430  0.690 47.250  44.930  1.980  69.230  615 635 
KM06447 4.750  3.800 59.440  57.580  1.570  27.590  435 400 
BTB03744 2.580  0.410 30.420  50.680  2.490  55.830  523 502 
BTB12478 4.790  4.640 36.090  36.790  3.170  48.490  548 621 
 
Table 4:  The ten compounds bought for biological testing and the values obtained from the 
seven scoring functions used to evaluate the ligand – protein interaction.  A high scoring function 
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2.7. Biological  Evaluation of Hits 
2.7.1. Thioredoxin/Thioredoxin  Reductase Insulin Reduction Assay 
The hit compounds were first subjected to the Trx/TrxR insulin reduction assay, 
as previously discussed in section 1.8.1.  An initial preliminary screen using two 
concentrations of hit compound was performed.  If any compound showed 
inhibitory activity in the initial screen, further tests were carried out at varying 
concentrations to generate a dose response curve, from which IC50 values were 
calculated using the programme GraphPad Prism
®. 
Plates were incubated for 30 minutes at 37°C in HEPES/EDTA buffer containing 
1 mM NADPH, 1 μM TrxR, 0.8 μM Trx, 2.5 mg/mL insulin and two (test) drug 
concentrations.  After this time, the reaction was stopped by adding a buffer 
containing 6 M guanidine-HCl, 50 mM tris (pH 8) and 10 mM DTNB.  The 
reduction of insulin was measured at an increase in absorbance at 412 nm using 
a spectrophotometer.  Each test was done in triplicate. 
Percentage activity for the drug solutions were calculated using the following 
formula: 
 
Percentage Activity = [(Absorbance (drug) – Absorbance (blank)) / (Positive 
Control – Absorbance (blank)] × 100 
 
Where; 
Absorbance (drug) was the mean absorbance of the wells containing, drug 
solution, Trx, TrxR, NADPH and insulin. 
Absorbance (blank) was the negative control in the assay.  There were three 
negative controls; 
  Wells containing Trx, TrxR and insulin: no NADPH;  
  Wells containing NADPH, insulin: no Trx and TrxR; 
  Wells containing NADPH, Trx and TrxR: no insulin. 
 
Positive Control was the mean absorbance of wells containing Trx, TrxR, NADPH 
and insulin (no drug solution).   62




Percentage Inhibition    
 (250 μM) 
Percentage Inhibition     
(1 mM) 
NRB00073 0.0  0.0 
HTS05503 0.0  0.0 
RDP00060 14.3  54.7 
S05636 0.0  0.0 
BTB07615 0.0  0.0 
KM08040 0.0  0.0 
HTS02422 0.0  0.0 
KM06447 0.0  0.0 
BTB03744 0.0  0.0 
BTB12478 0.0  0.0 
 
Table 5.  A table showing the percentage activity of the Trx/TrxR system for the ten compounds 
tested.  The compounds were tested at two concentrations, 250 μM and 1 mM. 
 
From Table 5, it can be seen that one hit compound, RDP00060, had modest 
inhibitory activity towards the thioredoxin enzyme system.  This compound was 
then tested further at varying concentrations to construct a dose response curve 
as shown in Figure 18. 
The IC50 value of RDP00060 was calculated to be 1.4 mM from the dose 
response curve, suggesting that RDP00060 has very low inhibitory activity 
towards the thioredoxin enzyme system.  From the initial screen, 54.7 percent 
inhibition of the enzyme system was achieved using 1 mM of RDP00060.   
Consequently, it was presumed that the IC50 of RDP00060 would be less than 1 
mM; however, this was not the case, with RDP00060 having a calculated IC50 of 
1.4 mM.  It was presumed that this variation was due to experimental error.  Even 
though the inhibitory activity was weak, it was clearly observed, illustrating that 
the SBF process had been successful.  This result allowed a move away from 
the ten hit compounds generated by SBF to focus on RDP00060, which 
subsequently became the lead compound.    63
Trx / TrxR, Insulin Reduction Assay for RDP00060










































Figure 18.  The dose response curve of absorbance as a percentage of the control against log 
concentration for RDP00060.   
 
2.7.2. MTT  Assay 
The hit compounds were next subjected to the MTT assay, which is a crude, but 
simple, way to measure cell proliferation.  Since psoriasis is a disorder of 
keratinocyte proliferation, any compound showing antiproliferative properties may 
have a role to play in the treatment of psoriasis.  Furthermore, it has been shown 
that inhibiting TrxR can induce cellular apoptosis in cell lines, demonstrating that 
TrxR inhibitors have antiproliferative properties [2007MI759].  It is important to 
note that the MTT assay is not a specific assay to determine activity towards the 
thioredoxin system, but a general assay to determine if a compound shows 
antiproliferative activity. 
Human papilloma virus-16 (HPV-16) immortalized keratinocytes were used as 
the cell line in the MTT assay. 
 
The percentage growth of cells was calculated by the following formula; 
 
Percentage Growth = [(Compound – Blank) / (Positive Control – Blank] × 100   64
Where: 
•  Compound was the mean absorbance of the wells containing drug, cells 
and medium; 
•  Blank was the mean absorbance of the wells containing medium (no cells 
or drug); 
•  Positive Control was the absorbance of the wells containing cells and 
medium (no drug). 
 
The results were plotted using GraphPad Prism.  A plot of percentage growth 
against logarithmic molar concentration was made and, from this, GI50 values 
were determined.  The results are summarized in Table 6. 
 
Compound Reference Number  Antiproliferative Activity (GI50) μM 
NRB00073 >  678.0 
HTS05503 >  550.5 
RDP00060 4.1 
S05636 >  776.1 
BTB07615 >  505.6 
KM08040 >  592.2 
HTS02422 >  448.1 
KM06447 >  562.6 
BTB03744 18.0 
BTB12478 >  979.5 
 
Table 6.  GI50 values of the ten compounds tested for antiproliferative activity 
 
It is useful to compare the GI50 values of the tested compounds with compounds 
of known antipsoriatic activity.  Methotrexate and dithranol are both used to treat 
psoriasis; they have GI50 values of 204.9 μM and 0.6 μM, respectively (values 
were kindly provided by Stiefel Laboratories Ltd. from MTT assays on HPV-16 
cell lines).  This suggests that any compound with a GI50 value below 200 μM 
may have potential for use in the treatment of psoriasis.    65
Two compounds, BTB03744 and RDP00060, showed potent activity with GI50 
values of 18.0 and 4.1 μM, respectively (Figure 19).  In particular, RDP00060 
showed results comparable to dithranol on the MTT assay.  This is an interesting 
observation as RDP00060 also showed modest inhibitory activity towards the 
thioredoxin system.  It is probable that TrxR inhibition would have antiproliferative 
effects, due to the disruption and consequent activation of the ASK1 – Trx 
complex.  However, no conclusions can be drawn on whether RDP00060 was 
acting on the Trx system without further testing; it was considered that 
RDP00060 was acting on another target within the cell.   
 
A Dose Response Curve of RDP00060 against Percentage Growth
of Human Keratinocytes






























         
A Dose Response Curve of BTB03744 against Percentage Growth
of Human Keratinocytes



































Figure 19.  Dose response curves of percentage growth vs. log concentration for compounds 
BTB03744 and RDP00060. 
 
It was interesting to note that BTB03744 was also active on the MTT assay 
despite having no detectable activity towards the Trx system; it is possible that 
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3.  Design and Synthesis of Lead Compound and Derivatives 
 
3.1.  Synthesis of RDP00060 
3.1.1. Retrosynthetic  Analysis 
Retrosynthetic analysis is a strategy introduced by E. J. Corey that is used for 
problem solving when planning organic synthesis [1988CSR111].  This is 
achieved by starting with the product and working backwards until suitable 
starting materials are reached.  At this point, a synthetic route can be planned 
based on suitable starting materials, preferably commercially available materials, 
and employing established chemical procedures.  
Retrosynthesis uses synthons to illustrate possible starting materials.  Synthons 
themselves are not starting materials, but are imaginary species required to 
effect a particular reaction.  Synthetic equivalents are real, commercially 
available forms of synthons.  The synthetic equivalents are then used in the final 
synthesis.  This technique was applied to designing a synthesis for RDP00060 













































Scheme 1.  Retrosynthetic analysis of RDP00060 and the corresponding synthetic equivalents 
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The first step in the synthesis was to prepare the methyl ester from the 
corresponding 3,4-diaminobenzoic acid (9) as shown by Scheme 2.  The ester 













Scheme 2.  Synthesis of methyl 3,4-diaminobenzoate (10).  Reagents and conditions: (a) dry 
methanol, conc. H2SO4, reflux, 18 h, 76 %. 
 
RDP00060 (12) was then prepared by reacting methyl 3,4-diaminobenzoate (10) 















































Scheme 3.  Synthesis of RDP00060 (12).  Reagents and conditions: (a) dry acetonitrile, pyridine, 
reflux, 72 h, 50 % yield; (b) dry acetonitrile, pyridine, DMAP, reflux, 72 h, 57 %; (c) dry acetonitrile, 
pyridine, 4-pyrrolidinopyridine, reflux, 72 h, 63 %. 
 
This reaction was not very efficient; RDP00060 (12) was obtained in low yield, 
thus the conditions were modified in order to try and increase the yield.  The 
1H 
NMR spectrum for RDP00060 (12) presented a doublet at δ 7.67, integrating to 2   69
protons and a multiplet at δ 7.57, integrating to 3 protons.  Both of these peaks 
couple to a doublet at δ 7.36, integrating to four protons, through the HH COSY 
spectrum. Additional coupling was also observed between the multiplet at δ 7.57 
and a doublet of doublets at δ 7.62.  As a result of this, the doublet at δ 7.67 was 
assigned to the protons at positions H2' / H6' or H2'' / H6'', the multiplet at δ 7.57 
was assigned to protons at positions H2' / H6' or H2'' / H6'' and H2, while the 
doublet at δ 7.36, was assigned to the protons at positions H3’ / H5’ and H3’’ / H5’’.  
The 
1H NMR spectrum (12) also revealed two overlapping singlets at δ 2.36 and 
at  δ 2.35 which were assigned to the two tosyl methyl groups present in 
RDP00060 (12).  The IR spectrum of RDP00060 (12) confirmed the presence of 
an S=O functionality with an absorption at 1157 cm
-1. 
 
3.1.2. Acylation  Catalysts 
Pyridine (13) is often employed as a catalyst in acylation reactions, but, when 
pyridine  (13) fails, other aminopyridines are often used, for example, 4-
dimethylaminopyridine (DMAP) (14) and 4-pyrrolidinopyridine (15) (Figure 20). 




(13) (14) (15)  
 
Figure 20.  Acylation catalysts: pyridine (13); 4-dimethylaminopyridine (14); 4-pyrrolidinopyridine 
(15). 
 
4-Pyrrolidinopyridine  (15) is the most efficient acylation catalyst of the 
aminopyridines, closely followed by 4-dimethylaminopyridine (DMAP) (14) 
[1978T2069].  The highest yield of RDP00060 (12) was obtained when 5 
equivalents of pyridine (13) were combined with 1 equivalent of 4-
pyrrolidinopyridine (15).    70
A mechanism for the formation of RDP00060 (12) is suggested in Figure 21 – in 
which the catalyst forms an intermediate with p-toluenesulfonyl chloride (11), 
which then reacts with methyl 3,4-diaminobenzoate (10).  The stability of the acyl 
pyridinium intermediate plays an important role in the efficiency of the 










































Figure 21.  A suggested mechanism for the formation of RDP00060 (12), using 4-
pyrrolidinopyridine (15) as catalyst. 
 
3.1.3.  Steric Hindrance  
The reaction between methyl 3,4-diaminobenzoate (10) and p-toluenesulfonyl 
chloride (11) is extremely rapid, with a new spot being visible by TLC analysis 
almost immediately.  This spot was isolated by column chromatography and 
analysed by 
1H NMR which suggested that the isolated product was a mixture of 
two monosubstituted products (Figure 22).   



















Figure 22. The proposed structures of the monosubstituted products isolated in the formation of 
RDP00060 (12). 
 
This result suggested that due to the relatively large steric demands of the p-
toluene sulfonamide groups, it was not going to be possible to improve the yield 
of the 3,4-derivative, therefore efforts were focused on the preparation of methyl 
3,5-diamino-N,N-bis-(toluene-4-sulfonylamino)benzoate (18) – a compound with 















































Scheme 4.  The formation of methyl 3,5-diamino-N,N-bis-(toluene-4-sulfonylamino)benzoate (18).  
Reagents and conditions: (a) dry methanol, conc. H2SO4, reflux, 18 h, 70 %; (b) dry acetonitrile, 
pyridine, reflux, 24 h, 75 %.   72
The 3,5-derivative (18) was prepared in a similar manner to RDP00060 (12).  
The yield of the 3,5-derivative (18) was significantly greater than the yield of 
RDP00060  (12), supporting the role of steric hindrance in the synthesis of 
RDP00060 (12).   
Interestingly, when 4-pyrrolidinopyridine (15) was used as the acylation catalyst, 
a trisubstituted product was isolated (Figure 23).  This was not observed in the 
formation of RDP00060 (12), in which 4-pyrrolidinopyridine (15) was also 
employed. 
The 
1H NMR spectrum for (18) presented a doublet at δ 7.50 (J = 8.3) and at δ 
7.23 (J = 8.3); each doublet integrated to 4 protons.  These peaks couple through 
the HH COSY spectrum and were consequently assigned to the tosyl protons at 
positions H2' / H6' and H3' / H5' respectively.  The 
1H NMR spectrum for (18) also 
presented a triplet at δ 7.30 (J = 2.1), integrating to one proton, and a doublet at 
δ 7.21 (J = 2.1), integrating to two protons.  These peaks also couple through the 
HH COSY spectrum and were assigned to the protons at positions H4 and H2 / H6 
respectively.  The IR spectrum of (18) confirmed the presence of an S=O 





















Figure 23.  The proposed structure of the trisubstituted product isolated in the formation of methyl 
3,5-diamino-N,N-bis-(toluene-4-sulfonylamino)benzoate (18) when using 4-pyrrolidinopyridine (15) 
as the acylation catalyst. 
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3.2.  The 3,4- and 3,5- Analogues (19a – 20e) 
3.2.1. Rationale 
In an attempt to increase activity against TrxR, a number of possible analogues 
of RDP00060 (12) were screened and modelled in silico.  The derivatives were 
designed to exploit further hydrogen bonding potential in the active site of TrxR.  
It was anticipated that increasing the activity of RDP00060 (12) towards TrxR 
would also increase the activity in the MTT assay.  Alteration of the electronic 
effects of the lead compound, which is often exploited when using the QSAR 
approach to drug design [B2001MI], was achieved using a number of different 
sulfonyl chlorides, all available commercially.  Since the synthesis of the lead 
compound had already been achieved and optimized, the preparation of a wide 
range of analogues was facilitated.  In addition to changing the electronics of the 
lead compound, the sulfonamide units were also varied from the 3,4- position to 
the 3,5- position.  It was anticipated that changing the electronic properties and 
the position of the sulfonamide units could allow the exploitation of further 
hydrogen bonding potential within the active site of TrxR, as suggested by the 
preliminary docking and scoring studies. 
 
3.2.2.  Synthesis of the 3,4- and 3,5- Analogues (19a – 20e) 
The 3,4-derivatives were prepared using the same methodology employed to 






























(10) (19)  
 
Scheme 5.  The synthesis of various 3,4-derivatives of RDP00060 (12). R = NO2 (19a); CF3 
(19b); OCF3 (19c); OCH3 (19d).  Reagents and conditions: (a) pyridine, pyrrolidinopyridine, dry 
acetonitrile, reflux, 24 hours, 61 – 86 %. 
 
The nature and position of R greatly influenced the reactivity of the sulfonyl 
chloride, which directly affected the yield of product.  For example, a better yield 
was obtained using 4-nitrobenzenesulfonyl chloride than with 4-
methoxybenzenesulfonyl chloride, which can be explained by examining the 
electronics of the different systems.  4-Nitrobenzenesulfonyl chloride is a very 
reactive sulfonyl chloride because of the strong electron withdrawing nitro group 
para to the sulfonyl group.  This increases the electrophilicity of the sulfur atom 
and leads to increased susceptibility to nucleophilic attack, thereby increasing its 
reactivity. 
Similarly, 4-trifluoromethylbenzenesulfonyl chloride is very electrophilic because 
of the electron withdrawing effect of the trifluoromethyl group.  While the nitro 
group acts by electron conjugation and inductive withdrawl, the trifluoromethyl 
group only withdraws electron density by induction and has less effect upon the 
sulfonyl group.  A consequence of this is that the sulfur of 4-nitrobenzenesulfonyl 
chloride is more electrophilic than the corrresponding 4-
trifluoromethylbenzenesulfonyl chloride, and hence, more reactive.    
In contrast, 4-methoxybenzenesulfonyl chloride bears an electron donating group, 
which decreases the electrophilicity of the sulfur atom; the sulfur atom is less 
susceptible to nucleophilic attack and is therefore less reactive.     75
This pattern can be observed when examining the yields of the products (19a-
19d) (Table 7). 
Also synthesized were the 3,5-disubstituted analogues, in which the sulfonamide 



























Scheme 6.  The synthesis of various 3, 5-RDP derivatives. R = NO2 (20a), CF3 (20b), OCF3 (20c), 
OCH3 (20d).  Reagents and conditions: (a) pyridine, dry acetonitrile, reflux, 24 hours, 69 – 94 %. 
 
This series of compounds was prepared using the same sulfonyl chlorides as 
were used to prepare the 3,4-derivatives.  Interestingly, these compounds were 
easier to prepare than the corresponding 3,4-derivatives and the yields obtained 
were always higher (Table 7).  Furthermore, the conditions required to prepare 
these compounds were different to those required for the 3,4-derivatives; pyridine 
(13) alone was an adequate acylation catalyst when preparing the 3,5-analogues.  
If the same conditions were employed as for the 3,4-derivatives, i.e. mixed 
catalysts, the trisubstituted sulfonamides were isolated, suggesting that steric, as 
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Substituent on  
Sulfonyl Chloride 






NO2  Electron Withdrawing (- M / - I) 
 
86 % (19a) 94  %  (20a) 
CF3  Electron Withdrawing (- I) 
 
77 % (19b) 93  %  (20b) 
OCF3  Electron Withdrawing (- I / + M) 
 
76 % (19c) 78  %  (20c) 
OCH3  Electron Donating (+ M / - I) 
 
61 % (19d) 69  %  (20d) 
 
Table 7.  The yield of 3,4- and 3,5-substituted bis-sulfonamides when synthesized using different 
sulfonyl chlorides.   
 
In an attempt to exploit further electronic changes to the lead compound, the two 
electron withdrawing nitro groups on the 3,4-derivatives and their 3,5-analogues 
were reduced to the corresponding amines using catalytic hydrogenation, with 

























































(20a) (20e)  
 
Scheme 7. The reduction of (19a) and (20a) to the corresponding amines.  Reagents and 
conditions: (a) H2, 10 % Pd/C, methanol, ethyl acetate, rt, 6 hours, 95 – 96 %. 
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The 3,4- and 3,5-analogues differed in their electronic properties by the nature of 
the substituent in the 4' position (Figure 24), which in turn changed the 
characteristics of the NMR spectra depending on the substituent.  For example, 
when the substituent was a nitro group, the carbon at the 4' position was 
deshielded, as were the protons in the 3' and 5' positions.  The effect of the R 
group on the 
13C NMR and 
1H NMR spectra of the 3,5-analogues is shown in 




































Figure 24.  A 3,5-disubstituted bis-sulfonamide with substituent R in the 4' position.  
 
Compound R  group  C4' 
13C (ppm)  H3' / H5' 
1H (ppm) 
(20a)  NO2 150.5 8.37 
(20b)  CF3 133.4 7.91 
(20c)  OCF3 151.7  7.52 
(20d)  OCH3 163.1  7.05 
(20e)  NH2 153.4 6.53 
  
Table 8.  The effects of R on the chemical shift of C4' and H3' and H5' in the 
13C and 
1H NMR 
spectra for the 3,5- analogues.   
 
In addition to the 
13C electronic effects of the R group, coupling between carbon 
and fluorine was observed in the spectra of (19b), (19c), (20b) and (20c).  In the 
example of (19b), coupling was seen through three bonds, as illustrated by 
Figures 25a, 25b, and 25c. 
 
 

















































































































































































































Figure 25a.   An expansion of the 75 MHz 
13C NMR spectrum of (19b) showing one bond (
1J) 
coupling between fluorine and carbon.  Two overlapping quartets were observed centred at 123.8 
ppm, with the peaks apparent at 129.3 ppm, 125.7 ppm, 125.6 ppm, 122.0 ppm, 122.0 ppm and 
118.4 ppm; JFC = 273.1 Hz.  It is interesting to note that the two trifluoromethyl groups of (19b) 
are slightly different, so there are two very similar quartets observed.   
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Figure 25b.   An expansion of the 75 MHz 
13C NMR spectrum of (19b) showing two bond (
2J) 
coupling between fluorine and carbon.  Two overlapping quartets were observed centred at 133.5 
ppm and 133.4 ppm, with the peaks apparent at 134.1 ppm, 134.1 ppm, 133.7 ppm, 133.6 ppm, 
133.3 ppm, 133.2 ppm, 132.8 ppm and 132.8 ppm corresponding to C4' and C4''; JFC4' = 32.4 Hz.  
It is interesting to note that to C4' and C4'' of (19b) are slightly different, so two very similar 
quartets are observed.   
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Figure 25c.   An expansion of the 75 MHz 
13C NMR spectrum of (19b) showing three bond (
3J) 
coupling between fluorine and carbon.  A quartet is observed centred at 127.1 ppm with peaks 
apparent at 127.2 ppm, 127.15 ppm, 127.1 ppm and 127.05 ppm corresponding to C3', C5', C3'' 
and C5''; J = 3.7 Hz.     
 
3.2.3.  Molecular modelling of 3,4- and 3,5- Analogues (18 – 20e) 
The two sets of derivatives were evaluated using the docking programme 
LigandFit within Cerius
2 (Accelrys, San Diego).  A conformational search, using a 
Monte Carlo algorithm, was performed on each derivative as it was docked into 
the active site of TrxR.  The docked pose was then assessed using a ligand 
scoring programme called Ligand Score.  This was the same scoring panel 
previously used to help identify the lead compound, RDP00060 (12).  
The ligand scoring panel contains many scoring functions, all of which evaluate 
the interaction between the docked ligand and the protein.  Scoring functions 
generally assess non-bonding interactions, such as lipophilic interactions and 
hydrogen bonds, although each function uses different parameters to calculate a 
score.  Unfortunately, scoring functions are unable to provide direct information 
on the biological activity of a ligand.   
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Table 9 shows the results from the ligand scoring panel when assessing the non-
bonding interactions between each derivative of RDP00060 (12), (18), (19a – e) 
and (20a – e) and TrxR.   
 
Derivative LigScore1  Ligscore2  -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
RDP00060 
(12) 
3.320 5.610  84.120  77.490 2.180 87.740  539  440 
(18)  3.060 5.598  78.290  75.528 1.759 90.783  478  443 
 (19a)  3.560 6.120  87.090  72.970 6.780 113.580  454  400 
 (19b)  3.690 6.100  89.480  74.430 1.110 75.660  453  430 
 (19c)   3.320 6.130  78.860  72.450 2.460 97.030  540  470 
(19d)  4.490 6.380  72.500  63.030 1.510 86.800  564  471 
(19e)  3.130 5.710  91.520  83.150 3.310 109.480  520  437 
(20a)  4.790 6.310  90.440  79.800 2.160 108.100  522  448 
(20b)  4.290 6.680  80.160  73.520 1.540 83.510  462  449 
(20c)  3.930 5.840  76.550  70.460 2.510 95.180  577  501 
(20d)  4.780 6.280  87.660  76.270 1.810 103.450  575  450 
(20e)  3.310 5.630  82.820  82.160 3.770 112.200  594  461 
 
Table 9.   The values obtained from eight scoring functions used to evaluate the ligand – protein 
interaction.  A high scoring function indicates that there is a good interaction between the ligand – 
protein complex. 
 
Most of the ligands scored more favorably than the lead compound, which was 
particulary evident with LigScore1 and LigScore2 scoring functions, suggesting 
increased activity towards TrxR.  The high scoring functions may indicate that the 
non-bonding interactions between each derivative and TrxR are more efficient 
than that to the lead compound.  However, each derivative has more potential to 
hydrogen bond with the active site of TrxR, due to the nature of the substituent 
on the two sulfonamide rings.  This is illustrated by examining (19a) docked in 
the active site of TrxR (Figure 26).  From the docked ligand, it can be observed 
that  (19a) can potentially form two hydrogen bonds with residues from TrxR, 
whereas there is no measurable hydrogen bonding from the lead compound to   82
TrxR.  It was anticipated that the extra hydrogen bonds would help ‘lock’ the 




Figure 26.  Hydrogen bonding between the 3,4-nitro compound (19a) and valine and isoleucine 
residues of TrxR.  The green lines represent hydrogen bonding. 
 
3.2.4. Biological  Evaluation of 3,4- and 3,5- Analogues (19a – 20e) 
The derivatives were first evaluated for inhibitory activity towards the thioredoxin 
system using the established insulin reduction assay [2003MI1695].  A 
preliminary screen was carried out using 500 μM concentrations of each 
compound.  The most active compounds from the preliminary screen were then 
tested at further lower concentrations to establish a dose response curve, from 
which the IC50 values could be calculated (Table 10). 
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Derivative  X  Percentage inhibition at 500 μM IC50 (μM) 
(18)  CH3 23.7  Not  determined 
(19a)  NO2 53.3  475 
(19b)  CF3 33.4  429 
(19c)  OCF3 43.7  546 
(19d)  OCH3 14.6  Not  determined 
(19e)  NH2 86.7  386 
(20a)  NO2 31.0  Not  determined 
(20b)  CF3 28.0  Not  determined 
(20c)  OCF3 13.0  Not  determined 
(20d) 
 
OCH3 9.5  Not  determined 

































Table 10.   Percentage inhibition of the Trx/TrxR system for the compounds tested at 500 μM.  
The most active compounds were then tested further to establish IC50 values.   
 
From the initial screen, (19a), (19b), (19c), (19e) and (20e) were selected for 
further testing.  These compounds were then tested at varying concentrations to 
generate dose response curves. 
The dose response curves were plotted using GraphPad Prism
®.  The 
absorbance, as a percentage of the control, was plotted against the logarithmic 
molar concentration and, from this, the IC50 values were determined (Figure 27). 
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Trx, TrxR, Insulin Reduction Assay for (19a)


































Trx, TrxR, Insulin Reduction Assay for (19b)









































Trx, TrxR, Insulin Reduction Assay for (19c)


































Trx, TrxR, Insulin Reduction Assay for (19e)










































Figure 27.  Dose response curves of absorbance as a percentage of the control against log 
concentration for compounds (19a), (19b), (19c) and (19e). 
 
The derivatives were then subjected to an MTT assay using a HPV-16 
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Derivative X  Antiproliferative  Activity  (GI50) μM 
(18)  CH3 5.0 
(19a)  NO2 11.2 
(19b)  CF3 5.4 
(19c)  OCF3 2.2 
(19d)  OCH3 5.2 
(19e)  NH2 >  420.1 
(20a)  NO2 22.9 
(20b)  CF3 6.7   






































Table 11.  GI50 values of the ten compounds tested on a HPV-16 immortalized keratinocyte cell 
line using an MTT assay. 
 
Examining the results of the two assays allows identification of one clear 
structure activity relationship: the 3,4-derivatives are more active on MTT and 
against TrxR than the corresponding 3,5-derivatives.  This result is quite 
surprising, as the 3,5-derivatives generally outscored the corresponding 3,4-
derivatives using the ligand scoring panel in Ligand Score.  This illustrates that, 
while scoring functions are useful to help identify lead compounds, they are still 
unable to predict accurately biological activity of ligands.  However, the scoring   86
functions correctly predicted that the derivatives would bind more favourably into 
the active site of TrxR when compared to the lead compound, RDP00060 (12). 
Hydrogen bonding may explain the results of increased inhibitory activity 
obtained in the Trx insulin reduction assay.  The lead compound, RDP00060 (12), 
only had modest activity on this assay with an IC50 of 1.4 mM, while the 3,4-nitro 
(19a), -trifluoromethyl (19b) and -trifluoromethoxy (19c) derivatives had an 
increase in activity compared to the lead.  By replacing the two methyl groups on 
the lead compound with nitro, trifluoromethyl and trifluoromethoxy groups, the 
potential non-bonding interactions of each compound have been increased.   
Measurement of the hydrogen bonding between the lead compound and TrxR 
using InsightII (Accelrys, San Diego) indicated that there was no hydrogen 
bonding between the ligand and the protein.  However, hydrogen bonding 
between the 3,4-nitro derivative (19a) and TrxR is clearly visible between the 
nitro group (in the sulfonamide unit para to the methyl ester) and residues from 
TrxR.  There are two hydrogen bonds, one to a valine and the other to an 
isoleucine residue (Figure 26) which could aid the binding of the ligand within the 
active site of TrxR and may help explain why the IC50 value of the 3,4-nitro 
derivative (19a) was considerably lower than the IC50 value of the lead compound, 
RDP00060 (12). 
Surprisingly, the compounds with the highest activity against TrxR did not 
necessarily have the highest activity in the MTT assay.  For example, the 3,4-
aniline compound (19e) had an IC50 value of 386 μM against TrxR, but showed 
no detectable activity on the MTT assay.  In comparison to the lead compound, 
RDP00060 (12), the IC50 of (19e) has been increased by a factor of five.  In 
contrast, the 3,4-trifluoromethoxy compound (19c) had an IC50 of 542 μM and a 
GI50 value of 2.2 μM against TrxR and HPV-16 immortalised keratinocyte 
proliferation, respectively.  Again, in comparison to the lead compound, 
RDP00060  (12), the activity towards TrxR has been increased by a factor of 
three and the activity on MTT has been increased by a factor of around two.   
The nature of the substituent on the two sulfonamide rings could help to explain 
these results.  The MTT assay is carried out on a HPV-16 immortalized   87
keratinocyte cell line, while the Trx insulin reduction assay is carried out directly 
on the enzyme system.   
In order for the compounds to have their desired response in the MTT assay, 
they must first cross the cellular membrane.  In the Trx insulin reduction assay, 
the compounds can act directly on the enzyme, as there are no cell membranes 
to cross.  If the compounds are hydrophilic, such as the two aniline derivatives, 
crossing the cell membrane will be a problem.  If, however, the compounds are 
lipophilic, such as the trifluoromethyl and trifluoromethoxy derivatives, crossing 
the cell membrane will be a less significant problem.  It is possible that the 
lipophilicity of a compound may directly influence the results in the MTT assay.  
This subject has been reviewed extensively and helps form the basis for the rule 
of five as outlined by Lipinski [2001ADDR3]. 
In an attempt to substantiate this observation, the log P values of the 3,4-
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Derivative X  CLog  P  Gi50 
RDP00060 (12)  CH3 4.4  4.2 
(19a)  NO2 3.9 11.2 
(19b)  CF3 6.0 5.4 
(19c)  OCF3 6.0  2.2 
(19d)  OCH3 3.8  5.2 

















Table 12. Calculated LogP values of compounds (19a-e), using ChemDraw compared with GI50 
values obtained from the MTT assay on HPV-16 immortalized keratinocyte cell line. 
 
Table 12 shows that the most active compound on MTT, (19c), has the highest 
CLog P value, whereas (19e), the least active compound, has the lowest CLog P.  
This suggests that the lipophilicity of a compound can directly influence the result 
on the MTT assay.    This is also further evidence to support the fact that the 




Bioisosterism is a strategy used in medicinal chemistry in which a functional 
group of a lead compound is replaced with another functional group with similar 
biological properties.  The use of bioisosterism in the pharmaceutical industry 
has contributed to the significant growth of ‘me-too’ drugs in many therapeutic 
areas.  There are many reasons to use bioisosterism, including the need to 
increase pharmalogical activity, optimise pharmacokinetics, or reduce side   89
effects of a lead compound.  A recent example of a bioisosteric replacement is in 
the development of Losartan, an angiotensin II receptor antagonist marketed by 
Merck Sharp and Dohme (Figure 28).  In this example, replacement of a 
carboxylic acid moiety with a tetrazole resulted in an increase in oral activity by a 
factor of around fourteen [2005MI23], presumably due to the increase in logP 
value, from 1.2 for the carboxylic acid to 4.5 for the tetrazole, which would have 
increased absorption after oral administration and, hence, increased 
bioavailability.  











Figure 28.  The structure of Losartan illustrating the bioisosteric tetrazole group. 
 
The lead compound, RDP00060 (12), has several functionalities that can be 
altered by   bioisosterism.  The first group, a methyl ester, is problematic because 
it is prone to hydrolysis in vivo.  1,2,4-Oxadiazoles make excellent bioisosteric 
replacements for esters [2005CMC23] and are also metabolically stable to 
esterases.  To evaluate whether the methyl ester of RDP00060 (12)  could be 
replaced with a 1,2,4-oxadiazole, the corresponding analogue could be 
synthesized.  
The sulfonamide moieties of RDP00060 (12) can also be replaced by bioisosteric 
groups.  Sulfonamides were first used in medicine as antibacterial drugs and 
have been very successful.  Sulfamethoxazole is an example of one antibacterial 
sulfonamide currently on the market.  Sulfamethoxazole is active towards 
Staphylococcus aureus and is commonly used for the treatment of acute urinary   90
tract infections.  However, the problem with sulfonamide drugs is that patients 
can become allergic to them, particularly if they are used in high doses.     
Furthermore, they can also cause serious side effects, for example, blood 
dyscrasias or hypersensitivity disorders, such as Steven Johnson Syndrome 
[B1996MI].  Amides have been shown to be excellent bioisosteric replacements 
for sulfonamides and lack the hypersensitivity problems associated with 
sulfonamides [2005MI23]. 
The last part of RDP00060 (12) to be subjected to bioisosteric replacement were 
the two benzene rings attached to the sulfonamide units.  These groups were 
replaced by thiophene, a classic bioisostere equivalent to benzene [2005MI23].  
 
3.3.2. Synthesis 
3.3.2.1.  1,2,4-Oxadiazole Bioisostere (21d)    
The 1,2,4-oxadiazole was prepared according to Scheme 7. 















































































Scheme 7.  The formation of the 1,2,4-oxadiazole (21d). Reagents and conditions: (a) pyridine 
(13), pyrrolidinopyridine (15), dry acetonitrile, reflux, 24 hours, 85 %; (b) hydroxylamine, ethanol, 
reflux, 12 hours, 94 %; (c) isobutyric acid, CDI, DMF, reflux, 18 hours, 82 %. 
 
The first part of the synthesis, the preparation of the nitrile bis-sulfonamide (21b), 
was carried out according to previous methodology.  The presence of the nitrile 
functionality was confirmed by the presence of a sharp peak at 2233 cm
-1 in the 
IR spectrum, which is indicative of a nitrile functionality.  
The nitrile bis-sulfonamide (21b) allowed the preparation of hydroxyamidine (21c) 
by heating the nitrile with hydroxylamine in ethanol (Scheme 7).  The IR 
spectrum of (21c) lacked the indicative peak for a nitrile at 2233 cm
-1.   92
The proton NMR spectrum of the hydroxyamidine (21c) was unusual as it 
showed six peaks for the three protons in the central ring (Figure 29) due to the 
presence of tautomers, as shown in Figure 30.  It was considered that rotomers 
could account for the unusual proton NMR of the hydroxyamidine (21c); however, 
running the proton NMR at higher temperatures did not change the proton NMR 
spectrum of the hydroxyamidine (21c).  If the unusual characteristics of the 
proton NMR spectrum were a consequence of rotomers it would be expected that 
running the proton NMR at higher temperatures would cause the two equivalent 
peaks to converge.  This lends support to the theory that tautomerism accounts 
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Figure 29.  An expansion of the 300 MHz proton NMR spectrum of the hydroxyamidine (21c) 
showing the two tautomeric forms.  The two doublets resonating at δ 6.97 and δ 6.89 correspond 
to H5, the two doublets of doublets resonating at δ 7.35 and δ 7.15 correspond to H6, while the 
doublet resonating at δ 7.44 corresponds to H2.  The other doublet of H2 is masked under the 
aromatic peaks of the tosyl protons at δ 7.46.  
































Figure 30. The two tautomeric forms of the hydroxyamidine (21c). 
 
Activation of isobutyric acid with CDI and then addition of the hydroxyamidine 
(21c), resulted in the formation of the corresponding 1,2,4-oxadiazole  (21d) 
(Scheme 7).   
The 
1H NMR spectrum of (21d) showed a septet integrating to one proton and a 
doublet integrating to six protons, indicative of an isopropyl group, as present in 
(21d).  Also present in the 
13C NMR spectrum were two peaks resonating 
downfield at δ 184.2 and 166.8, which were assigned to carbons 5 and 3 in the 
1,2,4-oxadiazole, respectively.  This is indicative of an 1,2,4-oxadiazole system 
[B2004MIb], as the carbons at 3''' and 5''' are deshielded due to the effects of the 
adjacent electronegative oxygen and nitrogen atoms. 
 
3.3.2.2.  Amide Bioisostere (23) 
The two sulfonamide units of RDP00060 (12) were replaced by amides according 
to Scheme 8.  The synthesis was similar to the preparation of the lead compound, 
but p-toluoyl chloride was used instead of p-toluenesulfonyl chloride. 
 
 


















(10) (22) (23)  
 
Scheme 8.  The formation of amide (23). Reagents and conditions; (a) pyridine (13), dry 
acetonitrile, reflux, 24 hours, 60 %. 
 
The synthesis of (23) was achieved in good yield using pyridine (13) as the 
acylation catalyst.  The more efficient 4-pyrrolidinopyridine (15) was not required 
for this reaction in comparison to the synthesis of RDP00060 (12), where a 
mixture of 4-pyrrolidinopyridine  (15) and pyridine (13) was required, probably 
because acid chlorides are generally more reactive than sulfonyl chlorides.  The 
13C NMR spectrum of (23) confirmed the presence of three carbonyl carbons at δ 
166.2, 166.1 and 166.0, indicative of the two amide carbonyl carbons and the 
ester carbonyl carbon present in (23). 
 
3.3.2.3. Thiophene  Bioisostere (25)  
The thiophene bioisostere was planned using thiophenesulfonyl chloride instead 
of p-toluenesulfonyl chloride.  Unfortunately, thiophenesulfonyl chloride was not 
available for purchase, so the commercially available 2-chlorothiophenesulfonyl 
chloride (24) was used.  In order to get a direct comparison between benzene 
and thiophene, the 4-chlorobenzene sulfonamide derivative (27) was also 
prepared (Schemes 10a and 10b). 
 
























(10) (24) (25)  
 
Scheme 10a.  Preparation of 2-chlorothiophene bis-sulfonamide (25). Reagents and conditions: 

























Scheme 10b.  Preparation of 2-chlorobenzene bis-sulfonamide (27): Reagents and conditions; (a) 
pyridine (13), 4-pyrrolidopyridine (15), dry acetonitrile, reflux, 24 hours, 34 %. 
 
The proton NMR of the 5-chlorothiophene bis-sulfonamide  (25)  showed three 
bond coupling consistent for thiophene heterocycles (Figure 31), while the 4-
chlorobenzene bis-sulfonamide (27) showed three bond coupling consistent for 
benzenoid systems.  Couplings in heteroaromatic systems, for example, furans, 
pyrroles and thiophenes, tend to be smaller than those in benzenoid systems.  
Unfortunately, full proton and carbon assignment of 4-chlorobenzene bis-
sulfonamide  (27)  was not possible due to the complexity of the proton NMR 
spectrum.  However, the IR spectrum of 4-chlorobenzene bis-sulfonamide (27) 
showed a stretch at  1161 cm
-1 which is indicative of a S=O functionality.   
Characterisation of derivatives (25) and (27) was also achieved using CHN 
analysis.   97
 
ppm (f1)










































































































































Figure 31.  An expansion of the 300 MHz proton NMR spectrum of 5-chlorothiophene bis-
sulfonamide (25), illustrating that the coupling constants (
3J) in thiophene are less than those of 
benzenoid systems, for example, the doublet resonating at δ 7.58 (J3',4' = 4.0 Hz) corresponds to 
a thiophene proton at position 3'; the doublet at δ 7.46 (J5, 6 = 8.7 Hz) corresponds to a benzenoid 
proton at position 5.         
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3.3.3.  Molecular Modelling of Bioisosteres (23, 25, 27) 
The three bioisosteres of RDP00060 (12) were docked into the active site of 
TrxR using the docking programme, LigandFit.  For comparison, the 4-
chlorobenzene sulfonamide (27) was subjected to the same evaluation.  The 
resulting protein – ligand interactions were then assessed using scoring functions 
as described previously.  The results of the scoring functions are summarized in 
Table 13.   
 
Derivative LigScore1  Ligscore2 -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
RDP00060 (12) 3.320  5.610 84.120 77.490 2.180  87.740  539  440 
(21b)  2.480 5.580  74.950 67.750 2.560  80.100  391  361 
(21c)  3.400 5.310  68.200 71.270 1.290  86.880  407  363 
(21d)  2.660 5.710  77.070 75.410 0.885  89.770  664  536 
(23)  2.330 5.620  70.840 61.000 0.410  78.190  444  439 
(25)  2.960 6.260  73.600 60.700 -0.770  56.200  448  368 
(27)  3.610 5.967  59.320 55.670 0.560  58.380  469  420 
 
Table 13.  The values obtained from eight scoring functions used to evaluate the ligand – protein 
interaction.  A high scoring function indicates that there is a good interaction between the ligand – 
protein complex. 
 
The nitrile bis-sulfonamide  (21b) and the hydroxyamidine (21c) are not 
bioisosteres of the lead compound, but were included in the docking run because 
of their potential to form non-bonding interactions, such as hydrogen bonds. 
The scoring of the nitrile bis-sulfonamide (21b) was poor when compared with 
the lead compound, RDP00060 (12) suggesting that the nitrile bis-sulfonamide 
would have lower activity than the lead compound; however, when the ligand 
was examined within the active site, it was revealed that one of the sulfonamide 
units (the sulfonamide meta to the nitrile) could form a hydrogen bond with the 
NH of the cysteine-A498 residue.  The cysteine residue at position 498 is 
involved in catalysis of TrxR; hydrogen bonding to this residue could be 
favourable for a potential inhibitor.  Furthermore, nitrile functionalities can 
undergo nucleophilic addition reactions, for example, the synthesis of the   99
hydroxyamidine  (21c) was achieved by the nucleophilic addition of 
hydroxylamine (a good nucleophile) to the nitrile bis-sulfonamide  (21b).  The 
active site of TrxR contains selenium in the form of a selenocysteine residue.  
The selenium is essential for catalysis, as replacement with sulfur results in the 
loss of catalytic activity.  Selenium is a potent nucleophile and it is possible that it 
could undergo a nucleophilic addition reaction with the nitrile functionality of (21b) 
resulting in inhibition of the TrxR through covalent bond formation to the inhibitor 
(21b).  It is important to note, however, that the crystal structure of TrxR used 
throughout this work contained a mutation where the selenocysteine residue had 
been replaced with a cysteine residue, as discussed previously.  Since sulfur has 
similar chemical properties to selenium, the mutant crystal structure was 
considered appropriate for this work.     
Evaluation of the hydroxyamidine (21c) docked within the active site of TrxR 
shows that four hydrogen bonds can be formed between the ligand and the 
protein (Figure 32); in comparison, the oxadiazole (21d) can form only one 
hydrogen bond.  The hydrogen bonding in (21c) involves the lone pair of 
electrons on the oxygen atom from the oxadiazole ring and the hydroxyl side 
chain of serine-A404.  These data suggest that the hydroxyamidine (21c) has the 
potential for greater inhibitory activity of TrxR than the oxadiazole (21d) due to 
increased hydrogen bonding; however, no clear conclusions could be drawn from 
the scoring functions, as some functions scored the hydroxyamidine (21c) higher, 
while others scored the oxadiazole (21d) higher.   100
 
 
Figure 32a.  The hydroxyamidine (21c) hydrogen bonding to four residues of TrxR.  A green line 
represents a hydrogen bond.  The yellow sphere represents the catalytic sulfur atom (from A498 
Cys) in CPK form.  Hydrogen bonding can occur between the hydroxyamidine (21c) and the 
residues glycine-A499, cysteine-A498, glutamic acid-A477 and tryptophan-A407 of TrxR 
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Figure 32b. The hydroxyamidine (21c) docked into the active site of TrxR.  The side chains of 
TrxR have been removed for clarity.  The yellow sphere represents the catalytic sulfur atom (from 
A498 Cys) in CPK form. 
  
It also is interesting to note that LigScore1 predicted more efficient binding from 
the hydroxyamidine (21c) when compared to the oxadiazole (21d), which 
supports the theory that the hydroxyamidine (21c) has higher potential inhibitory 
activity towards TrxR than the oxadiazole (21d), due to its hydrogen bond 
forming capacity. 
The amide and thiophene bioisosteres were also evaluated using the eight 
scoring functions.  The lead compound, RDP00060 (12) outscored the amide (23) 
on all of the scoring functions which suggests that the amide (23) should have 
less inhibitory activity towards TrxR than RDP00060 (12).  This is further 
supported by the fact that the amide (23) does not appear to form any non-  102
bonding interactions with TrxR.  In contrast, the chlorothiophene (25) and 
chlorobenzene (27) derivatives scored very similarly when compared to the lead 
compound.  The evaluation of the protein – ligand complex revealed no non-
bonding interactions between (25), (27) and TrxR.  It was also interesting to note 
that the docked conformations of the amide (23) and chlorothiophene (25) 
derivatives were almost identical, whereas the chlorobenzene derivative (27) 




Figure 33.  The conformations of amide (23) [red], chlorothiophene (25) [blue] and 
chlorobenzene (27) [yellow] when docked in the active site of TrxR.  
     
These data suggest that the chlorothiophene derivative (25) binds to TrxR in a 
similar manner to the amide (23), although the scoring functions implied that 
chlorothiophene  (25) could bind more efficiently than the amide (23).  
Furthermore, the chlorobenzene derivative (27) bound within 3 Å of the catalytic   103
cysteine at position 498, whereas the amide (23) and chlorothiophene (25) bound 
within 7 and 4 Å, respectively (Figure 34).  As the cysteine at position 498 is 
directly involved in catalysis, it would be desirable to have the ligands bind as 
close as possible to this residue, in order to disrupt the catalytic process.   
Overall, the modelling data and the results of the scoring functions, suggested 
that the chlorobenzene derivative (27) would display greater inhibitory activity 




Figure 34.  Chlorobenzene derivative (27) docked into the active site of TrxR.  The side chains of 
TrxR have been removed for clarity.  The yellow sphere represents the catalytic sulfur atom (from 
A498 Cys) in CPK form.  This figure illustrates (27) binding within 3 Å of the catalytic cysteine 
residue at position A498.  
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3.3.4. Biological  Evaluation 
The derivatives were first evaluated for inhibitory activity towards the Trx system 
using the insulin reduction assay.  As for the 3,4- and 3,5-derivatives (19a – 20e), 
a preliminary screen was carried out using 500 μM concentrations of each 
compound (Table 14).  The most active compounds from the preliminary screen 
were then tested at further concentrations to establish a dose response curve, 
from which the IC50 values could be calculated (Figure 35). 
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Table 14.   Percentage inhibition of the Trx/TrxR system for the compounds tested at 500 μM.  
The most active compounds were then tested further to establish IC50 values.   
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Trx, TrxR, Insulin Reduction Assay for (27)



































Figure 35.  A dose response curve of absorbance as a percentage of the control against log 
concentration for compound (27). 
 
The derivatives were then subjected to an MTT assay for antiproliferative activity 
using a HPV-16 immortalized keratinocyte cell line across a range of 
concentrations, as described previously (Table 15).  GI50 values were then 
calculated using GraphPad Prism
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Table 15.  GI50 values of the six compounds tested on a HPV-16 immortalized keratinocyte cell 
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A Dose Response Curve of (21b) against Percentage Growth
of Human Keratinocytes






























A Dose Response Curve of (21d) against Percentage Growth
of Human Keratinocytes




































A Dose Response Curve of (25) against Percentage Growth
of Human Keratinocytes

































A Dose Response Curve of (27) against Percentage Growth
of Human Keratinocytes
































Figure 36.  Dose response curves of percentage growth vs. log concentration for compounds 
(21b), (21d), (25) and (27). 
 
It is obvious from the biological data that the amide (23) showed no detectable 
activity against the Trx system; the amide (23) also showed weak activity in MTT 
assay, compared to the lead compound.  Earlier results showed that the logP of 
a compound can influence the results of the MTT assay, irrespective of activity 
against TrxR, presumably because for a compound to be active in the MTT 
assay, it first has to cross the cell membrane, as observed with the 3,4- and 3,5- 
aniline analogues (19e, 20e).  These compounds showed good activity in 
inhibiting the Trx system, but poor activity in the MTT assay, possibly as a result 
of the low logP.  The amine (23)  has a similar CLogP to the lead compound 
which suggests that (23) should be able to cross the cell membrane as efficiently 
as RDP00060 (12); however, the results showed no inhibitory activity towards 
TrxR and poor activity in the MTT assay.  It is possible that the poor result in the 
MTT assay is a result of the low inhibitory activity of (23)  towards TrxR.     108
Interestingly, the scoring functions used to assess the protein – ligand interaction 
scored the lead compound, RDP00060 (12), higher than (23), indicating that the 
in silico protein – ligand interaction between (23) and TrxR was less favorable.  
In contrast, the chlorothiophene (25) and chlorobenzene (27) derivatives showed 
good inhibitory activity towards the Trx system and good activity in the MTT 
assay.  The chlorobenzene derivative (27) showed superior inhibitory activity of 
the Trx system in the initial screen when compared to the chlorothiophene 
derivative (25); as a result, chlorobenzene (27) was tested further, to establish a 
dose response curve (Figure 35) from which, an IC50 of 277 μM was calculated.  
In comparison to the lead compound, the inhibitory activity towards the 
thioredoxin system has been increased by a factor of about five.  The majority of 
the scoring functions appear to favor the lead compound, over derivatives (25) 
and  (27); however, LigScore1 scores (25) and (27) higher than the lead 
compound, suggesting that LigScore1 is the most representative function of this 
system.   
The nitrile bis-sulfonamide (21b) showed good activity in the MTT assay with a 
GI50 of 4.7 μM, comparable to the lead compound, RDP00060 (12) with a GI50 of 
4.1  μM.  Compound (21b) also showed good inhibitory activity towards the 
thioredoxin system in the preliminary screen, but, because (21b) appeared to be 
less active than (27), it was not investigated further.   
Evaluation of the hydroxyamidine (21c) and the oxadiazole (21d) revealed that 
both compounds had modest inhibitory activity against the Trx system, with 32.4 
and 13.9 % inhibition obtained at 500 μM respectively.  Consideration of the 
hydrogen bonding potential of the ligands helps to rationalize these data: the 
hydroxyamidine (21c) can form up to four hydrogen bonds with TrxR, while the 
oxadiazole  (21d) can form only one hydrogen bond.  On comparing the 
oxadiazole (21d) with the lead compound, RDP00060 (12), the biological results 
are similar on MTT and TrxR inhibition; however, the oxadiazole offers the 
advantage that it is metabolically stable to esterases, where the lead compound, 
RDP00060 (12), is not.  It is also interesting to note that the hydroxyamidine (21c) 
showed poor activity on MTT with an GI50 of 107.5 μM when compared with the   109
lead compound; however, the hydroxyamidine (21c) is a polar compound with a 
ClogP of 2.3, suggesting that the hydroxyamidine (21c) may not cross the 
cellular membrane sufficiently to have an effect in the MTT assay and lending 
support to the trend already observed with the 3,4- and 3,5-analogues (19a – 
20e). 
 
3.4. Nitrile  bis-sulfonamide and related derivatives 
3.4.1. Rationale 
The nitrile functionality of (21b) allowed the construction of derivatives to explore 
further structure activity relationships, such as the effect of size and shape of a 
ligand upon the inhibitory activity towards the Trx system.  Comparison of the 
pivaloyl amide (28) and the primary amide (29) provided steric information on this 
system; both compounds were prepared directly from the nitrile bis-sulfonamide 
(21b).   
 
3.4.2. Synthesis 
3.4.2.1. The  Ritter  Reaction 
When the nitrile bis-sulfonamide (21b) was dissolved in tert-butanol and treated 
with 60 percent sulfuric acid, the nitrile was converted to pivaloyl amide (28) 
through the Ritter reaction (Scheme 11).  The IR spectrum of the pivaloyl amide 
(28) showed that the peak indicative of the nitrile functionality at 2233 cm
-1 was 
no longer present.  Furthermore, the 
1H NMR spectrum showed the tert-butyl 
group as a singlet at δ 1.31, integrating to 9 protons.  Also present in the 
13C 
NMR spectrum was a peak at δ 165.5, which corresponded to the carbonyl 
carbon in the amide functionality of (28).    


























(21b) (28)  
 
Scheme 11.  Formation of the pivaloyl amide (28).  Reagents and conditions; (a) tert-butanol, 
60% H2SO4, reflux, 18 hours, 47 %.  
 
The reaction involves the addition of a tertiary butyl carbocation, generated from 
the loss of water from protonated tert-butanol, to the nitrile group to give a 
nitrilium ion intermediate, which then undergoes hydrolysis to the corresponding 
amide (Figure 37).  This product is of interest as the amide functionality allows 
possible hydrogen bonding, to improve binding to the active site, while the bulky 








































Figure 37.   Mechanism of the Ritter Reaction. 
 
   111
3.4.2.2.  The Primary Amide (29)  
The nitrile functionality was hydrated to the corresponding primary amide using 
alkaline peroxide (Scheme 12).   It is quite a difficult transformation to carry out 
effectively, as amides can themselves undergo further hydrolysis to the 
carboxylic acid.  Another method was employed in an attempt to carry out this 
transformation prior to using alkaline peroxide.  Moorthy et al., [2005JOC1926] 
claimed that TFA and concentrated sulfuric acid can convert a nitrile to an amide 
in excellent yield, but the reaction conditions employed were extremely harsh and 
cleaved the two sulfonamide units in this system.   
The IR spectrum of the primary amide (29) showed an intense absorption at 
1659 cm
-1 and at 1615 cm
-1 which has been assigned to the C=O and NH2 units 
from the amide functionality of (29).  These absorptions are often known as 

























(21b) (29)  
 
Scheme 12.   Hydration of the nitrile bis-sulfonamide (21b) to the corresponding primary amide 
(29).  Reagents and conditions; (a) H2O2, NaOH (1M), rt, 18 hours, 71 %. 
 
The primary amide (29) was an important derivative to test, as the functional 
group contains both hydrogen bond acceptors and hydrogen bond donors, giving 
the derivative huge potential to form hydrogen bonds.  Comparing the primary 
amide (29) to the pivaloyl amide (28), the primary amide (29) is considerably 
smaller, as it lacks the bulky tert-butyl functional group; the comparison of these 
amides’ activities will help to further develop structure-activity relationships. 
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3.4.2.3.  The Primary Amine (30) 
The nitrile functionality of (21b) was efficiently reduced to the corresponding 
amine using catalytic hydrogenation, with palladium on carbon as catalyst 
(Scheme 13). The IR spectrum of (30) confirmed that the peak indicative of a 
nitrile functionality at 2233 cm
-1 was absent.  Furthermore, the DEPT spectrum of 
(30) showed a methylene group at δ 42.5 which coupled to the methylene 
protons at δ 3.77 in the HMQC spectrum.  Further characterisation of the primary 
amine (30) was achived using HRMS. 
The primary amine was an attractive functionality for several reasons; firstly, from 
this primary amine a whole range of derivatives can be prepared, such as 
pyrroles and azetidines [2006JOC7885].  Secondly, the amine functionality has a 
pKa of around ten; consequently, at physiological pH, the amine will be totally 
ionized, which could lead to the formation of salt bridge interactions between the 




























Scheme 13.  The reduction of the nitrile bis-sulfonamide (21b) to the corresponding amine (30).  
Reagents and conditions; (a) H2, Pd/C 10 %, methanol, 72 hours, 86 %. 
 
Generally, salt bridge interactions are stronger than hydrogen bonds; they are 
thought to contribute to maintaining protein structure, so are important non-
covalent interactions in proteins. 
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3.4.2.4. SN2 Reactions 
The primary amine (30) was reacted with one equivalent of 1-bromo-3-methyl-2-
butene or one equivalent of ethyl bromoacetate (Scheme 14).  In both reactions, 
however, no mono-substituted products were isolated, but the bis-substituted 
products were formed in poor yields.  As a result of these low yielding reactions, 
further functionalisation of (31) and (32) was not attempted.   
The 
1H NMR spectrum of (31) showed two methylene groups at δ 3.70 and 3.20 
which was confirmed by the DEPT spectrum.  The singlet at δ 3.70 integrated to 
two protons, which corresponded to the methylene protons at position a.  The 
peak at δ 3.20 was a doublet integrating to four protons, which corresponded to 
the two identical methylene groups at position b.  Since these protons are 
equivalent, only one peak was observed in the 
1H NMR spectrum.  This peak 
showed coupling to the triplet at δ 5.24, corresponding to the proton at position c, 
with a coupling constant equal to 6.2 Hz.  Also observed in the 
1H NMR was a 
singlet at δ 1.71 and a singlet at δ 1.50, both integrating to six protons, assigned 
to the four methyl groups at position d.   
 






























































































Scheme 14.  SN2 Reactions of (30).  Reagents and conditions; (a) 1-bromo-3-methyl-2-butene, 
diisopropylethylamine, acetonitrile, rt, 24 hours, 16 %; (b) ethyl bromoacetate, 
diisopropylethylamine, acetonitrile, rt, 24 hours, 18 %. 
 
The 
13C NMR spectrum of (32) showed a peak resonating at δ 170.4 assigned to 
the two carbonyl carbons of (32).  Only one peak was observed, as the two 
carbonyl carbons are equivalent.  The 
1H NMR spectrum of (32) showed a singlet 
at δ 3.71, integrating to two protons, which was assigned to the methylene group 
at position a.  The 
1H NMR spectrum also revealed a singlet at δ 3.36 integrating 
to four protons, which was assigned to the two methylene groups at position b.  
The two ethyl groups were observed in the 
1H NMR spectrum as a quartet at δ 
4.12, integrating to four protons, and a triplet at δ 1.19, integrating to six protons.  
The HH COSY spectrum confirmed coupling between the triplet and the quartet, 
with a calculated coupling constant of 6.9 Hz.   
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3.4.3. Molecular  Modelling 
The nitrile bis-sulfonamide related derivatives were docked into the active site of 
TrxR using the docking programme, LigandFit.  The docked poses were 
assessed for hydrogen bonding, and then evaluated using the eight scoring 
functions contained within the Ligand Scoring panel of Cerius
2.  The scores of 
the derivatives are summarized in Table 16. 
 
Derivative LigScore1  Ligscore2  -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
RDP00060 (12) 3.320  5.610 84.120  77.490  2.180  87.740  539 440 
(28)  3.390 5.380  66.450  60.360  2.660  92.770  615  501 
(29)  1.770 4.770  72.220  64.190  1.840  77.080  349  340 
(30)  3.580 6.070  81.060  76.110  1.600  68.780  402  346 
(31)  2.280 4.930  75.780  74.180  0.920  95.640  493  446 
(32)  1.940 2.480  79.060  87.050  3.700  87.410  592  512 
 
Table 16.  The values obtained from eight scoring functions used to evaluate the ligand – protein 
interaction.  A high scoring function indicates a good interaction between the ligand – protein 
complex. 
 
Evaluation of the docking and scoring studies of the pivaloyl amide (28) showed 
that it scored favorably when compared to the lead compound, RDP00060 (12), 
suggesting that the active site of TrxR was sufficiently spacious to accommodate 
(28).  Furthermore, when the most stable conformation of (28) in the TrxR active 
site was inspected for hydrogen bonding, the potential for a hydrogen bond from 
the carbonyl oxygen with the hydroxyl group of serine-A404 was observed.  In 
contrast, the smaller primary amide (29) scored less favorably when compared to 
the lead compound, despite the possibility of hydrogen bonds between two 
residues of TrxR and compound (29) – from the amide of (29) to the side chain of 
glutamic acid-A477 and from a sulfonamide unit (meta to the amide) of (29) with 
the carbonyl oxygen of glycine-A496. 
The primary amine (30) also scored favorably when compared to the lead 
compound, RDP00060 (12).  Furthermore, LigScore1 scored (30) higher than 
any other nitrile derivative.  Evaluation of previous RDP00060 (12) derivatives   116
has shown that LigScore1 appears to be the most efficient scoring functions 
when assessing ligand activity.  This would suggest that the primary amine (30) 
maybe the most active of the nitrile derivatives.  Surprisingly, no hydrogen 
bonding appeared to be occurring between (30) and TrxR.  However, when the 
conformation of (30) was examined, it was found that the amine functional group 
of  (30), which will be ionized at physiological pH, binds within 3 Å of the 
carboxylate side chain of glutamic acid-A477 (Figure 38) and could indicate the 
formation of a strong electrostatic salt bridge interaction between the ionized 
amine of (30) and the carboxylate side chain of glutamic acid-A477. 
Compounds (31) and (32) scored poorly when compared to the lead compound, 
RDP00060 (12), which could be due to the large size of both ligands.  When the 
scoring process occurs, a site model is generated using a flood filled algorithm 
(Figure 16).  If part of the ligand binds outside of the site model, the ligand is 
penalized.  This is particularly evident in the LigScore functions and may explain 
the poor scores of (31) and (32).  One possible solution to this problem would be 
to repeat the ligand scoring run with a larger site model and compare the results 
to the previous site model.  If the scores are significantly higher with the larger 
model, this would indicate the low scores were due to the ligands binding outside 
the site model rather than the poor binding of the ligands.  If, however, the scores 
remain the same, this would indicate there is a poor in silico interaction between 
the ligands and TrxR.  Further evaluation of (31) revealed that two groups were 
involved in hydrogen bonding with TrxR – the oxygen and the NH [from the 
sulfonamide para to the amine] can hydrogen bond with tryptophan-A407 and 
glutamine-A494, respectively.  Evaluation of (32) also revealed that it could 
hydrogen bond with residues from TrxR.  Indeed, the NH (from the sulfonamide 
unit para to the amine) can hydrogen bond with the hydroxyl side chain of serine-
A404, and the oxygen (from the sulfonamide unit meta to the amine) can 
hydrogen bond with the NH backbone of tryptophan-A407.  Furthermore, the two 
carbonyl oxygen atoms of (32) can form hydrogen bonds with the NH backbone 
of tryptophan-407 and the hydroxyl side chain of threonine-A481.     117
 
 
Figure 38.  The amine functional group of (30) can bind within 3 Å of the carboxylate side chain 
of glutamic acid-A477, potentially forming a salt bridge interaction.  The amine and carboxylate 
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3.4.4. Biological  Evaluation 
The nitrile derivatives were first evaluated for inhibitory activity towards the Trx 
system using the insulin reduction assay.  As for the previous RDP00060 (12) 
derivatives, a preliminary screen was carried using 500 μM concentrations of 
drug (Table 17).  The most active compounds from the preliminary screen were 
then tested at further concentrations to establish a dose response curve, from 
which the IC50 values could be calculated (Figure 39). 
 
Derivative  Y  Percentage inhibition at 500 μM IC50 (μM) 
(28)  CONH
tBu  10.0 Not  determined 
(29)  CONH2  19.9 Not  determined 
(30)  CH2NH2  98.7 377 
(31)  CH2N(CH2CHC[CH3]2)2  70.0 Not  determined 















Table 17.   Percentage inhibition of the thioredoxin system for the compounds tested at 500 μM.  
The most active compound was then tested further to establish the IC50 value.   
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Trx, TrxR, Insulin Reduction Assay for (30)




































Figure 39.  Dose response curve of absorbance as a percentage of the control against log 
concentration for compound (30). 
 
The derivatives were then subjected to an MTT assay using a HPV-16 
immortalized keratinocyte cell line as described previously (Table 18).  GI50 
values were then calculated using GraphPad Prism
® (Figure 40). 
 
Derivative Y  CLogP  Antiproliferative  Activity  (GI50) μM 
(28)  CONH
tBu  4.3 5.1 
(29)  CONH2  2.8 103.7 
(30)  CH2NH2  3.0   162.3 
(31)  CH2N(CH2CHC[CH3]2)2  5.0 7.9 















Table 17.  GI50 values of the five compounds tested on a HPV-16 immortalized keratinocyte cell 
line using an MTT assay.  The table also shows calculated LogP values (ChemDraw).    120
A Dose Response Curve of (28) against Percentage Growth
of Human Keratinocytes






























A Dose Response Curve of (30) against Percentage Growth
of Human Keratinocytes

































A Dose Response Curve of (31) against Percentage Growth
of Human Keratinocytes































A Dose Response Curve of (32) against Percentage Growth
of Human Keratinocytes


































Figure 40.  Dose response curves of percentage growth vs. log concentration for compounds, 
(28) , (30), (31) and (32). 
 
From the preliminary screen in the insulin reduction assay, the primary amine (30) 
showed very good inhibitory activity with 98.7 percent inhibition achieved at 500 
μM.  However, when (30) was tested at lower concentrations to construct a dose 
response curve, the inhibition was not as good as anticipated with an IC50 of 377 
μM obtained.  By comparison to the lead compound, RDP00060 (12), activity had 
still been increased about four fold. The increased activity of (30) towards the Trx 
system may be due to the formation of a strong salt bridge interaction between 
the ionized amine of (30) and the carboxylate side chain of glutamic acid-A477.  
In contrast, the GI50 obtained on the MTT assay was quite poor when compared 
to the lead compound; however, this appears to follow the trend of results where 
polar compounds show poor activity on the MTT assay, while showing good   121
inhibitory activity towards TrxR, as already observed with the 3,4-aniline 
analogue (19e) and the hydroxyamidine (21c).   
This trend was also seen with the primary amide (29).  This compound showed 
moderate inhibitory activity towards the Trx system, but poor activity in the MTT 
assay when compared to the lead compound.  The pivaloyl amide (28), in 
contrast, showed good activity in the MTT with a GI50 value of 5.1 μM.  However, 
the pivaloyl amide (28) has a ClogP of 4.3, where the primary amide (29) and 
primary amine (30) have a ClogP of 2.8 and 3.0, respectively.  Comparing the 
inhibitory activity of (28) and (29) at 500 μM,  (28) appeared to show greater 
inhibition, although the activity was similar for both compounds.   
Compounds (31) and (32) showed good inhibitory activity against the thioredoxin 
system in the initial screen; this was not supported by the scoring functions used 
to assess the protein – ligand complex which scored (31) and (32) poorly when 
compared to the lead compound.  This may indicate that the poor scores of (31) 
and (32) were due to the small site model used in the scoring run rather than a 
poor in silico interaction between ligand and protein.  One way to confirm this 
would be to repeat the scoring run, with a larger site model, and compare the 
scoring results.   
This class of compounds appears to suggest that the relative size of the ligand is 
not really an important factor when evaluating RDP00060 (12) analogues.  The 
primary amide (30) and the pivaloyl amide (29) showed similar activity against 
the thioredoxin system, despite the differing size of the functional groups.   
Furthermore, two ligands with large side chains, (31) and (32) also showed good 
inhibitory activity against the Trx system.  This is in agreement with the in silico 
docking studies that show there is adequate space in the active site of TrxR to 
accommodate such large ligands. 
 
3.5.  The aniline bis-sulfonamide and related derivatives 
3.5.1. Rationale   
The aniline bis-sulfonamide (33b) is an interesting compound to test in its own 
right, as it is capable of forming non-bonding interactions, such as hydrogen   122
bonds.  The aniline bis-sulfonamide  (33b) can also act as a useful synthetic 
intermediate, from which a wide range of compounds can be prepared. 
 
3.5.2. Synthesis 
3.5.2.1. The  aniline  bis-sulfonamide (33b) 
The aniline bis-sulfonamide was prepared by reacting 4-nitro-1,2-
benzenediamine  (33)  with  p-toluenesulfonyl chloride (11) under optimized 
acylation conditions.  The nitro bis-sulfonamide (33a) was then reduced to the 
corresponding aniline bis-sulfonamide  (33b) using catalytic hydrogen with 











































































Scheme 14.  The synthesis of the aniline bis-sulfonamide (33b)  via  the nitro bis-sulfonamide 
(33a).  Reagents and conditions: (a) pyridine (13), pyrrolidinopyridine (15), dry acetonitrile, reflux, 
24 hours, 82 %; (b) Pd/C 10 %, methanol/ethyl acetate, 6 hours, 94 %. 
 
The yield of the nitro bis-sulfonamide (33a) was surprisingly high, as one of the 
amines is para to the electron withdrawing nitro group.  It was thought that this   123
would considerably deactivate the system and it was anticipated that a mono-
substituted intermediate would contaminate the product.  This, however, was not 
the case as the nitro bis-sulfonamide (33a) was obtained in 82 % yield.  
The three protons of the central ring of the nitro bis-sulfonamide  (33a) are 
deshielded due to the electron withdrawing properties of the nitro group.  In 
contrast, the three protons in the central ring of the aniline bis-sulfonamide (33b) 
are shielded due to the electron donating properties of the amino group (Table 
16). 
 
Compound H2 (ppm)  H5 (ppm)  H6 (ppm) 
(33a)  7.83 7.40 7.93 
(33b)  6.48 6.36 6.07 
 
Table 16.  The shielding and deshielding effects of the amino and nitro functional groups on the 
H2, H5 and H6 protons of (33a) and (33b).  
 
3.5.2.2.  The Sulfamide (33c) 
The reduction of the nitro bis-sulfonamide (33a) to the aniline bis-sulfonamide 
(33b) opened up an avenue to prepare another genre of compounds, such as the 
sulfamide (33c) (Scheme 15).  The IR spectrum of the sulfamide (33c) showed a 
strong absorption at 1150 cm
-1 which is indicative of an S=O functionality.   
Further characterization was achieved using proton and carbon NMR and CHN 
analysis.    
Over the years, the sulfamide unit has played a significant role in medicinal 
chemistry [2007BMC1556].   The sulfamide was an attractive derivative, as the 
functionality contains both hydrogen bond acceptors and hydrogen bond donors, 
and, as a result, has a great potential to form hydrogen bonds.  It was anticipated 
that hydrogen bonding between the ligand and TrxR could increase the inhibitory 
activity of the ligand. 
 
 





























(33b) (33c)  
 
Scheme 15.  Synthesis of the sulfamide (33c) from the aniline bis-sulfonamide (33b).  Reagents 
and conditions: (a) sulfamide, 1,4-dioxane, reflux, 48 hours, 73 %. 
 
3.5.2.3.  Substituted Ureas (33d – 33e) 
Substituted ureas may also be prepared directly from the aniline bis-sulfonamide 
(33b) by reacting with an isocyanate.  The urea is also capable of forming 
hydrogen bonds, due to the presence of oxygen, nitrogen and hydrogen.   
Furthermore, the wide range of isocyanates commercially available enables the 
preparation of a variety of different ureas, all with different substituents.  For 
example, ethyl urea (33d) was prepared by reacting the aniline bis-sulfonamide 
(33b) with ethyl isocyanate.  Similarly, a phenyl urea (33e) was prepared by 
reacting the aniline bis-sulfonamide (33b) with phenyl isocyanate (Scheme 16).   
















































Scheme 16.  Synthesis of ethyl urea (33d) and phenyl urea (33e) from aniline bis-sulfonamide 
(33b).  Reagents and conditions: (a) ethyl isocyanate, dry 1,4-dioxane, 45 °C, 18 hours, 80 %; (b) 
phenyl isocyanate, dry 1,4-dioxane, 50 °C, 18 hours, 85 %. 
 
The 
1H NMR spectrum of (33d) clearly showed the ethyl moiety as a quartet and 
a triplet integrating to two and three protons, respectively.  Unfortunately, the 
1H 
NMR spectrum of (33e) could not be assigned to specific protons due to the 
complexity of the aromatic region.  However, the integrals of protons in the 
1H 
NMR spectrum and number of peaks in the 
13C NMR spectrum both correctly 
corresponded to (33e).  In addition, HRMS was also used to characterize (33e). 
The ethyl moiety of the ethyl urea could potentially participate in lipophilic 
interactions, whereas the phenyl ring of the phenyl urea could form aromatic ring 
stacking interactions.  These potential non-bonding interactions, coupled with the 
high probability of hydrogen bonding, maked the urea functionality an attractive 
functional group to test.    
Amides present another genre of compound synthetically available from the 
aniline bis-sulfonamide (33b).  The pivaloyl amide (28) and primary amide (29) 
were prepared directly from the nitrile bis-sulfonamide  (21b), as previously 
discussed, in which the carbonyl group is adjacent to the aromatic ring.  The   126
amides available from the aniline bis-sulfonamide  (33b) are slightly different, 
however; the nitrogen is adjacent to the benzene ring, so, in effect, the amide 
group has been reversed.  This is called retroisomerism and is an example of 
bioisosterism [2005MI23].    
 
3.5.2.4. Benzotriazole  Chemistry 
Rather than prepare the amide using the conventional approach with an acid 
chloride, an alternate approach was sought, largely due to the stability problems 
associated with acid chlorides.  It was decided to use the methodology 
developed by the research group of Katritzky to prepare the desired amides, 
which uses benzotriazole as a synthetic auxiliary [2000JOC8210].  The 
advantages of this approach are that each product prepared was stable and 
crystalline.  Benzotriazole shows numerous interesting reactivity patterns and 
easily inserts into molecules by addition reactions, substitution reactions or 
condensation reactions [1991T2683].  In this case, benzotriazole (34a) was used 
to activate a carboxylic acid to prepare the desired amide.  There are a variety of 
ways to activate a carboxylic acid, for example, 1-hydroxybenzotriazole (HOBt) 
and N, N-dicyclohexylcarbodiimide (DCC) have been successfully used.    
Methanesulfonylbenzotriazole (34b) may be prepared in high yields by adding 
methanesulfonyl chloride to benzotriazole (34a) in the presence of pyridine (13) 
[2000JOC8210].  The methanesulfonylbenzotriazole (34b) can then be reacted 
with a carboxylic acid to form an N-acylbenzotriazole [2000JOC8210]. Katritzky 
has shown that N-acylbenzotriazoles are excellent acylating agents, which react 
readily with amines, alkyl ketones and imines [2000T2683].     
Modelling studies suggest that the furanyl amide (33f) could bind favorably into 
the active site of TrxR.  As a result of these in silico studies, the furanyl amide 
(33f) was prepared using Katritzsky’s benzotriazole methodology (Scheme 17).  
The methanesulfonylbenzotriazole (34b) and the N-acylbenzotriazole (34c) were 
prepared in good yield, in agreement with the current literature; however, the final 
step of the preparation of the amide, when the N-acylbenzotriazole (34c) was 
reacted with the aniline bis-sulfonamide  (33b), was not as straightforward as   127
expected.  Previous work showed that N-acylbenzotriazoles efficiently acylate 
anilines with yields obtained in excess of 90 %.  In this case, however, the yield 
obtained of the furanyl amide (33f) was low at 44 %.  Furthermore, Katritzky also 
showed that the reaction conditions required for the acylation were relatively mild 
with an aniline and N-acylbenzotriazole stirred in THF at room temperature for 6 
hours [2000JOC8210].  In the present case, simply by TLC analysis, no product 
had formed using these conditions.  Indeed, for the product to form, even at low 
yield, the reaction mixture required heating in the presence of an acylation 
catalyst, DMAP (14).  The present low yielding reaction suggests that the two 
sulfonamide units hinder the reaction; this may be due to the electronic effects of 
the sulfonamides or it may be a steric effect, as benzotriazole is quite a large 
























































Scheme 17.  Synthesis of furoyl amide (33f) using Katritzky’s benzotriazole methodology 
[2000JOC8210].  Reagents and conditions: (a) methanesulfonyl chloride, pyridine (13), toluene, 
r.t. 24 hours, 79 %; (b) 2-furoic acid, triethylamine, THF, reflux, 18 hours, 77 %; (c) DMAP (14), 
THF, reflux, 72 hours, 44 %. 
 
Heterocycles such as furan show NMR couplings different to those in benzenoid 
systems.  Typical values of coupling constants in furan are shown in Figure 41.    128
The 
1H NMR spectra of (34c) and (33f) showed similar ring coupling when 
compared to Figure 41, as illustrated by Table 17.  The furanyl amide (33f) also 
showed the classic amide I and II bands in the IR spectrum, at 1656 cm
-1 and 
1599 cm






3J2,3 = 1.6 - 2.0 Hz
4J2,4 = 0.3 - 0.8 Hz
4J2,5 = 1.3 - 1.8 Hz
3J3,4= 3.2 - 3.8 Hz  
 








Typical Coupling  
Constants 
H2 – H3   1.8 Hz  1.5 Hz  1.6 – 2.0 Hz 
H2 – H4  0.6 Hz  0.6 Hz  0.3 – 0.8 Hz 
H3 – H4   3.8 Hz  3.3 Hz  3.2 – 3.8 Hz 
 
Table 17.  Coupling constants observed in the furan moiety of (34c) and (33f).  The values are 
compared to typical coupling constants for furan [B2001MIb]. 
 
3.5.3. Molecular  Modelling 
The aniline bis-sulfonamide (33b) and related derivatives were docked into the 
active site of TrxR using the docking programme, LigandFit.  The docked poses 
were then assessed for hydrogen bonding and evaluated using the eight scoring 
functions contained within the Ligand Scoring panel of Cerius
2.  The scores of 






   129
Derivative LigScore1  Ligscore2 -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
RDP00060 (12) 3.320  5.610 84.120  77.490 2.180 87.740  539  440 
(33a)  2.670 5.320  65.830  53.820 0.630 91.470  326  314 
(33b)  2.130 4.820  74.610  71.860 1.830 128.720  435  399 
(33c)  2.380 4.850  61.520  52.890 2.070 87.810  301  298 
(33d)  4.460 5.720  77.070  68.360 0.780 79.190  530  418 
(33e)  2.710 5.350  79.960  61.400 2.210 89.980  585  474 
(33f)  3.350 5.490  62.990  50.900 1.620 93.720  457  387 
 
Table 18.  The values obtained from eight scoring functions used to evaluate the ligand – protein 
interaction.  A high scoring function indicates that there is a good interaction between the ligand – 
protein complex. 
 
From the modelling studies, it was suggested that the nitro bis-sulfonamide (33a) 
and the aniline bis-sulfonamide  (33b) would not bind efficiently to TrxR, in 
comparison to the lead compound, RDP00060 (12).  The aniline bis-sulfonamide 
(33b) did not appear to hydrogen bond with any residues from TrxR, although the 
nitro bis-sulfonamide (33a) could form hydrogen bonds with two residues.  The 
oxygen from the nitro group of (33a) could hydrogen bond with the phenol side 
chain of tyrosine-B373 and the oxygen from the sulfonamide (meta to the nitro 
group) could hydrogen bond with the NH backbone of glutamine-B450.  
The sulfamide (33c) also appeared to bind less efficiently to TrxR than the lead 
compound, RDP00060 (12), as indicated by the eight scoring functions.   
However, the NH2 moiety of the sulfamide (33c) did appear to hydrogen bond 
with the carboxylate side chain of glutamic acid-A477. 
In contrast to derivatives (33a), (33b) and (33c), the substituted ureas scored 
favorably when compared to the lead compound.  In particular, the LigScore1 
value for the ethyl urea (33d) was very favorable when compared to the other 
aniline bis-sulfonamide derivatives.  Evaluation of the ethyl urea (33d) docked 
within TrxR revealed that it could hydrogen bond with two residues of TrxR.  The 
first hydrogen bond was formed between the carbonyl oxygen of the urea 
functional group and the protonated amine side chain of lysine-B29.  The second 
hydrogen bond was formed between the nitrogen from the sulfonamide unit (para   130
to the urea) and the alcohol side chain of serine-A404.  The phenyl urea (33e) 
could also hydrogen bond with two residues of TrxR.  As with the ethyl urea 
(33d), the first hydrogen bond involved the carbonyl oxygen from the urea 
functional group and the protonated amine side chain of lysine-B29.  The second 
hydrogen bond was formed between the NH from the urea of (33e) and the 
alcohol side chain of threonine-A481.  The phenyl ring of (33e) did not appear to 
form any ring stacking interactions with residues from TrxR, however.    
The furanyl amide (33f) also scored positively when compared to the lead 
compound, RDP00060 (12).  Surprisingly, the furanyl amide (33f) did not appear 
to hydrogen bond with any residues from TrxR.  The ligand did bind within 3 Å of 
the cysteine at position 498, however (Figure 42).  As this cysteine is directly 
involved in catalysis, it would be desirable to have the ligand bind to it as close 
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Figure 42.  The furanyl amide (33f) docked within the active site of TrxR.  The side chains of 
TrxR have been removed for clarity.  The cysteine at position 498 is shown in stick format and is 
colored according to atom type.  This figure illustrates (33f) binding within 3 Å of the catalytic 
cysteine residue at position A498. 
 
3.5.4. Biological  Evaluation 
The aniline bis-sulfonamide (33b) and related derivatives were first evaluated for 
inhibitory activity towards the Trx system using the insulin reduction assay.  As 
for the previous RDP00060 (12) derivatives, a preliminary screen was carried out 
using a 500 μM concentration of each compound (Table 19).  The most active 
compound from the preliminary screen were then tested at further concentrations 
to establish a dose response curve, from which the IC50 value could be 
calculated (Figure 43).  The furanyl amide (33f) was the most active compound 
of this class in the preliminary screen, and was consequently tested at further 
concentrations.   
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Derivative  Y  Percentage inhibition at 500 μM IC50 (μM) 
(33a)  NO2  No Inhibition  Not determined 
(33b)  NH2  31.6 Not  determined 
(33c)  NHSO2NH2  38.6 Not  determined 
(33d)  NHCONHCH2CH3  88.3 Not  determined 



















Table 19.   Percentage inhibition of the Trx/TrxR system for the compounds tested at 500 μM.  
The most active compound was then tested further to establish an IC50 value.   
 
Trx, TrxR, Insulin Reduction Assay for (33f)








































Figure 43. Dose response curve of absorbance as a percentage of the control against log 
concentration for compound (33f). 
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The derivatives were then subjected to an MTT assay using a HPV-16 
immortalized keratinocyte cell line as described previously (Table 20).  GI50 
values were then calculated using GraphPad Prism
® (Figure 44). 
 
Derivative Y  CLogP  Antiproliferative  Activity  (GI50) μM 
(33a)  NO2  4.3  > 363.2  
(33b)  NH2  2.8  48.9 
(33c)  NHSO2NH2  2.3  114.0 
(33d)  NHCONHCH2CH3  3.5  55.9 



















Table 20.  GI50 values of the compounds tested on a HPV-16 immortalized keratinocyte cell line 
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A Dose Response Curve for (33e) against Percentage Growth
of Human Keratinocytes


































A Dose Response Curve of (33f) against Percentage Growth
of Human Keratinocytes



































Figure 44.  Dose response curves of percentage growth vs. log concentration for compounds, 
(33e) and (33f). 
 
The first observation apparent from the biological results was that the nitro bis-
sulfonamide (33a) did not appear to be active on the MTT assay and showed no 
inhibition towards the thioredoxin enzyme system.  This could be due to 
interference of the colour of the nitro bis-sulfonamide (33a), which is yellow due 
to the conjugation between the electron withdrawing nitro group and the electron 
donating sulfonamide (Figure 45).  A similar yellow colour is also observed with 
the TNB anion in the insulin reduction assay.  In this procedure, the conjugation 
occurs between the thiolate anion and the nitro group (Figure 12), which is 
problematic as both assays use a colour change to test for activity, where the 
colour change is proportional to activity.  If a compound is already coloured, it is 
difficult to determine if the colour change in the assay is due to the colour of the 
compound, or the biological activity.   
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Figure 45.  Conjugation in the nitro bis-sulfonamide (33a) that causes its distinct yellow colouring. 
 
The aniline bis-sulfonamide  (33b) showed moderate activity against the 
thioredoxin system with 31.6 % inhibition at 500 μM.  This is in agreement with 
the modelling studies, where the aniline bis-sulfonamide  (33b) obtained low 
scores when compared to the other aniline derivatives. 
The aniline bis-sulfonamide  (33b) also showed moderate activity in the MTT 
assay with a GI50 value calculated as 48.9 μM.  This value was quite high when 
compared to the other RDP00060 (12) derivatives; however, the aniline bis-
sulfonamide (33b) was a polar compound with a ClogP equal to 2.8.  This result 
followed the trend of the 3,4- and 3,5-aniline analogues (19e, 20e), the 
hydroxyamidine (21c), the primary amide (29) and the primary amine (30), where 
the low ClogP appears to influence the result on the MTT assay.  This is possibly 
due to the poor permeability of the test compound into the cell in the MTT assay 
and, hence, giving a high GI50 value.  In contrast, the insulin reduction assay, 
used to determine inhibitory activity against the thioredoxin system, is not cellular 
based, so the ClogP of a ligand does not come into consideration.  This 
restriction was also observed for the sulfamide (33c), which had a GI50 value of 
114.0 μM and a ClogP of 2.3.  The sulfamide (33c) also showed 38.6 % inhibition 
of the thioredoxin system at 500 μM.  
The initial screen for activity against the Trx system also revealed that the ethyl 
urea (33d) showed good activity with 88.3 percent inhibition achieved at 500 μM, 
but unfortunately there was not enough TrxR to test this compound at further 
concentrations to establish an IC50 value; however, this work will be carried out in 
the future.   136
The good initial inhibitory activity of the ethyl urea (33d) is supported by the 
molecular modelling in silico studies.  The ethyl urea (33d) obtained a LigScore 
value of 4.460, which is the highest of the aniline bis-sulfonamide derivatives. 
The activity of (33d) on the MTT assay was moderate with a GI50 of 55.9 μM.  
Once more, the logP value appeared to influence the result in the MTT assay, as 
previously discussed. 
Interestingly, the phenyl urea (33e) showed no inhibitory activity towards the Trx 
enzyme system, but showed good activity in the MTT assay with a GI50 of 6.2 μM.  
This suggests that the phenyl urea (33e) may act upon another cellular target.  
Comparison of the in silico conformations of (33d) and (33e) docked within TrxR 
revealed that these compounds can bind in a different orientation to one another 
(Figure 46).  Furthermore, the ethyl urea (33d) can bind deep into the active site 
of TrxR, while the phenyl urea (33e) can only bind at the surface of the enzyme.  
This apparent difference of binding modes may help explain why the ethyl urea 
(33d) exhibits greater inhibitory activity towards TrxR than the phenyl urea (33e). 
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Figure 46.  The conformations of the ethyl urea (33d) [yellow] and phenyl urea (33e) [blue] when 
docked into the active site of TrxR using the docking programme LigandFit. 
 
The furanyl amide (33f) showed good inhibitory activity against the thioredoxin 
system with an IC50 equal to 37 μM.  This value is around thirty times greater 
than the lead compound, RDP00060 (12) and is also around eight times greater 
than any other RDP00060 (12) derivative.  Furthermore, the scoring functions do 
not prioritize the furanyl amide (33f) over the other aniline bis-sulfonamide 
derivatives, suggesting that this compound may have an alternative additional 
mode of binding to the enzyme.  Evaluation of the conformation of (33f) when 
docked within TrxR reveals that it can bind within 3 Å of the catalytic cysteine 
residue at 498 (Figure 42).  The crystal structure of TrxR used throughout this 
study is that of a mutant form in which the catalytic selenocysteine at 498 is   138
replaced with a cysteine residue; therefore, during the docking studies, the 
cysteine residue at 498 is considered as the essential catalytic residue.  Further 
evaluation of (33f) docked within TrxR shows that the sulfur atom of cysteine-
A498 can bind 3 Å from the C3''' atom of the furan ring of (33f) (Figure 47).   
Selenium is a super nucleophile [B2004MIa] and it is suggested that the 
selenium from the selenocysteine residue could attack the furan ring of (33f), 
forming an irreversible complex through a 1,4-conjugate addition reaction (Figure 
48), thereby rendering TrxR inactive.  This would explain why (33f) showed more 
inhibitory activity towards TrxR than any other RDP00060 (12) derivative. 
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Figure 47.  Illustrating how the furan ring of (33f) binds adjacent to the sulfur atom of cysteine-
A498.   
 
This is possible because furan has low aromatic character due to the high 
electronegativity of the oxygen heteroatom.  As a result of the low aromatic 
character, furan is able to participate in Diels-Alder reactions, where it acts as a 
diene, while the more aromatic analogous heterocycle, thiophene, does not.  







































































Figure 48.  A proposed mechanism of action of the furanyl amide (33f).  The mechanism involves 
the nucleophilic selenium attacking C3''' of the furan ring of (33f) in a 1,4-conjugate addition 
reaction. 
 
The furanyl amide (33f) also shows good activity on the MTT assay with an GI50 
value of 10.8 μM, which is not as active as the lead compound, RDP00060 (12), 
but this is to be expected as the furanyl amide (33f) has a lower CLogP than 
RDP00060 (12).   
 
3.6.  Hydrolysis of the Ester 
3.6.1. Rationale 
An ester group is commonly used as a prodrug for compounds containing 
carboxyl or hydroxyl functionalities [B2001MIa].  Esters are efficient prodrugs 
because the body is rich in enzymes capable of hydrolyzing ester bonds.  The 
prodrug approach is used for many reasons, including enhancing biomembrane 
transport, increasing bioavailability and preventing first pass metabolism. 
Furthermore, a significant number of drugs in the clinic that contain carboxylic 
acids or alcohols have been modified using the prodrug ester approach.  Since 
the lead compound, RDP00060 (12), contains a methyl ester functional group, it 
was desirable to hydrolyze the ester and examine the activity of the parent 
carboxylic acid.  Moreover, different oxidation states of the carboxylic acid group 
were examined by synthesis of the corresponding aldehyde and alcohol.  
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3.6.2. Synthesis 
The ester functionality of RD00060 (12)  was hydrolyzed to the corresponding 
carboxylic acid using sodium hydroxide in THF.  The transformation from the 
ester to the alcohol was achieved using lithium aluminum hydride as the reducing 





















































(36) (37)  
 
Scheme 18.  Reagents and conditions: (a) sodium hydroxide, THF, reflux, 6 hours, 72 %; (b) 
lithium aluminum hydride, dry THF, rt, 6 hours, 88 %; (c) PDC, dry DCM, rt, 4 hours, 78 %. 
 
The 
1H NMR spectrum of (35) lacked a peak at δ 3.74, which corresponded to 
the methoxy group of the ester functionality of RDP00060 (12).  The same peak 
was also absent from the 
1H NMR spectrum of (36).  The 
1H NMR spectrum of 
(36) also showed a methylene group at δ 4.30, which was confirmed by the 
DEPT and HMQC spectra.  Furthermore, the IR spectrum of (36) lacked the 
indicative peak for a carbonyl at 1704 cm
-1.  In contrast, the 
13C NMR spectrum 
of (37) showed a peak at δ 191.7, but no peak for a methylene carbon at δ 62.4.  
The peak at δ 191.7 was assigned to the carbonyl carbon of (37).  The aldehyde 
group of (37) was also confirmed by the presence of a carbonyl stretch at 1679 
cm
-1 in the IR spectrum. 
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3.6.3. Molecular  Modelling 
The carboxylic acid bis-sulfonamide  (35) and related derivatives were docked 
into the active site of TrxR using the docking programme, LigandFit.  The docked 
poses were then assessed for hydrogen bonding and evaluated using the eight 
scoring functions contained within the Ligand Scoring panel of Cerius
2.  The 
scores of the derivatives are summarized by Table 21. 
 
Derivative LigScore1  Ligscore2  -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
RDP00060 (12) 3.320  5.610  84.120 77.490  2.180 87.740  539 440 
(35)  3.630 5.670  69.810 62.020  0.530 100.720  294  281 
(36)  3.550 5.450  48.270 54.350  1.610 94.650  438  384 
(37)  2.960 4.960  55.250 49.410  1.610 111.110  394  331 
 
Table 21.  The values obtained from eight scoring functions used to evaluate the ligand – protein 
interaction.  A high scoring function indicated that there was a good interaction between the 
ligand – protein complex. 
 
The docking studies showed that most of the carboxylic acid bis-sulfonamide (35) 
scores were similar to those of the lead compound, RDP00060 (12), although the 
Ludi scores of (35) were quite poor by comparison.  Inspection of the carboxylic 
acid  bis-sulfonamide  (35) docked within the active site of TrxR revealed no 
hydrogen bonding between the ligand and the protein.   
The alcohol bis-sulfonamide (36) also had scores similar to the lead compound, 
RDP00060 (12), with the Ludi scores of (36) being much higher than those of the 
carboxylic acid bis-sulfonamide  (35).  Evaluation of the hydrogen bonding 
between (36) and TrxR showed that three hydrogen bonds could be formed.  The 
first hydrogen bond was formed between the alcohol group of (36) and the 
carboxylate side chain of glutamic acid-A477.  The next hydrogen bond was 
formed between the oxygen of the sulfonamide unit para to the alcohol of (36) 
and the NH backbone of glycine-A499.  The final hydrogen bond was formed 
between the oxygen of the sulfonamide unit (para to the alcohol) and the alcohol 
side chain of threonine-B116.     143
The aldehyde bis-sulfonamide  (37) scored poorly when compared to the lead 
compound, RDP00060 (12) with only one scoring function prioritizing (37) higher 
than RDP00060 (12), suggesting that the aldehyde bis-sulfonamide (37) bound 
less efficiently to TrxR by comparison to RDP00060 (12).  The docking results 
also showed that no hydrogen bonding occured between the aldehyde bis-
sulfonamide (37) and TrxR.   
It is interesting to note that the aldehyde bis-sulfonamide (37) could bind within 
3.0 Å of the catalytic cysteine residue at A498 of TrxR, while the carboxylic acid 
bis-sulfonamide (35) and the alcohol bis-sulfonamide (36) could bind within 4.3 
and 3.4 Å, respectively.   
 
3.6.4. Biological  Evaluation 
The carboxylic acid bis-sulfonamide  (35) and related derivatives were first 
evaluated for inhibitory activity towards the Trx system using the insulin reduction 
assay.  As for the previous RDP00060 (12) derivatives, a preliminary screen was 
carried using 500 μM concentrations of drug (Table 22).  The most active 
compounds from the preliminary screen were then tested at further 
concentrations to establish a dose response curve, from which the IC50 values 
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Derivative  Y  Percentage inhibition at 500 μM IC50 (μM) 
(35)  COOH  20.0 Not  determined 
(36)  CH2OH  50.0 Not  determined 















Table 22.   Percentage inhibition of the Trx/TrxR system for the compounds tested at 500 μM.  
The most active compound was then tested further to establish IC50 values.   
 
Trx, TrxR, Insulin Reduction Assay for (37)











































Figure 49. Dose response curve of absorbance as a percentage of the control against log 
concentration for compound (37). 
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The derivatives were then subjected to an MTT assay using a HPV-16 
immortalized keratinocyte cell line as described previously (Table 23).  GI50 
values were then calculated using GraphPad Prism
® (Figure 50). 
 
Derivative Y  CLogP  Antiproliferative  Activity  (GI50) μM 
(35)  COOH  4.1   67.3 
(36)  CH2OH  3.0 19.1 















Table 23.  GI50 values of the compounds tested on a HPV-16 immortalized keratinocyte cell line 
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A Dose Response Curve of (35) against percentage Growth
of Human Keratinocytes































A Dose Response Curve of (36) against Percentage Growth
of Human Keratinocytes




































A Dose Response Curve of (37) against Percentage Growth
of Human Keratinocytes




































Figure 50.  Dose response curves of percentage growth vs. log concentration for compounds 
(35), (36) and (37). 
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The carboxylic acid bis-sulfonamide  (35) showed moderate inhibitory activity 
towards the thioredoxin system with 20 percent inhibition achieved at 500 μM.  
This activity is comparable to the lead compound, RDP00060 (12).  However, 
what was evident from the MTT assay was that the carboxylic acid bis-
sulfonamide (35) showed less activity when compared to the lead compound.  
This can be explained by examining the lipophilicity of the carboxylic acid bis-
sulfonamide (35).  The LogP of (35) was estimated using ChemDraw and it was 
evident that (35) has a lower LogP than the lead compound, thus suggesting that 
(35) is less lipophilic than RDP00060 (12).  Furthermore, it is highly probable that 
the carboxylic acid functional group of (35) will be ionized during the MTT assay 
and therefore further altering the lipophilicity.  This was not taken into account 
when estimating the LogP of (35) using ChemDraw.  This result illustrates why 
esters are often used in the pharmaceutical industry as prodrugs for carboxylic 
acids.  Ester functional groups are effective prodrugs because they offer a 
compound increased lipophilicity when compared to the parent carboxylic acid 
and they are easily hydrolyzed in vivo by esterases.   
The alcohol bis-sulfonamide (36) showed moderate inhibitory activity against the 
thioredoxin system in the preliminary screen with 50 percent inhibition obtained 
at 500 μM, while the aldehyde bis-sulfonamide  (37) showed good inhibitory 
activity with 81.0 percent inhibition obtained at 500 μM.  The aldehyde bis-
sulfonamide (37) was then tested at further concentrations to establish a dose 
response curve and from this an IC50 value of 374 μM was obtained.  The 
preliminary screen suggests that (37) had more inhibitory activity towards the 
thioredoxin system than (36).  This result was surprising as the modelling studies 
suggested that (36) would have higher activity than (37).  This was predicted by 
the scoring functions which generally prioritized (36) over (37) and also by the 
fact that (36) appeared to form three hydrogen bonds with TrxR, while (37) only 
appeared to form one.  However, the modelling studies also showed that (37) 
binds closer to the catalytic cysteine residue at A498 than (36).  Since the 
cysteine residue at position 498 is involved in catalysis of TrxR, it is favourable 
for a ligand to bind adjacent to it in order to disrupt the catalytic process of the   148
enzyme.  This suggests that where a ligand binds in relation to the cysteine 
residue at A498 can also influence the activity of the ligand.  This may explain 
why the aldehyde bis-sulfonamide (37) shows higher inhibitory activity than the 
alcohol bis-sulfonamide (36), despite the lower results obtained from the scoring 
functions. 
The alcohol bis-sulfonamide (36) and the aldehyde bis-sulfonamide (37) showed 
similar activity on the MTT assay with GI50 values of 19.1 and 12.0 μM obtained 
respectively.  These results follow the trend observed with other RDP00060 (12) 
analogues where the LogP of the ligand appears to influence the activity on MTT 
assay.      
  
3.7. Irreversible  Inhibitors 
3.7.1. Rationale 
The furanyl amide (33f) exhibited the greatest inhibition of the thioredoxin system 
with an IC50 value calculated as 37 μM.  The IC50 of (33f) is around eight times 
lower than any other RDP00060 (12) derivative.  It is proposed that the selenium 
from TrxR attacks the furan ring of (33f) through a 1,4-conjugate addition 
reaction (Figure 48), thus rendering TrxR inactive.  To investigate further the 
possibility of irreversible inhibition of TrxR, with the aim of increasing the 
inhibitory activity, additional derivatives of RDP00060 (12) were prepared as 
potential irreversible inhibitors.  
α,β-unsaturated esters, amides and ketones can all undergo 1,4-conjugate 
addition reactions.  However, among the most common unsaturated systems, 
α,β-unsaturated amides show lower reactivity when compared to the equivalent 
enone or α,β-unsaturated ester counterparts.  This is because the alkenic double 
bond of an α,β-unsaturated amide is more localized, making it less susceptible to 
nucleophilic attack, due to reduced delocalization of electron density with the 
carbonyl unit.  This is owing to the efficient delocalization of electron density 
between the nitrogen and carbonyl of the amide functionality in the α,β-
unsaturated amide.   149
Generally, a potent nucleophile, such as selenolate or a Grignard reagent, is 
needed to react with a α,β-unsaturated amide through a 1,4-conjugate addition 
mechanism [2008TA1702], [B2004MIa].  This is advantageous as TrxR uses a 
selenolate nucleophile in catalysis to reduce various substrates, such as oxidized 
Trx.  It is anticipated that the selenolate nucleophile of TrxR will attack the α,β-
unsaturated amide functionality of (39) through a 1,4-conjugate addition 
mechanism and render the TrxR inactive.  A more reactive unsaturated system, 
such as an enone, was not prepared, as this was expected to react with other 
nucleophiles in the body, for example, thiols from cysteine residues.  This is 
undesirable as the ligand would loose its selectivity towards TrxR and increase 
the risk of adverse effects.   
 
3.7.2.   Synthesis 
3.7.2.1. Enamide  (39) 
The enamide (39) was prepared by reacting the aniline bis-sulfonamide (33b) 






























O (33b) (38) (39)  
 
Scheme 19.  Synthesis of the enamide (39). Reagents and conditions: (a) dry pyridine (13), dry 
acetonitrile, r.t., 20 minutes, 60 %.   
 
The 
1H NMR spectrum of (39) revealed three doublets of doublets resonating at 
δ 6.37, δ 6.23 and δ 5.74 (Figure 51), signals consistent with a terminal alkene.  
Generally, alkene protons with trans relative geometry have 
3J values of 14 – 16 
Hz, while protons on a cis alkene have 
3J values of around 8 Hz.  The doublet of 
doublets at δ 6.37 had coupling constants of 16.8 Hz and 9.9 Hz and was   150
consequently assigned to Ha.  The coupling constant of 16.8 Hz is characteristic 
of trans coupling, while the smaller coupling constant of 9.9 Hz is characteristic of 
cis coupling.  The second doublet of doublets at δ 6.23 was assigned to Hb2.  
This proton coupled with Ha (J = 16.8 Hz) and Hb1 (J = 2.4 Hz).  The final doublet 
of doublets at δ 5.74 was assigned to Hb1.  This proton coupled to Ha with a 
coupling constant of 9.9 Hz, which is typical for cis coupling.  Hb1 also coupled to 
Hb2 with a coupling constant of 2.4 Hz.  The coupling of the methylene protons in 
(39) is an example of two-bond geminal coupling in a terminal alkene and J 
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Figure 51.  An expansion of the 300 MHz proton NMR spectrum of (39) showing the terminal 
alkene protons.  The doublet of doublets resonating at δ 6.37 (Ja, b2 = 16.8 Hz, Ja, b1 = 9.9 Hz) 
corresponds to Ha.  The doublet of doublets resonating at δ 6.23 (Jb2, a = 16.8 Hz, Jb1, b1 = 2.4 Hz) 
corresponds to Hb2 and the doublet of doublets resonating at δ 5.74 (Jb1, a = 9.9 Hz, Jb1, b2 = 2.4 
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  Hb1 
     Hb2   152
3.7.2.2.  Uracil Derivative (42) 
The uracil derivative (42) was considered an attractive compound to test as it 
contains functional groups capable of forming non-bonding interactions, such as 
hydrogen bonds, but also has a functionality similar to the enamide (39), that is 
able to undergo 1,4-conjugate addition reactions.  Therefore, the uracil derivative 
(42) has the potential to be a potent inhibitor of the Trx system.   
Firstly, reaction of uracil (40) with bromoacetic acid (41) gave uracil-1-acetic acid 
(40a) for reaction with the aniline bis-sulfonamide  (33b) to provide the uracil 
derivative (42). 
The first attempt used CDI to activate (40a); however, this approach failed with 
just starting material isolated.  This was presumably due to the poor 
nucleophilicity of the aniline moiety of (33b).  CDI is often used in organic 
synthesis to activate carboxylic acids as illustrated by the mechanism in Figure 
52 [B2004MIb]. 






























Figure 52.  A proposed mechanism using CDI to activate a carboxylic acid and form an amide 
bond. 
 
The next approach used the potent benzotriazole based coupling reagent, HBTU, 
which is often used in peptide synthesis.  Interestingly, the coupling mechanism 
of HBTU can go through an N-acylbenzotriazole intermediate [2001JCS(P2)113], 
similar to (34c), which was isolated in the synthesis of the furanyl amide (33f).  
The latter attempt utilizing HBTU gave the uracil derivative (42) in a good yield 
(Scheme 20). 







































































Scheme 20. Synthesis of (42). Reagents and conditions: (a) bromoacetic acid, KOH, H2O, r.t., 2 
hours, 67 %; (b) HBTU, dry diisopropylethylamine, dry DMF, r.t., 48 hours, 53 %.   
 
The 
1H NMR spectrum of the uracil derivative (42) showed a singlet integrating to 
two protons at δ 4.48, which was assigned to the methylene protons of (42).  The 
DEPT spectrum of the uracil derivative (42) showed a peak at δ 50.6 
corresponding to a methylene carbon.  The HMQC spectrum of the uracil 
derivative (42) confirmed that the singlet at δ 4.48 coupled with the methylene 
carbon at δ 50.6.   155
The 
13C NMR spectrum of the uracil derivative (42) also showed three peaks 
resonating at δ 166.1, δ 164.3 and δ 151.6.  Analysis of the DEPT spectrum 
revealed that these peaks were due to quaternary carbons.  The HMBC 
spectrum showed that the peak at δ 166.1 couples to the methylene protons at δ 
4.48 and consequently has been assigned to the amide carbonyl carbon adjacent 
to the central ring of the uracil derivative (42).  Similarly, the two quaternary 
carbons at δ 164.3 and δ 151.6 couple to Ha in the HMBC spectrum and have 
been assigned to the two carbonyl carbons in the uracil moiety of (42) (Figure 53).  
The more deshielded carbon at δ 164.3 was assigned to the carbonyl carbon 
adjacent to Hb, while the carbon at δ 151.6 was assigned to the carbonyl carbon 
adjacent to the two nitrogen atoms.  The carbonyl carbon at δ 151.6 is more 
shielded than the carbonyl carbon at δ 164.3 due to the + M effects of the two 

















Figure 53.  An expansion from the HMBC spectrum of the uracil derivative (42) (300 MHz, d6-
DMSO), showing the coupling between the quaternary carbons at δ 164.3 and δ 151.6 and the 
doublet at δ 7.58,  which corresponds to Ha. 
 
3.7.2.3. Nitrohalobenzene related derivatives 
Until this point, the method of inhibiting TrxR irreversibly had focused on utilizing 
a 1,4-conjugate addition mechanism, in which the selenium of TrxR covalently 
attached to the ligand.  Derivatives (39) and (42) were prepared in an attempt to 
further explore this mechanism.  However, 1,4-conjugate addition is not the only 
method for covalent bond formation to TrxR, for example, 1-chloro-2,4-
dinitrobenzene is known to inhibit TrxR irreversibly, by arylating cysteine and 
selenocysteine residues of the carboxyl-terminal peptide, through a nucleophilic 
aromatic substitution mechanism [1998JBC10835].   
To investigate this alternative mechanism, derivatives of the lead compound 
RDP00060  (12) were prepared that could theoretically undergo nucleophilic   157
aromatic substitution reactions with the selenocysteine residue of TrxR (Figure 




























(52) (53)  
 
Figure 54a.  RDP00060 (12) derivatives with the potential to undergo nucleophilic aromatic 


















































Figure 54b.  The fluorobenzonitrile (52) analogue irreversibly inhibiting TrxR through a 
nucleophilic aromatic substitution mechanism. 
 
3.7.2.3.1. Suzuki  Coupling 
In order to prepare the necessary biaryl skeleton of (52) and (53), a Suzuki 
coupling reaction was performed.  A Suzuki coupling is a palladium based 
coupling reaction that couples halides or pseudohalides with boronic acids or   158
boronic esters (Figure 55) [2002T9633].  This reaction provides a powerful and 
general method for forming carbon-carbon bonds. 
 
+ R2 X R2 R
Pd
Base
Where X = I, Br, Cl, OTf
RB ( R 1)2 + XB ( R 1)2
 
 
Figure 55.  A general scheme for a Suzuki coupling reaction. 
 
To perform the Suzuki coupling, the bromo bis-sulfonamide (43a) was prepared 










































Scheme 21.  Synthesis of the bromo bis-sulfonamide  (43a). Reagents and conditions: (a) 
pyridine (13), pyrrolidinopyridine (15), dry acetonitrile, reflux, 24 hours, 93 %. 
 
The 
1H NMR spectrum of the bromo bis-sulfonamide (43a) presented a multiplet 
at δ 7.43 and at δ 7.19; both multiplets integrated to four protons.  These peaks 
couple together through the HH COSY spectrum and consequentely were 
assigned to the aromatic tosyl protons of the bromo bis-sulfonamide (43a).  The 
deshielded multiplet at δ 7.43 was assigned to the protons at positions H2' / H6' 
and H2'' / H6'' (43a) due to the electron withdrawing properties of the adjacent   159
sulfonyl group.  In contrast, however, the multiplet at δ 7.19 was assigned to the 
protons at positions, H3' / H5' and H3'' / H5''.  The 
1H NMR spectrum also revealed 
at singlet at δ 2.19, integrating to six protons, which was assigned to the two 
tosyl methyl groups of the bromo bis-sulfonamide (43a). 
Another advantage of the Suzuki coupling is that there is a wide range of boronic 
acids (or esters) available commercially, so the coupling partner of the halide can 
be quite diverse.  If the required coupling partner is not available, another 
approach can be used to obtain the desired product.  Here, a pinacol borane 
ester can be coupled to the halide using standard Suzuki conditions.  From this, 
the newly coupled borane ester can then be coupled to the halide substrate.   
Since a wider range of halides are available commercially than boronic acids (or 
esters), the coupling partner then becomes broad and diverse.  This 
methodology was attempted on the bromo bis-sulfonamide (43a); however, no 
coupling was observed and only starting material was isolated.  It was 
rationalized that the sulfonamide units of (43a) were interfering with catalysis, 
even though in the literature, palladium based coupling reactions have been 
carried out successfully on sulfonamides [2000OL89].  Suzuki coupling directly 
with 4-bromo-1,2-benzenediamine  (43), also failed, with only starting material 
isolated.  It is known that aniline functionalities can be problematic in palladium 
based coupling reactions, as they can bind to the active palladium-0 complex and 
halt the catalytic cycle which may explain why no product was obtained in this 
reaction.  As a result of these failed reactions, the two aniline functionalities of 
(43)  were protected with BOC groups (Scheme 22), and the Suzuki coupling 
again attempted.      
 
 


















(43) (43b)  
 
Scheme 22.  Protection of 4-bromo-1,2-benzenediamine (43) using BOC2O.  Reagents and 
conditions: (a) DMAP, dry THF, reflux, 18 hours, 82 %.    
 
The 
1H NMR spectrum of the BOC protected 4-bromo-1,2-benzenediamine (43b) 
showed a singlet at δ 1.59 and at δ 1.58; both singlets integrate to nine protons 
and were assigned to the two tert butyl groups present in (43b).  Two separate 
signals for the tert butyl groups were observed because the protons are not 
chemically equivalent.  In addition, the 
13C NMR spectrum revealed two 
quaternary carbons at δ 148.3 and δ 148.2 which were assigned to the two 
carbonyl carbons in the BOC protected 4-bromo-1,2-benzenediamine (43b).  
The Suzuki coupling on the BOC protected 4-bromo-1,2-benzenediamine (43b) 
failed, with only starting material isolated.  Variation of the Suzuki coupling 
conditions was also unsuccessful: change of catalyst, solvent, catalyst loading, 
base, reaction time and coupling partner.  
Electronic effects can also influence a Suzuki coupling, for example, electron 
deficient species are more reactive than electron rich species [2002T9633].  The 
electron rich character of 4-bromo-1,2-benzenediamine (43) may be the cause of 
the failed reactions.  By contrast, the electronics of 4-bromo-2-nitroaniline (44) 
are different to those of 4-bromo-1,2-benzenediamine (43)  due to the electron 
withdrawing nitro group; Suzuki coupling of the electron deficient 4-bromo-2-
nitroaniline (44) was successful with product (46) obtained in good yield (Scheme 
23). 














(44) (46) (45)  
 
Scheme 23.  A Suzuki coupling of 4-bromo-2-nitroaniline (44) with the pinacol borane dimer (45). 
Reagents and conditions: (a) 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride 
dichloromethane, potassium acetate, DMF, 80 °C, 24 hours, 56 %. 
 
The 
1H NMR spectrum of (46) revealed a singlet at δ 1.29 integrating to twelve 
protons.  This peak was assigned to the four equivalent methyl groups from the 
boronate ester moiety of (46).  The IR spectrum of (46) also showed strong 
absorptions at 3471 cm
-1, 3329 cm
-1, 1553 cm
-1 and 1342 cm
-1.  The absorptions 
at 3471 cm
-1 and 3329 cm
-1 are indicative of NH stretches and were assigned to 
the NH2 unit of (46), while the absorptions at 1553 cm
-1 and 1342 cm
-1 are 
indicative of N–O stretches and were assigned to the NO2 unit of (46).
  
Subsequent reduction of the nitro group of (46) was achieved using catalytic 


























Scheme 24.  Reduction of (46) to (47).  Reagents and conditions: (a) H2, Pd/C 10 %, methanol, 
18 hours, 85 %.  
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The IR spectrum of (47) lacked the two indicative stretches of a nitro group, as 
present in (46).  The 
1H NMR spectrum of (47) showed the proton at H3 is 
shielded (δ 7.17) due to the + M effects of the adjacent NH2 group.  In contrast, 
however, the 
1H NMR spectrum of (46) showed the proton at H3 is deshielded (δ 
8.28) due to the – M and – I effects of the adjacent nitro group. 
Compound  (47) is an important synthetic intermediate, from which both 
derivatives (52) and (53) can be prepared.  An attempt was made to prepare (52) 
by performing another Suzuki coupling reaction on (47) with 4-bromo-1-fluoro-2-
nitrobenzene  (48) as the coupling partner.  Unfortunately, under standard 
conditions, no product was obtained; instead a compound was isolated, which 
subsequent NMR analysis suggested that the compound was the corresponding 
phenol (Figure 56).  The Suzuki coupling was performed under anhydrous 
conditions, using dry solvents, so it was rather surprising to isolate the phenolic 
compound. 






Figure 56.  The proposed structure of the phenolic compound isolated from the attempted Suzuki 
coupling of (47) and 4-bromo-1-fluoro-2-nitrobenzene (48) under standard conditions. 
 
The potassium acetate used in the Suzuki coupling was of high grade, but still 
contained a small amount of water, which could account for the formation of the 
phenolic compound.  The next attempted Suzuki coupling used an anhydrous 
grade of sodium carbonate as base and, consequently, did not produce any 
phenol; however, the anticipated product was not produced, with a proposed tri-
aryl product isolated from the reaction mixture (Figure 57), as suggested by 
1H 
and 
13C NMR analysis. 
The proposed structure obtained would result from the desired Suzuki coupling 
between the boronate ester (47) and 4-bromo-1-fluoro-2-nitrobenzene  (48)   163
followed by further reaction of an aniline group of the product with another 
molecule of 4-bromo-1-fluoro-2-nitrobenzene  (48)  in a nucleophilic aromatic 
substitution reaction.  This illustrates the high reactivity of 1-fluoro-2-nitro-aryl 
compounds, as it was not expected that the aniline moiety of (47) would be a 
strong enough nucleophile to react with 4-bromo-1-fluoro-2-nitrobenzene  (48) 









Figure 57.  The proposed structure of the tri-aryl product isolated from the attempted Suzuki 
coupling of (47) with 4-bromo-1-fluoro-2-nitrobenzene (48).   
 
The high reactivity of 1-fluoro-2-nitro aromatic species could lead to the inhibition 
of other enzymes, which would be undesirable, as it could lead to adverse effects.  
It is desirable to design a TrxR inhibitor that shows good inhibitory activity 
towards TrxR, but also shows high selectivity for TrxR.  It was considered that 
the latter aspect would not be achieved through (52) and, as a result of this, the 
synthesis was abandoned.      
To reduce overall reactivity, while improving selectivity for TrxR, biaryl bis-
sulfonamide  (53) was synthesized from boronate ester (46) and 2-fluoro-5-
iodobenzonitrile (49) according to the same coupling methodology outlined above 
(Scheme 25).  A Suzuki coupling reaction was not performed on (47) because it 
was a sticky gum and, consequently, was difficult to handle.  It was therefore 
decided to perform the Suzuki coupling on (46) and then reduce the nitro group 
using catalytic hydrogenation with palladium on carbon as catalyst.  The 
sulfonamide units were then attached using the standard optimized conditions to   164
afford (53).  Analogue (53) is theoretically less reactive than (52) because the 
nitrile functional group is less efficient at withdrawing electron density than the 
nitro group.   
Analogues (50) and (51) showed a characteristic stretch indicative of a nitrile 
functionality at 2230 cm
-1.  Analogue (50) also showed absorptions at 1558 cm
-1 
and 1356 cm
-1, characteric of N–O stretches, which were assigned to the nitro 
group of (50).  In contrast, however, no such absorptions were observed in the IR 












































Scheme 25. Formation of (53) through a Suzuki coupling reaction. Reagents and conditions: (a) 
1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II), dry sodium carbonate, dry DMF, 80 °C, 
24 hours, 86 %; (b) H2, Pd/C 5 %, MeOH, rt., 18  hours, 97 %; (c) pyridine (13), acetonitrile, reflux, 
18 hours, 69 %. 
 
The IR spectrum of (53) showed an absorption at 2238 cm
-1, indicative of a nitrile 
functional group.  The 
1H NMR spectrum of (53) revealed a doublet of doublet of 
doublets resonating at δ 7.48 which was assigned to H6 (Figure 58) and arises 
due to coupling with H5 (J6,5 = 8.7 Hz), H2 (J6,2 = 2.4 Hz) and fluorine (J6,F = 5.4   165
Hz).  Also observed in the 
1H NMR spectrum was a doublet of doublets at δ 7.31 
which was assigned to H2.  This peak resonates as a doublet of doublets and not 
as a triplet because the 3 bond coupling constant between a proton and fluorine 
is generally larger than that between a proton and a proton; in the case of H2, J2,F 
= 6.0 Hz and J2,6 = 2.4 Hz.  The two singlets resonating at δ 2.36 and δ 2.32, 
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Figure 58. An expansion of the 300 MHz proton NMR spectrum of (53), illustrating the proton - 
fluorine coupling observed in (53).  The doublet of doublet of doublets at δ 7.48 (J6,5 = 8.7 Hz, J6,F 
= 5.4 Hz, J6,2 = 2.4 Hz) corresponds to H6.  The doublet of doublets at δ 7.31 (J2,F = 6.0 Hz, J2,6 = 
2.4 Hz) corresponds to H2. 
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3.7.2.4.  Thiophenyl Amide  
For direct comparison with the furanyl amide (33f), the thiophenyl amide 
analogue (55) was synthesized by reaction of the aniline bis-sulfonamide (33b) 
with 2-thiophenecarbonyl chloride (54), Scheme 26.  The IR spectrum of the 
thiophenyl amide (55) showed the classic amide I and II bands at 1648 cm
-1 and 
1597 cm
-1, which are indicative of carbonyl and NH functionalities respectively.  
The 
1H NMR spectrum of the thiophenyl amide (55) also showed three bond 
coupling consistent for thiophene heterocycles [B2001MIb]. 
The potent inhibitory activity of the furanyl amide (33f) to TrxR could be through 
an irreversible 1,4-conjugate addition mechanism, possible due to the low 
aromatic character of furan and its ability to undergo reactions characteristic of 
dienes, such as the Diels Alder reaction. 
By comparison, thiophene shows high aromatic character with reactions 
characteristic of aromatic systems, such as electrophilic aromatic substitution 
reactions; the thiophenyl amide (55) was unlikely to show potent inhibition of 
TrxR through conjugate addition, even though it has similar steric features to the 




































Scheme 26.  The synthesis of the thiophenyl amide (55). Reagents and conditions: (a) dry 
pyridine (13), dry acetonitrile, reflux, 18 hours, 79 %. 
 
3.7.3. Molecular  Modelling 
The irreversible inhibitors were docked into the active site of TrxR using the 
docking programme, LigandFit.  The docked poses were then assessed for 
hydrogen bonding and evaluated using the eight scoring functions contained   168
within the Ligand Scoring panel of Cerius
2.  The scores of the derivatives are 
summarized by Table 22. 
 
Derivative LigScore1  Ligscore2 -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
RDP00060 (12) 3.320  5.610  84.120 77.490 2.180 87.740  539 440 
(39)  3.740 5.380  62.460 57.290 1.650 77.720  493  411 
(42)  5.120 5.420  70.010 57.760 2.200 127.210  479  412 
(53)  2.290 5.580  78.250 75.200 2.800 58.510  487  487 
(55)  2.400 4.460  79.570 84.550 3.300 50.090  652  575 
 
Table 22.  The values obtained from eight scoring functions used to evaluate the ligand – protein 
interaction.  A high scoring function indicates a good calculated interaction between the ligand 
and the protein. 
 
The modelling studies suggested that the enamide (39) was able to bind to TrxR 
as efficiently as the lead compound, RDP00060 (12), through two hydrogen 
bonds with TrxR.  The first hydrogen bond was formed between the sulfonamide 
oxygen (para to the enamide) and the ionized amine side chain of lysine-B29 and 
the second between the NH of the sulfonamide meta to the enamide and the 
alcohol side chain of threonine-A481.   
The scoring functions also suggested that the uracil derivative (42) could bind to 
TrxR very efficiently.  The LigScore1 function scored the uracil derivative (42) at 
5.120, while the lead compound, RDP00060 (12) only scored 3.320.  This is to 
be expected as the uracil derivative (42) has many functional groups capable of 
forming non-bonding interactions, such as hydrogen bonds.  Evaluation of the 
hydrogen bonding showed that three hydrogen bonds could be formed between 
the uracil moiety of (42) and the protonated side chains of lysine residues B29, 
B33 and B123.   
In contrast, the fluoronitrile (53) did not appear to bind favourably to TrxR, with 
six out of the eight scoring functions scoring the lead compound, RDP00060 (12), 
higher; however, the scoring functions purely evaluate non-covalent interactions 
and cannot be expected to provide a realistic comparison to an analogue that   169
was designed to inhibit TrxR irreversibly through a nucleophilic aromatic 
substitution mechanism.  The docking studies also showed that the NH from the 
sulfonamide unit of (53) ( para to the aryl ring) could hydrogen bond with the 
carbonyl backbone of isoleucine-A478. 
The thiophenyl amide (55) did not score as highly as the lead compound, 
RDP00060 (12), in most of the scoring functions; however, as discussed above, 
the scoring functions only measure non-covalent interactions, and cannot predict, 
or take into account an analogue that was designed to inhibit irreversibly TrxR. 
Inspection of the in silico binding of thiophenyl amide (55) to TrxR indicated a 
preference for a similar conformation and comparable scoring to that of the 
analogous furanyl amide (33f). 
Interestingly, in silico modelling shows that the C3 unit from the thiophene ring of 
(55) was positioned within 5 Å of the catalytic residue at A498, whilst the C3 unit 
from the furan ring of (33f) was positioned within 3 Å of the same residue (Figure 
59).  Since the furanyl amide (33f) and the thiophenyl amide (55) appear to bind 
to TrxR in similar conformations, a direct comparison can be made to determine 
how the reactivity of thiophene and furan influence inhibitory activity towards 
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Figure 59.  The sulfur from cysteine A498 can bind within 3 Å of C3''' from the furan ring of (33f), 
whilst C3''' from the thiophene ring of (55) was positioned with 5 Å of the sulfur from cysteine A498. 
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3.7.4. Biological  Evaluation 
The potentially irreversible inhibitors were first evaluated for inhibitory activity 
towards the Trx system using the insulin reduction assay.  As for the previous 
RDP00060  (12) derivatives, a preliminary screen was carried using 500 μM 
concentrations of compound (Table 23).  After the preliminary screen, all of the 
potentially irreversible inhibitors (39, 42, 53, 55) were tested at further 
concentrations and, from this, dose response curves were plotted and IC50 
values established (Figure 60). 
 
Derivative  Y  Percentage inhibition at 500 μM IC50 (μM) 
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Trx, TrxR, Insulin Reduction Assay for (39)










































Trx, TrxR, Insulin Reduction Assay for (53)












































Trx, TrxR, Insulin Reduction Assay for (42)










































Trx, TrxR, Insulin Reduction Assay for (55)











































Figure 60. Dose response curves of absorbance as a percentage of the control against log 
concentration for compounds (39), (42), (53), and (55). 
 
The derivatives were then subjected to an MTT assay using a HPV-16 cell line as 
described previously (Table 24).  GI50 values were calculated using GraphPad 
Prism
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Derivative Y  CLogP Antiproliferative  Activity  (GI50) μM 





























Table 24.  GI50 values of the compounds tested on a HPV-16 immortalized keratinocyte cell line 
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A Dose Response Curve of (39) against Percentage Growth
of Human Keratinocytes




































A Dose Response Curve of (42) against Percentage Growth
of Human Keratinocytes




































A Dose Response Curve of (53) against Percentage Growth
of Human Keratinocytes

































A Dose Response Curve of (55) against Percentage Growth
of Human Keratinocytes



























Figure 61.  Dose response curves of percentage growth vs. log concentration for compounds 
(39), (42), (53), (55). 
 
The  in vitro results indicated a lower activity for these potentially irreversible 
inhibitors than had been anticipated.  Even the most active of these compounds, 
the fluorobenzonitrile analogue (53), was only half as active (IC50 109 μM) as the 
most active compound to date, the furanyl amide (33f) (IC50 37 μM), while the 
enamide  (39), uracil derivative (42) and thiophenyl amide (55) showed lower 
inhibition of the Trx system with IC50 values of 156, 339 and 494 μM, respectively.  
To rationalize these data, the in silico model of compound binding to TrxR was 
carefully inspected.  The catalytic selenocysteine residue is presumed to be key 
in the irreversible inhibition of TrxR, due to its high nucleophilicity and ability to 
react with suitable electrophilic systems [2001FRBM1287]. 
For irreversible inhibition of TrxR by the synthetic compounds introduced above, 
the potentially reactive electrophilic centre of each compound (e.g. Cb of the   174
enamide (39) or C4 of fluorobenzonitrile (53)) should be positioned adjacent to 
the catalytic selenocysteine residue, represented in the in silico model by 
cysteine A498.  Although this situation was observed in the in silico model of 
furanyl amide (33f), in which C3''' of the furan ring was sited at 3 Å from the sulfur 
atom of cysteine A498, it was not the case for any of the compounds (39), (42) or 
(53); the electrophilic functional groups of these compounds were positioned 
greater than 10 Å away from cysteine A498 (Figures 62, 63, 64), preventing 
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Figure 62.  Comparison of the favoured conformations of enamide (39) [magenta] and furanyl 
amide  (33f) [red] when docked in the active site of TrxR.  The residues of TrxR have been 
removed for clarity apart from the catalytic cysteine-A498, which has been colored according to 
atom type.  The C3''' atom from the furan ring of (33f) binds within 3 Å of the sulfur atom of 
cysteine-A498, while the Cb atom from the enamide functionality of (39) binds over 10 Å away 
from cysteine-A498. 
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Figure 63.  Comparison of the favoured conformations of uracil (42) [blue] and furanyl amide (33f) 
[red] when docked in the active site of TrxR.  The residues of TrxR have been removed for clarity 
apart from the catalytic cysteine-A498, which has been colored according to atom type.  The C3''' 
atom from the furan ring of (33f) binds within 3 Å of the sulfur atom of cysteine-A498, while the 
uracil functionality of (39) binds over 10 Å away from cysteine-A498. 
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Figure 64.  Comparison of the favoured conformation of fluoronitrile (53) [white] and furanyl 
amide (33f) [red] when docked in the active site of TrxR.  The residues and backbone ribbon of 
TrxR have been removed for clarity apart from the catalytic cysteine-A498, which has been 
colored according to atom type.  The C3''' atom from the furan ring of (33f) binds within 3 Å of the 
sulfur atom of cysteine-A498, while the C4 atom from the fluorobenzonitrile functionality of (53) 
binds over 10 Å away from cysteine-A498.  The fluorine atom of (55) is shown in CPK format. 
   
The scoring functions were developed to identify and evaluate non-covalent 
interactions that could favourably contribute to the binding of a compound to a 
biological molecule, such as an enzyme.  For favourable binding, 
complementarity of shape and suitable non-covalent interactions, such as   178
hydrogen bonding, ionic interactions and Van der Waals interactions, are 
required.  A molecule that can form a covalent bond to TrxR does not require the 
same significant non-covalent interactions to maintain its binding to the active 
site, as the formation of a covalent bond confers strong and irreversible binding.  
Complementarity of shape and the position of the reactive functional group in the 
near vicinity of the reactive residue are of greater importance for these potential 
inhibitors. 
It is not suprising, therefore, that the scoring functions do not produce a close 
guide to the inhibitory activity of compounds (39),  (42) and (53) when they 
evaluate only some of the possible interactions between ligand and TrxR. 
The enamide (39) and fluorobenzonitrile (53) still show good inhibitory activity 
towards TrxR, in comparison with the other RDP00060 (12) analogues, despite 
not being as active as the furanyl amide (33f).  It is possible that the good 
inhibitory activity is a result of irreversible inhibiton of TrxR.  The in silico binding 
modes of the enamide (39) and the fluorobenzonitrile (53) analogue were 
carefully examined (Figure 62 and 64).  This model suggested that the reactive 
functional groups of each ligand bind over 10 Å away from the catalytic cysteine 
residue at A498; however, it is possible that the ligands bind to TrxR in a different 
conformation, as LigandFit only picks the most stable conformation of each 
ligand.  In such a case, a different conformation may allow the reactive functional 
groups of each ligand to bind closer to the catalytic cysteine residue and thus 
allowing covalent attachment to occur.  It should also be noted that the models 
illustrated in Figures 62, 63 and 64 are static, when in fact the system is dynamic 
and in constant motion.  This may allow the reactive functional group of each 
ligand to move close enough to the cysteine residue at A498 for covalent 
attachment to occur.  It is important to note that the present model does not 
account for this. 
The inhibitory activity of the thiophenyl amide (55) towards TrxR was around ten 
times less than the corresponding furanyl amide (33f), which supports the 
previous discussion on the aromaticity of these heterocycles and their ability to 
undergo reactions characteristic of dienes.   Since both ligands adopted similar in   179
silico conformations and the C3''' atom of thiophene (from (55)) and furan (from 
(33f)) positioned within 5 Å and 3 Å, respectively, from the sulfur atom of cysteine 
A498, the difference in activity of both ligands can be explained in terms of the 
differing reactivity of thiophene and furan.  It is assumed the activity of the 
thiophenyl amide (55) towards TrxR is a result of non-covalent binding 
interactions rather than covalent irreversible inhibition. 
The results in the MTT assay continue to follow the trend observed with all of the 
RDP00060 (12) derivatives.  The trend shows that the hydrophilic RDP00060 (12) 
derivatives tend to be less active in the MTT assay than the lipophilic derivatives, 
for example, (42), the most polar ligand from this series of compounds, shows 
the least activity in the MTT assay.  Since the MTT assay is a cellular based 
assay, this observation is probably related to the ability of the ligand to cross the 
cellular membrane and enter the cell.  In contrast, compound (53) showed good 
inhibitory activity against the Trx system, but also showed excellent activity in the 
MTT assay, with a GI50 value of 156.3 nM.  It is possible that the excellent activity 
of  (53) on the MTT assay is due to the combination of the high lipophilic 
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4.  Further Biological Testing. 
The work undertaken to improve the inhibitory activity of the lead compound, 
RDP00060 (12) towards the thioredoxin enzyme system proved successful with 
(33f) being the most active analogue.  Indeed, it is thought that (33f) acts through 
an irreversible 1,4-conjugate addition mechanism, which is consistant with the 
low IC50 towards the thioredoxin system.  The MTT assay was used as a crude 
and quick measure to determine the ability of the RDP00060 (12) analogues to 
reduce cellular proliferation; however, it does not identify whether the analogues 
were causing cellular apoptosis or necrosis.  It is desirable that the analogues 
are triggering apoptosis, rather than causing necrosis.  This is important because 
cellular necrosis can damage the lysosome membrane within the cell.  This can 
lead to the release of digestive enzymes, such as hydrolases, which can cause 
adverse effects; furthermore, release of the intracellular content though necrosis 
can also lead to inflammation.  It is also important to note that PUVA and UV-B 
therapy, both successfully used in the management of severe plaque psoriasis, 
are thought to act by inducing T-cell apoptosis.  The experimental work described 
in this chapter was carried out by Mr Graeme Burns-Parker, University of 
Sunderland, UK. 
 
4.1.  Annexin V-Pe Assay 
To determine if the analogues were causing apoptosis or necrosis, an Annexin V-
Pe assay was used.  Annexin V is a member of the annexin family of 
phospholipid binding proteins and has a high affinity for phosphatidylserine (PS) 
containing bilayers.  During apoptosis, large changes in cell morphology occur, 
for example, PS translocates from the inner leaflet of the cellular membrane to 
the outer cell surface.  Once the PS is exposed on the cell surface, annexin V is 
able to bind to it.  The annexin V is attached to a fluorescent probe that is used 
for detection by flow cytometry.  Exposure of the PS on the external surface of 
the cell provides a simple way of detecting cells undergoing early apoptosis.  The 
assay is also used in conjugation with 7-aminoactinomycin D (7-AAD).  During 
cellular necrosis and the latter stages of apoptosis, the membrane integrity of a   182
cell is lost.  As the plasma membrane becomes increasingly permeable, 7-AAD 
can move readily across the cell membrane and bind to cellular DNA, thereby 
providing a way of identifying cells that have lost their membrane integrity; 
however, when the cell is viable or undergoing early stages of apoptosis, it is 
impermeable to 7-AAD.   
This assay was carried out on human T-cells using the furanyl amide (33f) and 
the amide (23) (Figure 65).  These analogues were chosen because the furanyl 
amide (33f) showed excellent inhibitory activity towards the Trx system and also 
good activity in the MTT assay, while the amide (23) had poor activity in both 
assays.  Ciclosporin, an agent used in the management of severe plaque 
psoriasis, and also known to trigger cellular apoptosis, was used as a positive 
control in the assay.  It was interesting to compare the activity of the most active 
analogue, the furanyl amide (33f) with the amide (23) and ciclosporin (6). 
When the cells are double stained with annexin V and 7-ADD, three different 
cellular populations are possible:  
(i)  viable cells that do not stain with either annexin V or 7-ADD (found in 
lower left quadrant),  
(ii)  necrotic cells or cells undergoing late stages of apoptosis that stain 
with both reagents (found in upper right quadrant), 
(iii)  cells undergoing early stages of apoptosis that stain with annexin V 
only (found in lower right quadrant).   
 
For a compound to show high apoptotic activity it is desirable that the majority of 
the cell population is found in the lower right quadrant, if, however, a compound 
shows high necrotic activity, the majority of the cell population is found in the 
upper right quadrant.  This is an undesirable characteristic and would indicate 
that a compound is toxic.  When a cell is found in the upper right quadrant, it is 
not possible to determine whether the cell has undergone necrosis or late stage 
apoptosis.  This is because when a cell undergoes early stage apoptosis the 
membrane is impermeable to 7-ADD and consequently stains the lower right 
quadrant.  When the cell is late stage apoptotic, the cell membrane becomes   183
permeable to 7-ADD and consequently moves from the lower right quadrant to 
the upper right quadrant.  If, however, the cell has undergone necrosis it will also 
be permeable to 7-ADD, so will also stain the upper right quadrant.  As a result of 
this, it is not possible to differentiate when a cell is found in the upper right 
quadrant if it has undergone necrosis or late stage apoptosis. Nonetheless, if a 
compound causes apoptosis, the majority of the cell population will be found in 
the lower right quadrant (indicating early stage apoptosis), while some of the 
cells will be found in the upper right quadrant (indicating late stage apoptosis).  If 
a compound causes necrosis, the majority of the cell population will be found in 
the upper right quadrant with very few cells found in the lower right quadrant.  
This is one possible way to differentiate crudely if a cell has undergone late stage 
apoptosis or necrosis when found in the upper right quadrant.  
Examing the control experiment (i.e. with no compound added) revealed that 50 
percent of the cell population was viable.  These cells stained negative for 
annexin V and 7-ADD.  The control experiment also revealed that 29 percent of 
the cell population showed signs of early stage apoptosis, while 15 percent of the 
cell population showed signs of late stage apoptosis or necrosis.  In contrast, 
however, when the cell population was pretreated with ciclosporin, an agent used 
successfully in the management of psoriasis, only 37 percent of the cell 
population was viable, while 39 percent showed signs of early stage apoptosis, 
and 13 percent showed signs of late stage apoptosis or necrosis.  These data 
suggest that in comparison to the control, ciclosporin appeared to trigger 
apoptosis in T-cells.   
Ciclosporin inhibits an enzyme called calcineurin, which leads to the inhibition of 
cytokine production.  Interestingly, it has also been shown that ciclosporin 
induces apoptosis in a number of different cell types [2005MI430, 2006MI2237], 
which appears to support the results of this current work. 
In comparison to the control, the furanyl amide (33f), also appeared to trigger 
apoptosis in human T-cells, with 37 percent of the cell population showing signs 
of early apoptosis.  The results also showed that 37 percent of the cell population 
remained viable.   184
The cell population showing signs of early stage apoptosis (i.e. staining positive 
for annexin V and negative for 7-ADD), was very similar for both the furanyl 
amide (33f) (37 percent) and ciclosporin (39 percent) (Table 25).  This suggests 
the furanyl amide (33f) and ciclosporin induced apoptosis in T-cells to a similar 
extent.  It is important to note that, despite exhibiting similar properties in the 
annexin V-Pe assay, it is anticipated that both compounds act on different 
cellular targets, with ciclosporin targeting calcineurin and the furanyl amide (33f) 
targeting TrxR. 
The control also showed that 29 percent of the cell population showed signs of 
early apoptosis; in comparison, addition of the amide (23) resulted in 31 percent 
of the cell population showing early signs of apoptosis.  As these results were 
similar to those of the control, it was concluded that the amide (23) does not 
significantly promote apoptosis in human T-cells.  This conclusion is in 
agreement with the previous results when the amide (23) was found to have no 
detectable inhibitory activity against the Trx system and also poor activity in the 
MTT assay.  
 
Compound  Viable Cells (%)  Early Apoptotic 
Cells (%) 
Late Apoptotic / 
Necrotic Cells (%) 
Control 50  29  15 
Ciclosporin (6) 37  39  13 
Furanyl amide (33f) 37  37  17 
Amide (23) 46  31  13 
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Figure 65.  Human T-cells stained with Annexin V and 7-ADD and analysed by flow cytometry.  
Distribution of cells are as follows; viable cells (lower left quadrant), early apoptotic (lower right 
quadrant), late apoptotic or necrotic (upper right quadrant). Values refer to the percentage total in 
each quadrant.  Work carried out by Mr. Graeme Burns-Parker; University of Sunderland; 2008.  
Reproduced with permission. 
 
These data are consistant with the ability of the furanyl amide (33f) to inhibit the 
Trx system, as reduced Trx binds to and inactivates ASK1, which controls and 
regulates apoptosis.  This binding is lost under oxidative conditions when Trx 
becomes oxidised.  It is anticipated that (33f) inhibits TrxR, which therefore 
prevents the reduction of oxidised Trx and the regeneration of active reduced Trx.    186
As a consequence of TrxR inhibition, ASK1 becomes activated and triggers 
cellular apoptosis, which was observed in the results of (33f). 
 
4.2. CFSE Assay 
Analogues (33f) and (23) where then subjected to a CFSE assay to determine if 
they show antiproliferative properties in human T-cells.  The CFSE assay is 
considered a safer alternative to the classical [
3H]-thymidine incorporation assay 
often used to determine cell proliferation.  Carboxyfluoroscein diacetate 
succinimidyl ester (56a) (CFSE) is a cell permeable compound which readily 
enters the cell, upon which, the ester group is cleaved by esterases to produce a 
fluorescent compound (known as carboxyfluorescein succinimidyl ester (56b)) 
that is less cell permeable (Scheme 27).  As cells divide, the carboxyfluorescein 
succinimidyl ester (56b) is split equally between the daughter cells, which results 
in reduced carboxyfluorescein succinimidyl ester (56b) signal detection with each 
subsequent cell division (Figure 66).  The attenuation of the signal gives an 
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Scheme 27.  Intracellular esterases cleave the acetate groups of CFSE (56a), producing 















Figure 66.  A schematic diagram illustrating the concept of the CSFE Assay.  The left hand side 
represents a cell undergoing division (each cell division coloured differently).  The right hand side 
represents a typical control CSFE plot; as cell division occurs the concentration of 
carboxyfluorescein succinimidyl ester (56b) is split equally between daughter cells resulting in 
diminished signal detection. 
 
For a compound to show good antiproliferative properties in the CFSE assay, the 
majority of the cells should remain in the parent state (the blue cell illustrated in 
Figure 66).  If, however, a compound shows weak antiproliferative properties, the 
cells will undergo division.  As cell division occurs, the carboxyfluorescein 
succinimidyl ester (56b) is split equally between daughter cells, which results in 
attenuated signal detection. 
The control experiment (i.e. no drug added to the cells) showed each cell division 
as an individual colour on the graph (Figure 67).  The parent cells are coloured 
blue, while cells undergone one cell division are coloured orange.  The remaining 
cells are coloured according to their division number.  In the control, it can be 
observed that the majority of the cells are in the fifth division (corresponding to 
turquoise blue on the graph).  Comparing this to ciclosporin (6), an agent known 
to have antiproliferative properties in T-cells, it can be seen that ciclosporin (6) 
inhibits cell division with the majority of the cells remaining in the parent state 
(corresponding to dark blue on the graph). 



















Figure 67.  Flow plots depicting the percentage of divided CFSE labeled T-cells treated with 
either  (33f),  (23), ciclosporin (6) or control.  Work carried out by Mr. Graeme Burns-Parker; 
University of Sunderland; 2008.  Reproduced with permission. 
 
The results also show that the furanyl amide (33f) inhibits cell division, with a 
calculated proliferation index (PI) of 1.36.  The PI is the sum of the cells in all 
generations divided by the calculated number of the original parent cells.  In 
comparison, ciclosporin (6) had a PI equal to 1.22, which is similar to that of the 
furanyl amide (33f).  However, it should be noted that ciclosporin was used at a 
concentration of 500 ng per mL, while the furanyl amide (33f) and the amide (23) 
were used at a concentration of 2000 ng per mL.  As a result of this, it is not 
really appropriate to compare PI values between ciclosporin and the furanyl   190
amide (33f).  Nonetheless, the results still illustrate that the furanyl amide (33f) 
exhibits antiproliferative properties in T-cells when compared to the control data. 
The results also show that the amide (23) had no antiproliferative properties 
when compared to the control.  The proliferation index of the control and the 
amide (23) were both found to equal 5.62.  These data are also in agreement 
with the previous work, in which the amide (23) was found to have no detectable 
inhibitory activity against the Trx system, poor activity on MTT and no ability to 
induce apoptosis in human T-cells.  In contrast, however, the furanyl amide (33f) 
was found to induce apoptosis in human T-cells, inhibit the Trx system, and 
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5. Future  Work 
There are a number of possible avenues for future research as a direct result of 
this project.  Relating to the project described here, there are four intermediate 
pieces of work that would benefit the results and conclusions; these are 
described briefly below. 
 
(i) The  aldehyde  bis-sulfonamide  (37) was evaluated for inhibitory activity 
against the Trx system; however, it was not subjected to derivatization due to 
time contraints.  The aldehyde moiety of (37) is a useful functional group 
because it can undergo numerous diverse chemical reactions, offering the 
preparation of a wide range of RDP00060 (12) analogues.  For example, 
oxazoles can be prepared directly from aldehydes in a one pot synthesis using 
the reagent toluenesulphonylmethyl isocyanide (TOSMIC).  TOSMIC is an 
extremely versatile synthon developed by the Dutch chemist Albert van Leusen 
[B2004MIc].  Aldehydes can also be reacted with trimethylsilyl cyanide to form 
the corresponding cyanohydrin which can then be reduced to the beta-amino-
alcohol.  Such compounds are directly available from the aldehyde bis-
sulfonamide (37) and attempts will be made to prepare them in the near future.   
 
(ii) Analogue  (52) was designed to inhibit thioredoxin reductase irreversibly 
through a nucleophilic aromatic substitution mechanism, in a similar manner to 
which 1-chloro-2, 4-dinitrobenzene inhibits TrxR irreversibly by arylation of 
cysteine and selenocysteine residues near the carboxy-terminus 
[1998JBC10835].  However, initial efforts to prepare (52)  were  unsuccessful.  
Several attempts were made to couple 4-bromo-1-fluoro-2-nitrobenzene (48) with 
(47) through a Suzuki coupling reaction.  However, these reactions failed 
because of the highly reactive fluorine of (48) undergoing various substitution 
reactions.  In view of these failed reactions, the less reactive fluoronitrile 
analogue (53) was successfully prepared using similar methodology.  Despite the 
successful preparation of (53), it would be desirable to make analogue (52) to 
compare its inhibitory activity with the less reactive (53), which may allow the   193
construction of a structure activity relationship leading to the development of 
further irreversible inhibitors.  One possible solution to the synthetic problem is to 
carry out the Suzuki coupling reaction first to construct the biaryl skeleton, and 
then add the fluorine functionality via a Balz-Schiemann reaction (Scheme 28).  
This proposed synthesis offers an alternative route to (52) and will be attempted 
























































Scheme 28. A proposed synthesis for the formation of (52) using a Balz-Schiemann reaction to 
add the fluorine after the Suzuki coupling.    
 
(iii)  A trend that was observed with all of the RDP00060 (12) analogues was 
the lipophilicity of a compound appeared to influence the activity on the MTT 
assay.  The partition coefficients of the RDP00060 (12) analogues were 
calculated using the programme ChemDraw; however, this programme only 
estimates the partition coefficient of a compound.  In order to explore further the 
relationship between lipophilicity and activity in the MTT assay, it is necessary to   194
measure the accurate partition coefficients of the RDP00060 (12) analogues 
experimentally.  This will be carried out in the future. 
 
(iv)  It has been suggested in this work that Trx could play a role in the 
pathology of psoriasis.  In view of this, it is anticipated that inhibition of the Trx 
system either directly by inhibiting Trx, or indirectly by inhibiting TrxR, could open 
up an avenue for the discovery of novel compounds with potential use in the 
treatment of psoriasis.  It is thought that Trx or TrxR inhibition will prevent the 
activation of the transcription factor NFκB and thereby inhibit the DNA binding; 
however, it is not yet known if the RDP00060 (12) analogues inhibit the DNA 
binding of NFκB through inhibition the thioredoxin system.  Recent evidence 
suggests that there is a link between NFκB and psoriasis [2009MI199]; it is 
acknowledged in the literature, that curcumin, a TrxR inhibitor, inhibits the 
activation of NFκB [2008CL199], so it is anticipated that the furanyl amide (33f), 
the most potent thioredoxin reductase inhibitor from the RDP00060 (12), series 
will also inhibit the activation of NFκB.  This will be investigated in the future.   
 
The four pieces of work described above relate to the the current work; however, 
this research has also opened up an avenue for future projects, which will be 
briefly outlined below. 
One limitation of the work described herein is that the insulin reduction assay 
does not distinguish between compounds acting upon Trx or TrxR.  It was 
assumed that since the RDP00060 (12) analogues were designed to inhibit TrxR, 
any activity observed in the the insulin reduction assay was a consequence of 
TrxR inhibition. 
One future research project could examine specifically which part of the Trx 
system the RDP00060 (12) analogues are acting upon.  This could be achieved 
by conducting an assay specifically designed to identify TrxR inhibition.  One 
such assay is known as the DTNB assay and is based on the concept that DTNB 
is a direct substrate for TrxR as illustrated by Figure 68.  
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Figure 68.  The reduction of DTNB to TNB by TrxR. 
 
As the DTNB is reduced, the corresponding product, TNB, is a distinct yellow 
colour which can be measured quantitatively at 405 – 412 nm.  The intensity of 
the yellow colour is proportional to TrxR activity.  Inhibition of TrxR will prevent 
the reduction of DTNB and, consequently, prevent the formation of the yellow 
TNB.   
Measuring the absorbance of TNB at various time intervals allows the 
construction of a plot in which reaction kinetics can be determined.  Investigating 
the enzyme kinetics will provide information about the type of inhibition being 
observed (i.e. reversible or irreversible) between the ligand and TrxR.  The 
different types of enzyme inhibition produce characteristic plots which vary in 
distinctive ways with different inhibitor concentrations.  From these data, the type 
of inhibition between ligand and TrxR can be determined. 
This information will help provide an insight into the mechanism by which the 
ligand binds to TrxR.  A comparison can also be made between observed binding 
modes through enzyme kinetics and postulated theoretical binding modes. 
Another aspect the current work did not explore was why BTB03744 displayed 
high activity in the MTT assay, but had no detectible inhibitory activity towards 
the Trx system.  BTB03744 was a hit compound identified through the SBF 
process (Figure 17).  It was postulated that BTB03744 was acting upon another 
target within the cell.  A future project could examine the biological activity of 
BTB03744 and attempt to identify its cellular target.  One way to start this 
process would be to use a technique called proteomics.  Proteomics can be 
defined as the qualitative and quantitative comparison of proteomes under 
different conditions to further unravel biological processes [2003MI128].     196
Proteomics is an extremely complex, but powerful, technique.  Indeed, a single 
proteome can consist of more than a million individual proteins, with 
concentrations varying by a factor of one hundred million.  There are two major 
techniques used to separate, detect and analyse the complete proteome of a cell.  
The first technique uses an electrophoresis approach called two-dimensional gel 
electrophoresis (2DGE), while the second technique uses an HPLC approach 
called two-dimensional nano-high performance liquid chromatography / mass 
spectroscopy (2D nano – HPLC/MS).  Proteomics can be used on a cell line to 
identify which proteins are expressed.  The same cell line can then be treated 
with BTB03744, and then the proteins can be identified that are either down or up 
regulated, using the techniques described above.  This methodology can be used 
to help establish what cellular processes BTB03744 may act upon.   
The future project can also explore the potential synthesis and characterisation of 
BTB03744.  Once a synthetic route has been established, BTB03744 could then 
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6. Conclusion 
Structure based focussing was used successfully to identify ten hit compounds to 
inhibit thioredoxin reductase.  The ten compounds identified were purchased 
from the Maybridge screening library and evaluated for inhibitory activity against 
thioredoxin reductase.  The compounds were also evaluated for antiproliferative 
activity using an MTT assay on an HPV-16 immortalized keratinocyte cell line.  
One of the compounds, BTB03744, showed no inhibitory activity towards the 
thioredoxin system, but had good activity in the MTT assay with a GI50 of 18 μM.  
In contrast, however, RDP00060 (12), showed moderate inhibitory activity 
against thioredoxin reductase, with an IC50 of 1.4 mM, and good activity in the 
MTT assay, with a GI50 of 4.1 μM.  It is possible that the inhibitory activity of 
RDP00060 towards thioredoxin reductase may account for the activity on the 
MTT assay, as thioredoxin reductase inhibition can trigger apoptosis due to the 
disruption and consequent activation of the ASK1 – Trx complex.  It is also 
interesting to note that BTB03744 is active on the MTT assay, despite having no 
activity towards the Trx system, suggesting that BTB03744 is acting on another 
target within the cell.   
A range of molecular modelling techniques were used to identify RDP00060 (12) 
analogues with potential for high binding affinity towards TrxR.  The hydrogen 
bonding potential of each analogue was also evaluated to establish if any 
functional groups could participate in hydrogen bonding with residues from 
thioredoxin reductase.  As a result of the modelling studies, several novel 
RDP00060  (12) analogues were prepared and characterised.  The lead 
compound, RDP00060 (12), was also subjected to bioisosteric replacement, in 
which the ester functionality was replaced with an oxadiazole, the sulfonamide 
units were replaced with amides, and the benzene rings were replaced with 
thiophene.  Interestingly, when the sulfonamide functionalities of RDP00060 (12) 
were replaced with amides, all inhibitory activity against thioredoxin reductase 
was lost.  Furthermore, the amide analogue (23) also showed poor activity in the 
MTT assay.     199
One of the RDP00060 (12) analogues, N-(3,4-bis-(toluene-4-
sulfonylamino)phenyl)-2-furamide (33f), prepared using Katritzky’s benzotriazole 
methodology, showed good inhibitory activity towards the thioredoxin system with 
an IC50 value of 37 μM.  This analogue showed the highest inhibitory activity 
towards the thioredoxin system of all the RDP00060 (12) derivatives prepared.  
In comparison, to other Trx enzyme system inhibitors, such as, AW464 and 
curcumin,  N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-furamide (33f) had 
similar inhibitory activity with AW464 and curcumin having IC50 values of 23 μM 
and 3.6 μM respectively [2005JBC25284, 2003MI1695].  
It is anticipated that N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-furamide (33f) 
binds to thioredoxin reductase irreversibly through a 1,4-conjugate addition 
mechanism.  This is supported by molecular modelling studies that showed the 
C3'''  atom of the furan ring of N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-
furamide (33f) could bind adjacent to the sulfur atom of cysteine-A498.  Further 
work also showed that replacement of the furan ring of (33f) by the more 
aromatic thiophene heterocycle resulted in a compound with considerably less 
inhibitory activity towards thioredoxin reductase despite comparative binding to 
TrxR.  Examination of the aromaticity of the two heterocycles offers an 
explanation: the high electronegativity of the oxygen results in the low aromatic 
character of furan and it can consequently act as a diene in Diels Alder reactions. 
In contrast, the sulfur of thiophene has much lower electronegativity, similar to 
that of carbon, which results in the high aromatic character of thiophene and 
precludes it acting as a diene in Diels Alder reactions. 
The lower activity of the thiophene analogue (55) as an inhibitor of TrxR further 
supports the irreversible binding of (33f) to TrxR through a 1,4-conjugate addition, 
a characteristic reaction of conjugated unsaturated non-aromatic carbonyl 
compounds. 
A carbonyl alpha to furan provides an extended α, β, γ, δ carbonyl system which 
could participate in conjugate addition reactions (Figure 69). 
 






Figure 69.  An example of an α, β, γ, δ carbonyl system as present on analogue (33f).    
 
Further biological testing was then used to establish if the most active RDP00060 
(12) analogue, N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-furamide (33f), 
showed apoptotic and antiproliferative properties; both desirable features of   
antipsoriatic compounds.   
All of the analogues were subjected to an MTT assay to determine if they 
exhibited antiproliferative properties.  This assay, however, is only a crude 
measurement of antiproliferation and is often only used to determine the 
mitochondrial activity of a cell.  The CSFE assay was used to determine if N-(3,4-
bis-(toluene-4-sulfonylamino)phenyl)-2-furamide (33f), the most active compound 
against the thioredoxin system, had antiproliferative properties.  The CFSE assay 
is considered a safer alternative to the classical ‘gold standard’ [
3H]-thymidine 
incorporation assay, often used to determine antiproliferation.  The results of the 
assay showed that N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-furamide (33f) 
had antiproliferative properties comparable to ciclosporin, an agent often used in 
the treatment of severe plaque psoriasis.  It is possible that that N-(3,4-bis-
(toluene-4-sulfonylamino)phenyl)-2-furamide’s (33f) ability to inhibit thioredoxin 
reductase accounts for the antiproliferative activity, due to the activation of the 
ASK1 complex that occurs as a consequence of thioredoxin reductase inhibition.  
This is further supported by the fact that methyl 4-bis-(4-methyl-
benzoylamino)benzoate  (23), an agent that had no inhibitory activity towards 
thioredoxin reductase, showed no antiproliferative activity on the CSFE assay.   
An Annexin V-Pe assay was then used to determine if  N-(3,4-bis-(toluene-4-
sulfonylamino)phenyl)-2-furamide (33f) triggered apoptosis in T-cells.  The 
results showed that N-(3,4-bis-(toluene-4-sulfonylamino)phenyl)-2-furamide (33f) 
triggered apoptosis with 37 % of the cell population showing signs of early stage 
β      γ 
  α        δ   201
apoptosis.  This is an important result as it illustrates that N-(3,4-bis-(toluene-4-
sulfonylamino)phenyl)-2-furamide (33f) causes programmed cell suicide through 
apoptosis, rather than killing the cells through necrosis. 
In conclusion, thioredoxin reductase inhibition appears to offer a novel 
therapeutic route for the treatment of psoriasis.  Using a molecular modelling 
technique known as structure based focusing, a novel class of compounds were 
identified, synthesized and characterized, that inhibit the thioredoxin enzyme 
system (Table 26).  The most active compound from the class, N-(3,4-bis-
(toluene-4-sulfonylamino)phenyl)-2-furamide (33f),  was also shown to have 
apoptotic and antiproliferative properties in human T-cells; two desirable 
properties of antipsoriatic compounds.  As a result, N -(3,4-bis-(toluene-4-
sulfonylamino)phenyl)-2-furamide (33f) has been selected for further 
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Table 26a.  A summary of the biological properties of the 3,4-RDP00060 (12) analogues 
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Table 26b.  A summary of the biological properties of the 3,5-RDP00060 (12) analogues 











































Melting points were determined on a Stuart Scientific SMP10 apparatus and are 
uncorrected.  IR spectra were recorded on Unicam research series FTIR 
spectrophotometer. 
 1H NMR spectra were recorded using DMSO as solvent on a 
Bruker AVANCE 300 at 300 MHz unless otherwise stated.  Chemical shifts are 
given in ppm, while coupling constants are in Hz.  
13C NMR were obtained using 
a Bruker AVANCE 250 (at 75 MHz).  Low-resolution electron impact mass 
spectra were obtained on a Fisons VG Platform 2 or Trio 2000 VG using 
electrospray ionization.  High resolution mass spectra were obtained on a Bruker 
FTMS-Apex II.  Elemental analysis was performed on an Exeter Analytical CE-
440 elemental analyzer at ChemiSpec, University of Sunderland, United 
Kingdom.  Thin layer chromatography was performed on Merck silica gel 60F254; 
column chromatography was performed using Fluka silica gel 60.  Starting 
materials and reagents were obtained commercially from Sigma Aldrich; solvents 
were used without further purification.  Solvents were dried when required 
according to the procedure of Perrin [B1997MI01].  Compounds were named 
using AutoNom.  When the AutoNom name changed the numbering of the 
compound from the standard format, the compound was named and numbered in 
a similar manner to the lead compound, RDP00060 (12).  In this case, the 
AutoNom name is given in brackets after the standard naming and numbering 
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3, 4-Diaminobenzoic acid (9) (2 g, 0.014 mol) was added to dry methanol (50 mL) 
under nitrogen.  The mixture was cooled with ice and conc. H2SO4 added (2 mL).  
The resulting solution was then refluxed for 18 hours.  After this time, the solution 
was cooled and washed with sodium hydrogen carbonate 10 % (40 mL).  The 
solution was transferred to a separating funnel and ethyl acetate added (40 mL).  
The aqueous layer was further extracted with ethyl acetate (3 × 20 mL).  The 
combined organic layers were washed with sodium hydrogen carbonate 5 % (20 
mL) and dried (MgSO4).  The solvent was removed in vacuo to afford a brown 
solid which was purified by recrystallisation from petroleum ether (40/60): ethyl 
acetate to yield methyl 3, 4-diaminobenzoate (10) as brown needles (1.65 g, 75.5 
%); mp 105 °C [lit. 103 – 105 °C [1999BMC2487]]; Rf = 0.47 (ethyl acetate); m/z 
167.0 (MH
+); νmax (KBr) / cm
-1 1705 (CO), 1267 (C–O); δH (d6-DMSO, 300 MHz) 
7.16 (1H, d, J2, 6 = 2.0, H2), 7.10 (1H, dd, J6, 5 = 8.1, J6, 2 = 2.0, H6), 6.51 (1H, d, J5, 
6 = 8.1, H5), 5.28 (2H, s, NH2), 4.66 (2H, s, NH2), 3.71 (3H, s, OCH3); δC (d6-
DMSO, 75 MHz), 167.3 (CO), 141.0 (C4), 134.3 (C3), 120.7 (C6), 117.6 (C1), 
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7.3.  Synthesis of methyl 3,4-diamino-N, N-bis-(toluene-4-



































Methyl 3, 4-diaminobenzoate (10) (1.0 g, 0.006 mol), p-toluenesulfonyl chloride 
(11) (2.52 g, 0.013 mol) and 4-pyrrolidinopyridine (0.90 g, 0.006 mol) were added 
to dry acetonitrile (25 mL) under argon.  Dry pyridine (2.4 mL, 0.03 mol) was then 
added and the resulting solution was heated at reflux for 72 hours.  After this time, 
the acetonitrile was removed in vacuo to afford a brown oily residue.  The residue 
was dissolved in DCM (30 mL) and washed with 0.5 M HCl (3 × 30 mL).  The 
organic layer was dried (MgSO4) and the solvent removed in vacuo to yield a 
brown powder, which was purified by column chromatography on silica, eluting 
with DCM : methanol (95 : 5) to afford crude methyl 3,4-diamino-bis-(toluene-4-
sulfonylamino)benzoate  (12).  This was recrystallised from DCM : petroleum 
ether to yield pure methyl 3,4-diamino-bis-(toluene-4-sulfonylamino)benzoate (12) 
as brown crystals (1.78 g, 62.6 %); mp 175 °C; Rf = 0.44 (DCM : methanol, 9 : 1); 
m/z 496.9 (MNa
+); Analysis Calcd. for C22H22N2O6S2: C, 55.68; H, 4.67; N, 5.90 
%. Found C, 55.86; H, 4.70; N, 5.74 %; νmax (KBr) / cm
-1 3217 (NH), 1704 (C=O), 
1157 (S=O); δH (d6-DMSO, 300 MHz) 9.62 (2H, s, 2 × NH), 7.67 (2H, d, J = 8.4, 
H2’ / H6’ or H2’’ / H6’’), 7.62 (1H, dd, J6, 5 = 8.4, J6, 2 = 1.8, H6), 7.57 (3H, m, H2 and 
H2’ / H6’ or H2’’ / H6’’), 7.36 (4H, d, J  = 8.4, H3’ / H5’ and H3’’ / H5’’ ) 7.26 (1H, d, J5, 6 = 
8.4, H5), 3.74 (3H, s, OCH3), 2.36 (3H, s, CH3), 2.35 (3H, s, CH3); δC (d6-DMSO, 
75 MHz) 165.5 (CO), 144.5 (C4’ and C4’’), 144.3 (C4), 136.4 (C1’ and C1’’), 135.8   209
(C3), 130.3 (C3’ / C5’ or C3’’ / C5’’), 130.3 (C3’ / C5’ or C3’’ / C5’’), 127.7 (C6), 127.4 
(C2’ / C6’ or C2’’ / C6’’), 127.4 (C2’ / C6’ or C2’’ / C6’’), 125.7 (C2), 125.6 (C1), 120.5 
(C5), 52.6 (OCH3), 21.5 (2 × CH3).  
 













Product (17) was prepared according to the procedure of (10) using 3, 5-
diaminobenzoic acid (16) (4 g, 0.026 mol) and dry methanol (100 mL).  After 
work up, the pink solid was purified by recrystallisation from petroleum ether 
(40/60): ethyl acetate to yield methyl 3, 5-diaminobenzoate (17) (3.00 g, 69.6 %); 
mp 132 – 133 °C [lit. 131 – 134 ° C [Aldrich]]; Rf = 0.40 (ethyl acetate); m/z 167.0 
(MH
+); νmax (KBr) / cm
-1 1700 (CO), 1267 (C–O); δH (d6-DMSO, 300 MHz) 6.34 
(2H, d, J = 2.1, H2, H6), 5.93 (1H, t, J4, 2 / 6 = 2.1, H4), 4.87 (4H, s, 2 × NH2), 3.64 
(3H, s, OCH3); δC (d6-DMSO, 75 MHz) 167.7 (CO), 149.8 (C3 / C5), 131.0 (C1), 
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This compound was prepared as described for (12), from methyl 3,5-
diaminobenzoate  (17)  (0.50 g, 0.003 mol) and p-toluenesulfonyl chloride (11) 
(1.26 g, 0.006 mol) using dry pyridine (1.2 mL, 0.015 mol) as catalyst.  After work 
up, column chromatography, eluting with DCM : methanol (90 : 10) gave methyl 
3,5-diamino-N,N-bis-(toluene-4-sulfonylamino) benzoate (18) as a white solid 
(1.07 g, 75.2 %); mp 175 °C; Rf = 0.33 (DCM : methanol, 9 : 1); m/z 496.9 
(MNa
+); Analysis Calcd. for C22H22N2O6S2: C, 55.68; H, 4.67; N, 5.90 %. Found C, 
55.90; H, 4.57; N, 5.86 %; νmax (KBr) / cm
-1 3259 (NH), 1700 (C=O), 1184 (S=O); 
δH (d6-DMSO, 300 MHz) 7.50 (4H, d, J = 8.3, H2’ / H6’), 7.30 (1H, t, J4, 2 / 6 = 2.1, 
H4), 7.23 (4H, d, J = 8.3, H3’ / H5’), 7.21 (2H, d, J6 / 2, 4 = 2.1, H2 / H6), 3.67 (3H, s, 
OCH3), 2.25 (6H, s, 2 × CH3); δC (d6-DMSO, 75 MHz) 165.6 (CO), 144.0 (C4’), 
139.6 (C1’), 136.7 (C3 / C5), 131.6 (C1), 130.2 (C3’ / C5’), 127.1 (C2’ / C6’), 115.4 
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Methyl 3,4-diaminobenzoate (10) (1.0 g, 0.006 mol), 4-nitrobenzenesulfonyl 
chloride (2.9 g, 0.013 mol) and 4-pyrrolidinopyridine (0.9 g, 0.006 mol) were 
added to dry acetonitrile (25 mL) under argon.  Dry pyridine (2.4 mL, 0.030 mol) 
was added and the resulting solution was heated at reflux for 24 hours.  After this 
time, the acetonitrile was removed in vacuo to afford a brown residue, which was 
dissolved in ethyl acetate (30 mL) and washed with 1 M HCl (3 × 30 mL).  The 
organic layer was dried (MgSO4) and the solvent removed in vacuo to yield a 
cream coloured solid, which was purified by column chromatography on silica, 
eluting with ethyl acetate: petrol (60 : 40) to afford methyl 3,4-bis-(4-nitro-
benzenesulfonylamino)benzoate (19a) as a cream coloured solid (2.76 g, 85.8 
%); mp 262 – 264 °C; Rf = 0.44 (DCM : methanol, 8 : 2); m/z 559.0 (MNa
+); 
Analysis Calcd. for C20H16N4O10S2: C, 44.77; H, 3.01; N, 10.44 %.  Found C, 
44.81; H, 2.86; N, 10.22 %; νmax (KBr) / cm
-1 3257 (NH), 1716 (C=O), 1515 (NO2), 
1349 (NO2), 1164 (S=O);
 δH (d6-DMSO, 300 MHz), 8.39 (4H, d, J  = 8.9, H3’ / H5’ 
and H3’’ / H5’’), 8.06 (2H, d, J  = 8.9, H2’ / H6’ or H2’’ / H6’’), 7.94 (2H, d, J  = 8.9, H2’ 
/ H6’ or H2’’ / H6’’), 7.69 (1H, dd, J6, 5 = 8.7, J6, 2 = 2.1, H6), 7.50 (1H, d, J2, 6   = 2.1, 
H2), 7.23 (1H, d, J5, 6  = 8.7, H5), 3.75 (3H, s, OCH3); δC (d6-DMSO, 75 MHz) 
165.3 (CO), 150.55 (C4’ or C4’’), 150.50 (C4’ or C4’’), 145.1 (C1’ or C1’’), 145.0 (C1’ 
or C1’’), 136.2 (C4), 129.0 (C2’ / C6’ or C2’’ / C6’’), 128.9 (C2’ / C6’ or C2’’ / C6’’), 128.6   212
(C6), 128.2 (C3), 126.9 (C2), 126.7 (C1), 125.25 (C3’ / C5’ or C3’’ / C5’’), 125.20 (C3’ / 
C5’ or C3’’ / C5’’), 122.0 (C5), 52.7 (OCH3).  
 




































Product (19b) was prepared according to the procedure of (19a) using methyl 
3,4-diaminobenzoate  (10) (0.5 g, 0.003 mol) and  4-
trifluoromethylbenzenesulfonyl chloride (1.62 g, 0.0066 mol).  After work up, the 
crude product was recrystallised from DCM to afford the title compound as a pale 
white solid (1.35 g, 77 %); mp 216 – 218 °C; Rf = 0.25 (ethyl acetate : petroleum 
ether, 6 : 4); m/z 581.0 (M–H)
–; Analysis Calcd. for C22H16F6N2O6S2: C, 45.36; H, 
2.77; N, 4.81 %.  Found C, 45.21; H, 2.66; N, 4.49 %; νmax (KBr) / cm
-1 3256 (NH), 
1702 (C=O), 1163 (S=O); δH (d6-DMSO, 300 MHz) 7.95 (2H, d, J  = 8.4, H2’ / H6’ 
or H2’’ / H6’’), 7.87 (4H, d, J  = 8.4, H3’ / H5’ and H3’’ / H5’’), 7.80 (2H, d, J  = 8.4, H2’ 
/ H6’ or H2’’ / H6’’), 7.58 (1H, dd, J6, 5 = 8.4, J6, 2 = 1.8, H6), 7.33 (1H, d, J2, 6 = 1.8, 
H2), 7.17 (1H, d, J5, 6 = 8.4, H5), 3.64 (3H, s, OCH3); δC (d6-DMSO, 75 MHz) 165.3 
(CO), 143.6 (C1’ or C1’’), 143.4 (C1’ or C1’’), 136.5 (C4), 133.5 (q, JF, C4’/ 4’’ = 32.4, 
C4’ or C4’’), 133.4 (q, JF, C4’/ 4’’ = 32.4, C4’ or C4’’), 128.6 (C6), 128.4 (C2’ / C6’ or C2’’ 
/ C6’’), 128.3 (C2’ / C6’ or C2’’ / C6’’), 127.7 (C3), 127.2 (q, JF, C3’/ C5’ = 3.7, JF, C3’’/ C5’’ 
= 3.7 C3’ / C5’ and C3’’ / C5’’), 127.0 (C2) 126.2 (C1), 123.8 (q, JFC = 273.1, CF3), 
121.2 (C5), 52.6 (OCH3).   213




































Product (19c) was prepared according to the procedure of (19a) using methyl 
3,4-diaminobenzoate  (10) (1.0 g, 0.006 mol) and  4-
trifluoromethoxybenzenesulfonyl chloride (3.45 g, 0.013 mol).  After work up, the 
crude product was recrystallised from DCM to afford the title compound as a 
white solid (2.79 g, 76 %); mp 173 °C; Rf = 0.42 (DCM : methanol, 9 : 1), m/z 
613.1 (M–H)
–; Analysis Calcd. for C22H16F6N2O8S2.
1/2CH2Cl2 C, 41.64; H, 2.64; N, 
4.32 %. Found C, 41.66; H, 2.57; N, 4.42 %; νmax (KBr) / cm
-1 3250 (NH), 1708 
(C=O) 1152 (S=O); δH (d6-DMSO, 300 MHz) 9.78 (2H, s, 2 × NH), 7.96 (2H, d, J 
= 9.0, H2’ / H6’ or H2’’ / H6’’), 7.79 (2H, d, J = 9.0, H2’ / H6’ or H2’’ / H6’’), 7.68 (1H, dd, 
J6, 5 = 8.4, J6, 2 = 2.1, H6), 7.55 (4H, m, H3’ / H5’ and H3’’ / H5’’), 7.44 (1H, d, J2, 6 = 
2.1, H2), 7.31 (1H, d, J5, 6 = 8.4, H5), 3.74 (3H, s, OCH3);  δC (d6-DMSO, 75 
MHz),165.3 (CO), 151.9 (C4’ and C4’’), 138.5 (C1’ or C1’’), 138.2 (C1’ or C1’’), 136.6 
(C4), 130.0 (C2’ / C6’ and C2’’ / C6’’), 128.5 (C6), 127.6 (C3), 126.8 (C2), 126.0 (C1), 
121.9 (C3’ / C5’ and C3’’ / C5’’), 120.8 (C5), 120.3 (OCF3, q, J = 258.6), 52.6 
(OCH3).     
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Derivative (19d) was prepared according to the procedure of (19a) using methyl 
3,4 diaminobenzoate (10) (1.0 g, 0.006 mol) and 4-methoxybenzenesulfonyl 
chloride (2.7 g, 0.013 mol).  After work up, the crude product was recrystallised 
from ethyl acetate : petroleum ether to afford the title compound as a brown solid 
(1.85 g, 60.9 %); mp 133 °C;  Rf = 0.50 (DCM : methanol, 9 : 1); m/z 505.0 (M–
H)
–; Analysis Calcd. for C22H22N2O8S2: C, 52.16; H, 4.38; N, 5.53 %. Found C, 
52.34; H, 4.52; N, 5.60 %; νmax (KBr) / cm
-1 3237 (NH), 1717 (C=O), 1153 (S=O); 
δH (d6-DMSO, 300 MHz) 9.52 (2H, s, 2 × NH), 7.72 (2H, d, J = 8.9,  H2’ / H6’ or H2’’ 
/  H6’’), 7.62 (4H, m, H2’ /  H6’ or H2’’ /  H6’’ and H2 and H6), 7.29 (1H, d, J5, 6 = 8.4, 
H5), 7.07 (4H, d, J  = 8.9, H3’ / H5’  and H3’’ / H5’’), 3.83 (6H, s, 2 × OCH3), 3.77 (3H, 
s, OCH3 [ester]); δC (d6-DMSO, 75 MHz) 165.5 (CO ester), 163.4 (C4’ or C4’’), 
163.3 (C4’ or C4’’), 135.8 (C4), 130.7 (C1’ or C1’’), 130.7 (C1’ or C1’’), 129.7 (C2’ / C6’ 
or C2’’ / C6’’), 129.6 (C2’ / C6’ or C2’’ / C6’’), 127.9 (C3), 127.7 (C6), 125.9 (C2), 125.7 
(C1),  120.5 (C5), 115.0 (C3’ / C5’ or C3’’ / C5’’), 115.0 (C3’ / C5’ or C3’’ / C5’’), 56.2 (2 
×OCH3), 52.6 (OCH3 [ester]).   
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To a solution of methyl 3,4-bis-(4-nitrobenzenesulfonylamino)benzoate (19a) (1.0 
g, 0.0018 mol) in methanol (50 mL) and ethyl acetate (50 mL) was added 
carefully 10 % Pd/C (0.1 g).  The resulting mixture was hydrogenated (3 atm) at 
room temperature for 18 hours.  After this time, the catalyst was removed by 
filtration through a bed of Celite.  The filtrate was concentrated in vacuo to afford 
(19e) as a pale pink crystalline solid (0.84 g, 94.6 %); mp 125 °C; m/z 475.0 (M–
H)
–; Analysis Calcd. for C20H20N4O6S2: C, 50.41; H, 4.23; N, 11.76 %.  Found C, 
50.22; H, 4.25; N, 11.78 %; νmax (KBr) / cm
-1 3376 (NH), 3223 (NH), 1709 (C=O), 
1592, 1146 (S=O); δH (d6-DMSO, 300 MHz) 9.26 (2H, s, 2 × NH), 7.63 (1H, br s, 
H2), 7.61 (1H, dd, J6, 5 = 8.4, J6, 2 = 2.1, H6), 7.44 (2H, d, J = 8.7, H2’ / H6’ or H2’’ / 
H6’’), 7.35 (2H, d, J = 8.7, H2’ / H6’ or H2’’ / H6’’), 7.29 (1H, d, J5, 6 = 8.4, H5), 6.60 
(4H, d, J = 8.7, H3’ / H5’ and H3’’ / H5’’), 3.81 (3H, s, OCH3); δC (d6-DMSO, 75 MHz) 
165.7 (CO), 153.8 (C4’ or C4’’), 153.7 (C4’ or C4’’), 136.2 (C4), 129.6 (C2’ / C6’ or 
C2’’ / C6’’), 129.4 (C2’ / C6’ or C2’’ / C6’’), 128.2 (C3), 127.2 (C6), 125.4 (C2), 125.1 
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A flame-dried three necked round bottomed flask was charged with methyl 3,5-
diaminobenzoate (17) (1g, 0.006 mol), 4-nitrobenzenesulfonyl chloride (2.92 g, 
0.013 mol) and dry acetonitrile (25 mL) under argon.  To this, dry pyridine (2.4 
mL, 0.03 mol) was added and the resulting solution was heated at reflux for 18 
hours.  After this time, the solvent was removed in vacuo to afford a brown 
residue which was taken up in DCM (30 mL) and vigorously washed with 1M HCl 
(3 × 30 mL).  The resultant  precipitate was collected by filtration and dried under 
high vacuum for 3 hours to afford the title compound as a pale orange solid (3.02 
g, 94 %); mp 196 - 198 °C; Rf = 0.45 (DCM : methanol, 9.5 : 0.5); m/z 559.0 
(MNa
+); Analysis Calcd. for C20H16N4O10S2: C, 44.77; H, 3.01; N, 10.44 %. Found 
C, 44.84; H, 2.79; N, 10.32; %; νmax (KBr) / cm
-1 3236 (NH), 1696 (C=O), 1535 
(NO2), 1348 (NO2), 1151 (S=O);
  δH (d6-DMSO, 300 MHz) 10.94 (2H, s, 2 × NH), 
8.37 (4H, d, J  = 9.0, H3 / H5’), 7.96 (4H, d, J  = 9.0, H2’ / H6’), 7.41 (2H, d, J = 2.1, 
H2 / H6), 7.33 (1H, t, J  = 2.1, H4) 3.80 (3H, s, OCH3); δC (d6-DMSO, 75 MHz) 
165.4 (CO), 150.5 (C4’), 144.8 (C1’), 138.9 (C3 / C5), 132.1 (C1), 128.7 (C2’ / C6’), 
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Derivative (20b) was prepared according to the procedure of (20a) using methyl 
3,5-diaminobenzoate  (17) (0.5 g, 0.003 mol) and  4-
trifluoromethylbenzenesulfonyl chloride (1.62 g, 0.0066 mol).  After work up, the 
crude product was recrystallised from ethyl acetate : petroleum ether to afford the 
title compound as a pale pink solid (1.62 g, 93 %); mp 195 – 198 °C; Rf = 0.45 
(DCM : methanol, 9 : 1); m/z 581.0 (M–H)
–; Analysis Calcd. for C22H16F6N2O6S2: 
C, 45.36; H, 2.77; N, 4.81 %. Found C, 45.12; H, 2.78; N, 4.66 %; νmax (KBr) / cm
-
1 3246 (NH), 1698 (C=O), 1152 (S=O); δH (d6-DMSO, 300 MHz) 10.87 (2H, s, 2 × 
NH), 7.95 (4H, d, J, = 9.0, H2’ / H6’), 7.91 (4H, d, J  = 9.0, H3’ / H5’), 7.41 (1H, t, J  
= 2.1, H4), 7.37 (2H, d, J  = 2.1, H2 / H6), 3.78 (OCH3); δC (d6-DMSO, 75 MHz) 
165.4 (CO), 143.3 (C1’), 139.1 (C3 / C5), 133.3 (q, JFC4’ = 32.6, C4’), 132.1 (C1), 
128.1 (C2’ / C6’), 127.1 (C3’ / C5’), 123.7 (q, JFC = 273.1, CF3), 116.4 (C2 / C6), 
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7.13.  Synthesis of methyl 3,5-bis-(4-





































Derivative (20c) was prepared according to the procedure of (20a) using methyl 
3,5-diaminobenzoate  (17) (1.0 g, 0.006 mol) and  4-
trifluoromethoxybenzenesulfonyl chloride (3.45 g, 0.013 mol).  After work up, the 
crude product was recrystallised from DCM to afford the title compound as a 
cream coloured solid (2.88 g, 78 %); mp 188 °C; Rf = 0.50 (DCM : methanol, 9 : 
1); m/z 613.1 (M–H)
–; Analysis Calcd. for C22H16F6N2O8S2: C, 42.97; H, 2.62; N, 
4.56 %. Found C, 43.01; H, 2.70; N, 4.75 %; νmax (KBr) / cm
-1 3247 (NH), 1702 
(C=O), 1151 (S=O); δH (d6-DMSO, 300 MHz) 7.82 (4H, d, J  = 8.7, H2’ / H6’), 7.52 
(4H, d, J = 8.7, H3’ / H5’), 7.36 (3H, s, H2, H4, H6), 3.73 (OCH3); δC (d6-DMSO, 75 
MHz) 165.4 (CO), 151.7 (C4’), 139.2 (C3 / C5), 138.3 (C1’), 131.9 (C1), 129.7 (C2’ / 
C6’), 121.8 (C3’ / C5’), 120.2 (q, JFC = 258.4, OCF3), 116.3 (C2 / C6), 115.1 (C4), 
52.9 (OCH3).   
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Product (20d) was prepared according to the procedure of (20a) using methyl 
3,5-diaminobenzoate  (17) (0.5 g, 0.003 mol) and  4-methoxylbenzenesulfonyl 
chloride (1.40 g, 0.0066 mol).  After work up, the crude product was recrystallised 
from ethyl acetate : petroleum ether to afford the title compound as yellow 
crystals (1.04 g, 69 %); mp 135 °C; Rf = 0.47 (ethyl acetate: petroleum ether, 6 : 
4); m/z 505.0 (M–H)
–; Analysis Calcd. for C22H22N2O8S2: C, 52.16; H, 4.38; N, 
5.53 %.  Found C, 52.17; H, 4.65; N, 5.51 %; νmax (KBr) / cm
-1 3233 (NH), 1703 
(C=O) 1146 (S=O), 1598; δH (d6-DMSO, 300 MHz)  10.43 (2H, s, 2 × NH), 7.66 
(4H, d, J = 8.9, H2’ / H6’), 7.40 (1H, t, J = 1.9, H4), 7.32 (2H, d, J = 1.9, H2 / H6), 
7.05 (4H, d, J  = 8.9, H3’ / H5’), 3.81 (6H, s, 2 × CH3), 3.78 (3H, s, OCH3 [ester]); 
δC (d6-DMSO, 75 MHz) 165.7 (CO), 163.1 (C4’), 139.7 (C3 / C5), 131.6 (C1), 131.2 
(C1’), 129.3 (C2’ / C6’), 115.4 (C2 / C6), 114.9 (C3’ / C5’), 114.3 (C4), 56.1 (2 × 
OCH3), 52.8 (OCH3 [ester]).    
 






































Methyl 3,5-bis-(4-aminobenzenesulfonylamino)benzoate  (20e) was prepared 
according to the procedure of (19e) using (20d) (1 g, 0.0018 mol) and 10 % Pd/C 
(0.1 g) to give (20e) as an orange solid (0.93 g, 96 %); mp 196 – 198 °C; Rf = 
0.40 (ethyl acetate : petroleum ether, 5 : 5); m/z 475.0 (M–H)
–; Analysis Calcd. 
for C20H20N4O6S2: C, 50.41; H, 4.23; N, 11.76 %. Found C, 50.16; H, 4.53; N, 
11.51 %; νmax (KBr) / cm
-1 3464 (NH2), 3369 (NH2), 1704 (CO), 1316 (C-N) 1156 
(S=O); δH (d6-DMSO, 300 MHz) 7.36 (4H, d, J = 8.9, H2’ / H6’), 7.34 (1H, t, J = 2.1, 
H4), 7.25 (2H, d, J = 2.1, H2 / H6), 6.53 (4H, d, J = 8.9, H3’ / H5’), 5.96 (4H, s, 2 ×   220
NH2), 3.77 (3H, s, OCH3);  δC (d6-DMSO, 75 MHz) 165.9 (CO), 153.4 (C4’), 140.1 
(C3 / C5), 131.2 (C1), 129.2 (C2’ / C6’), 124.5 (C1’), 114.8 (C2 / C6), 113.9 (C4), 
113.1 (C3’ / C5’), 52.8 (OCH3).     
 
 

































Product (21b) was prepared according to the procedure of (12) using 3,4-
diaminobenzonitrile (10) (2.0 g, 0.015 mol) and p-toluenesulfonyl chloride (11) 
(6.3 g, 0.033 mol).  After work up, the crude product was purified by column 
chromatography on silica, eluting with ethyl acetate: petrol (60 : 40) to afford 3,4-
bis-(toluenesulfonylamino)benzonitrile (21b) as a pink solid (5.63 g, 85 %); mp 
198 – 201 °C; Rf = 0.43 (ethyl acetate : petroleum ether, 6 : 4); m/z 440.0 (M–H)
–; 
Analysis Calcd. for C21H19N3O4S2: C, 57.13; H, 4.34; N, 9.52. Found C, 56.98; H, 
4.17; N, 9.56 %; νmax (KBr) / cm
-1 3275 (NH), 3202 (NH), 2233 (CN), 1158 (S=O); 
δH (d6-DMSO, 300 MHz) 9.82 (2H, s, 2 × NH), 7.73 (2H, d, J = 8.1, H2’ / H6’ or H2’’ 
/ H6’’), 7.66 (2H, d, J  = 8.1, H2’ / H6’ or H2’’ / H6’’), 7.56, (1H, dd, J6, 5 = 8.7, J6, 2 = 
2.0, H6), 7.43, (4H, d, J  = 8.1, H3’ / H5’ and H3’’ / H5’’), 7.38 (1H, d, J2, 6 = 2.0, H2), 
7.33 (1H, d, J5, 6 = 8.7, H5), 2.42 (6H, s, 2 × CH3); δC (d6-DMSO, 75 MHz) 144.7 
(C4’ or C4’’), 144.5 (C4’ or C4’’), 136.35 (C1’ or C1’’), 136.30 (C1’ or C1’’), 136.0 (C3 
and C4), 130.8 (C6), 130.45 (C3’ / C5’ or C3’’ / C5’’), 130.40 (C3’ / C5’ or C3’’ / C5’’),   221
128.1, (C2), 127.45 (C2’ / C6’ or C2’’ / C6’’), 127.40 (C2’ / C6’ or C2’’ / C6’’), 120.8 (C5), 
118.4 (CN), 106.7 (C1), 21.5 (2× CH3).     
 




































To a stirred solution of ethanol was added (21b) (1.00 g, 0.002 mol) and 50 % 
w/v 
aqueous hydroxylamine (0.2 mL, 0.0026 mol).  The resulting solution was heated 
at reflux for 12 hours.  After this time, the solvent was removed in vacuo to afford 
(21c)  (N-hydroxy-3,4-bis-(toluene-4-sulfonylamino)benzamidine) as a fluffy pink 
solid (1.01 g, 94 %); mp 180 °C; Rf = 0.49 (DCM : methanol, 9.5 : 0.5); m/z 473.0 
(M–H)
–; Analysis Calcd. for C21H22N4O5S2.
1/2C2H5OH; C, 53.06; H, 5.06; N, 11.25 
%. Found C, 53.25; H, 4.60; N, 11.01 %; νmax (KBr) / cm
-1 3374 (OH), 1756, 1596, 
1155 (S=O); δH (d6-DMSO, 300 MHz) 9.52 (2H, s, 2 ×NH), 7.46 (4.2 H, d, J = 8.3, 
H2’ / H6’ and H2’’ / H6’’ and H2 [masked]), 7.44 (0.8H, d, J2, 6 = 1.8, H2), 7.35 (0.2H, 
dd, J6, 5 = 8.4, J6, 2 = 2.1, H6), 7.25 (4H, d, J = 8.3, H3’ / H5’ and H3’’ / H5’’), 7.15 
(0.8H, dd, J6, 5 = 8.4, J6, 2 = 2.1, H6), 6.97 (0.2H, d, J5, 6 = 8.4, H5), 6.89 (0.8H, d, J5, 
6 = 8.4, H5), 5.73 (1H, br s, OH), 2.36 (6H, s, 2 × CH3); δC (d6-DMSO, 75 MHz) 
167.1 (C=NH), 150.4 (C4), 144.1 (C4’ and C4’’), 136.8 (C1’ or C1’’), 136.75 (C1’ or 
C1’’), 136.70 (C3), 130.25 (C3’ / C5’ or C3’’ / C5’’), 130.20 (C3’ / C5’ or C3’’ / C5’’), 
129.5 (C1), 127.4 (C2’ / C6’ or C2’’ / C6’’), 127.3 (C2’ / C6’ or C2’’ / C6’’), 123.2 (C6), 
122.4 (C5), 120.9 (C2), 21.5 (2 × CH3).    222













































To a stirred solution of dry DMF (15 mL) was slowly added isobutyric acid (0.1 
mL, 0.001 mol) and carbonyl diimidazole (0.17 g, 0.001 mol) under argon.  The 
resulting solution was stirred at room temperature for 30 minutes; the 
hydroxyamidine (21c) (0.45 g, 0.001 mol) was then added and the solution was 
heated at reflux for 18 hours.  After this time, the solution was cooled and water 
added (100 mL).  The resulting brown precipitate was collected by filtration, taken 
up into DCM (30 mL) and washed with water (3 × 30 mL).  The DCM was 
removed under reduced pressure to afford a brown solid, which was subjected to 
column chromatography eluting with ethyl acetate : petroleum ether (60 : 40), to 
yield (21d) as a brown solid (0.43 g, 82 %); mp 144 °C; Rf = 0.53 (ethyl acetate : 
petroleum ether, 4 : 6); (HRMS found: [MNa
+] 549.1243.  Calc. for 
C25H26N4O5S2Na: [MNa
+], 549.1231); νmax (KBr) / cm
-1 3253 (NH), 1596, 1568, 
1157 (S=O); δH (CDCl3, 300 MHz)  7.68 (1H, dd, J6, 5 = 8.4, J6, 2 = 1.8, H6), 7.58 
(2H, d, J = 8.1, H2’ / H6’ or H2’’ / H6’’), 7.51 (2H, d, J = 8.1, H2’ / H6’ or H2’’ / H6’’), 
7.43 (1H, d, J2, 6 = 1.8, H2), 7.15 (5H, m, H3’ / H5’ and H3’’ / H5’’ and H5), 3.14 (1H, 
septet, J  =  7.1, CH [isopropyl]), 2.30 (6H, s, 2 × CH3 [tosyl]), 1.33 (6H, d, J  = 7.1,   223
2 × CH3 [isopropyl]); δC (CDCl3, 75 MHz) 184.2 (C5’’’), 166.8 (C3’’’), 144.5 (C4’ or 
C4’’), 144.4 (C4’ or C4’’), 135.5 (C1’ or C1’’), 134.9 (C1’ or C1’’), 134.4 (C4 or C3), 
129.8 (C3’ / C5’ or C3’’ / C5’’), 129.7 (C3’ / C5’ or C3’’ / C5’’), 129.4 (C4 or C3), 127.7 
(C2’ / C6’ or C2’’ / C6’’), 127.6 (C2’ / C6’ or C2’’ / C6’’), 126.71 (C6), 125.6 (C2), 125.1 
(C1), 124.4 (C5), 27.5 (CH, [isopropyl]), 21.6 (2 × CH3 [tosyl]) 20.1 (2 × CH3 
[isopropyl]). 
 
































Product (23) was prepared according to the procedure of (20a) using methyl 3,4-
diaminobenzoate (10) (0.5 g, 0.003 mol) and 4-methylbenzoyl chloride (1.0 mL, 
0.006 mol).  After work up, the crude product was recrystallised from toluene to 
afford the title compound as a pale white solid (0.73 g, 60 %); mp 216 – 218 °C; 
Rf = 0.55 (DCM : methanol, 9.5 : 0.5); (HRMS found: [MNa
+] 425.1484.  Calc. for 
C24H22N2O4Na: [MNa
+], 425.1472); νmax (KBr) / cm
-1 1716 (CO [ester]), 1660 (CO 
[amide]), 1611 (NH); δH (d6-DMSO, 300 MHz) 10.15 (2H, s, 2 × NH), 8.28 (1H, d, 
J2, 6  = 1.8, H2), 7.90 (6H, m, H2’ / H6’ and H2’’ / H6’’ and H5, H6), 7.35 (4H, d, J  = 
8.1, H3’ / H5’ and H3’’ / H5’’), 3.90 (3H, s, OCH3), 2.39 (6H, s, 2 × CH3); δC (d6-
DMSO, 75 MHz) 166.2 (CO), 166.1 (CO), 166.0 (CO), 142.7 (C4’, C4’’), 136.5 (C4), 
131.6 (C1’, C1’’), 131.2 (C3), 129.6 (C3’ / C5’ or C3’’ / C5’’), 129.6 (C3’ / C5’ or C3’’ / 
C5’’), 128.2 (C2’ / C6’ or C2’’ / C6’’), 128.1 (C2’ / C6’ or C2’’ / C6’’), 127.5 (C2), 126.8 
(C6), 126.5 (C1), 125.6 (C5), 52.7 (OCH3), 21.5 (2 × CH3).  
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7.20.  Synthesis of methyl 3,4-bis-(5-chloro-thiophene-2-



































Product (25) was prepared according to the procedure of (19a) using methyl 3,4-
diaminobenzoate  (10) (0.5 g, 0.003 mol) and  5-chloro-2-thiophenesulfonyl 
chloride (1.42 g, 0.006 mol).  After work up, the crude product was recrystalised 
from toluene to afford the title compound as a pale white solid (0.74 g, 46.8 %); 
mp 167 °C; Rf = 0.29 (DCM : methanol, 19 : 1); Analysis Calcd. for 
C16H12Cl2N2O6S4 C, 36.44; H, 2.29; N, 5.31 %. Found C, 36.58; H, 2.20; N, 5.24 
%; νmax (KBr) / cm
-1 3272 (NH), 1713 (CO), 1156 (SO), 1086 (C–Cl); δH (d6-
DMSO, 300 MHz) 7.80 (1H, dd, J6, 5  = 8.7, J6, 2 = 2.1, H6), 7.70 (1H, d, J2, 6  = 2.1, 
H2), 7.58 (1H, d, J  = 4.0, H3’ or H3’’), 7.46 (1H, d, J5, 6  = 8.7, H5), 7.39 (1H, d, J  = 
4.0, H3’ or H3’’), 7.24 (2H, overlapping doublet, J  = 4.0, H4’, H4’’), 3.82 (3H, s, 
OCH3); δC (d6-DMSO, 75 MHz) 165.4 (CO), 138.1 (C5’ or C5’’), 138.0 (C5’ or C5’’), 
136.7 (C2’ or C2’’), 136.6 (C2’ or C2’’), 136.0 (C4), 133.9 (C3’ or C3’’), 133.6 (C3’ or 
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Product (27) was prepared according to the procedure of (19a) using methyl 3,4-
diaminobenzoate (10) (0.5 g, 0.003 mol) and 4-chlorolbenzenesulfonyl chloride 
(1.40 g, 0.0067 mol).  After work up, the crude product was recrystallised from 
toluene to afford the title compound as a pale white solid. (0.53 g, 34.3 %); mp 
163 °C; Rf = 0.42 (DCM : methanol, 9.5 : 0.5); Analysis Calcd. for 
C20H16Cl2N2O6S2 C, 46.61; H, 3.13; N, 5.44 %. Found C, 46.83; H, 3.08; N, 5.41 
%; νmax (KBr) / cm
-1 3242 (NH), 1712 (C=O), 1161 (S=O), 1084 (C–Cl); δH (d6-
DMSO, 300 MHz) 9.75 (2H, s, 2 × NH), 7.81 (2H, d, J = 8.7, H2’ / H6’ or H2’’ / H6’’), 
7.67 (7H, m, H2’ / H6’ or H2’’ / H6’’ and H3’ / H5’ and H3’’ / H5’’ and H6), 7.53 (1H, d, 
J2, 6 = 2.1, H2), 7.28 (1H, d, J5, 6 = 8.7, H5), 3.71 (3H, s, OCH3); δC (d6-DMSO, 75 
MHz) 165.4 (CO), 138.9 (quat.), 138.8 (quat.), 138.3 (quat.), 138.2 (quat.), 136.1 
(quat.), 130.1 (C3’ / C5’ or C3’’ / C5’’), 130.0 (C3’ / C5’ or C3’’ / C5’’), 129.3 (C2’ / C6’ 
and C2’’ / C6’’), 128.3 (C6), 127.8 (quat.), 126.5 (C2), 126.2 (quat.), 121.2 (C5), 
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A solution of (21b) (0.2 g, 0.00045 mol), tert-butanol (30 mL) and 60 % H2SO4 (8 
mL) was heated at reflux for 18 hours.  After this time, the mixture was cooled to 
room temperature and poured into ice water (100 mL).  The resultant precipitate 
was collected by filtration and recrystallised from chloroform to afford (28) as a 
white solid (0.11 g, 47 %); mp 205 - 207 °C; Rf = 0.46 (DCM); m/z 514.0 (M–H)
–; 
Analysis Calcd. for C25H29N3O5S2.CHCl3; C, 49.18; H, 4.68; N, 6.61 %. Found C, 
49.23; H, 4.96; N, 6.33 %;  νmax / cm
-1 3256 (NH), 1660 (C=O), 1602 (NH), 1150 
(S=O); δH (d6-DMSO, 300 MHz) 7.57 (2H, d, J = 8.3, H2’ / H6’ or H2’’ / H6’’), 7.45 
(2H, d, J = 8.3, H2’ / H6’ or H2’’ /  H6’’), 7.30 (1H, dd, J6, 5 = 8.7, J6, 2 = 1.5, H6), 7.14 
(4H, m, H3’ / H5’ and H3’’ / H5’’), 7.04 (2H, m, H2, H5), 2.31 (6H, s, 2 × CH3 [tosyl]), 
1.31 (9H, s, 3 × CH3 [tert-butyl]); δC (d6-DMSO, 75 MHz) 165.5 (CO), 144.5 (C4’ 
or C4’’), 144.4 (C4’ or C4’’), 135.5 (C4), 135.0 (C1’ or C1’’), 134.9 (C1’ or C1’’), 133.3 
(C3), 129.8 (C3’ / C5’ or C3’’ / C5’’), 129.7 (C3’ / C5’ or C3’’ / C5’’), 128.8 (C1), 127.7 
(C2’ / C6’ or C2’’ / C6’’), 127.6 (C2’ / C6’ or C2’’ / C6’’), 126.2 (C6), 125.5 (C2), 123.2 
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To a stirred solution of 1 M NaOH (10 mL) and 30 % 
v/v aqueous H2O2 (3 mL) 
was added the nitrile bis-sulfonamide (21b)  (0.5 g, 0.001 mol).  The resulting 
solution was stirred at room temperature for 18 hours, then acidified with 2 M HCl 
(10 mL) and extracted with DCM (3 × 30 mL).  The combined organic layers were 
dried (MgSO4) and the solvent removed under reduced pressure to afford a white 
residue, which was recrystalised from aqueous ethanol to afford the title 
compound as a white solid (0.36 g, 71.3 %); mp 201 – 202 °C; Rf = 0.26 (DCM : 
methanol, 9 : 1); m/z 458.0 (M–H)
–; Analysis Calcd. for C21H21N3O5S2.
1/2H2O; C, 
53.83; H, 4.62; N, 8.97 %. Found C, 53.66; H, 4.49; N, 8.92 %; νmax (KBr) / cm
-1 
3467 (NH2), 3354 (NH2), 1659 (C=O), 1615 (NH [amide]), 1150 (S=O); δH (d6-
DMSO, 300 MHz) 9.51 (2H, s, 2 × NH), 7.65 (2H, d, J = 8.1, H2’ / H6’ or H2’’ / H6’’), 
7.59 (3H, m, H2’ / H6’ or H2’’ / H6’’ and H2), 7.51 (1H, dd, J6, 5 = 8.4, J6, 2 = 2.1, H6), 
7.36 (4H, m, H3’ / H5’ and H3’’ / H5’’), 7.09 (1H, d, J5, 6 = 8.4, H5), 2.37 (6H, s, 2 × 
CH3); δC (d6-DMSO, 75 MHz) 167.0 (CO), 144.4 (C4’ or C4’’), 144.1 (C4’ or C4’’), 
136.6 (C1’ or C1’’), 136.5 (C1’ or C1’’), 133.4 (C4), 131.3 (C3), 130.3 (C3’ / C5’ or C3’’ 
/ C5’’), 130.2 (C3’ / C5’ or C3’’ / C5’’), 128.5 (C1), 127.4 (C2’ / C6’ or C2’’ / C6’’), 127.3 
(C2’ / C6’ or C2’’ / C6’’), 125.4 (C6), 124.7 (C2), 121.0 (C5), 21.5 (2 × CH3). 
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To a solution of nitrile bis-sulfonamide (21b) (0.5 g, 0.001 mol) in methanol (50 
mL) and ethyl acetate (50 mL) was added carefully 10 % Pd/C (0.1 g).  The 
resulting mixture was hydrogenated (3 atm) at room temperature for 72 hours.  
After this time, the catalyst was removed by filtration through a bed of Celite.  
The combined organic layers were dried (MgSO4) and removed under reduced 
pressure to afford (30) as a pale yellow solid (0.41 g, 86 %); mp 104 °C; Rf = 
0.15 (DCM : methanol, 9 : 1); (HRMS found: [MNa
+] 468.1022.  Calc. for 
C21H23N3O4S2Na: [MNa
+], 468.1016); νmax (KBr) / cm
-1 2923 (NH), 1597, 1156 
(S=O); δH (d6-DMSO, 300 MHz) 8.60 (2H, s, 2 × NH), 7.65 (2H, d, J = 8.3, H2’ / 
H6’ or H2’’ / H6’’), 7.55 (2H, d, J  = 8.3, H2’ / H6’ or H2’’ / H6’’), 7.26 (5H, m, H3’ / H5’ 
and H3’’ / H5’’ and H2), 6.97 (1H, d, J5, 6 = 8.4, H5), 6.88 (1H, dd, J6, 5 = 8.4, J6, 2 = 
1.5, H6), 3.77 (2H, s, CH2), 2.33 (6H, s, 2 × CH3); δC (d6-DMSO, 75 MHz) 143.1 
(C4’ or C4’’), 142.8 (C4’ or C4’’), 138.7 (C1’ or C1’’), 138.3 (C1’ or C1’’), 131.3 (C1 or 
C3 or C4), 129.95 (C3’ / C5’ or C3’’ / C5’’), 129.90 (C1 or C3 or C4), 128.4 (C1 or C3 
or C4), 127.2 (C2’ / C6’ or C2’’ / C6’’), 127.1 (C2’ / C6’ or C2’’ / C6’’), 124.4 (C6), 121.5 
(C2), 120.1 (C5), 42.5 (CH2), 21.5 (CH3), 21.4 (CH3). 
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To a stirred solution of the primary amine (33b) (0.5 g, 0.001 mol)  in dry 
acetonitrile (20 mL) was added dropwise dry DIPEA (0.6 mL, 0.003 mol).  1-
Bromo-3-methyl-2-butene (0.13 mL, 0.001 mol) was then added dropwise over 
five minutes.  The resulting solution was stirred under nitrogen at room 
temperature for 24 hours.  After this time, the organic layer was removed under 
reduced pressure to yield a dark brown residue, which was taken up in ethyl 
acetate (30 mL).  The organic layer was washed with 0.5 M HCl (3 × 30 mL), 
brine (3 × 30 mL) and dried (MgSO4).  The organic layer was removed in vacuo 
to give a white solid which was purified by column chromatography on silica, 
eluting with a gradient of petroleum ether through to ethyl acetate, to afford the 
title compound as a white solid (0.09 g, 15.5 %); mp 100 – 102 °C; Rf = 0.48 
(ethyl acetate : petroleum ether, 4 : 6); (HRMS found: [MH
+] 582.2464.  Calc. for 
C31H40N3O4S2: [MH
+], 582.2451); νmax / cm
-1 2920 (NH), 1597 (C=C), 1158 (S=O); 
δH (CDCl3, 300 MHz) 7.55 (4H, m, H2’ / H6’ and H2’’ / H6’’), 7.11 (7H, m, H3’ / H5’ 
and H3’’ / H5’’ and H2, H5, H6), 5.24 (2H, t, Jc, b = 6.2, Hc), 3.70 (2H, s, Ha), 3.20 
(4H, d, Jb, c = 6.2, Hb), 2.29 (3H, s, CH3 [tosyl]), 2.27 (3H, s, CH3 [tosyl]), 1.71 (6H, 
s, 2 × CH3 [alkenic]), 1.50 (6H, s, 2 × CH3 [alkenic]); δC (CDCl3, 75 MHz) 144.1 
(C4’ or C4’’), 144.0 (C4’ or C4’’), 141.7 (Cd), 135.9 (quat), 135.6 (quat), 132.0 (quat),   230
130.3 (quat), 129.7 (C3’ / C5’ and C3’’ / C5’’), 128.9, 127.6, 127.6 (C2’ / C6’ or C2’’ / 
C6’’), 127.5 (C2’ / C6’ or C2’’ / C6’’), 124.7, 114.5 (Cc), 55.4 (Ca), 49.7 (Cb), 26.1 (2 × 
CH3 [alkenic]), 21.6 (CH3 [tosyl]), 21.6 (CH3 [tosyl]), 18.3 (2 × CH3 [alkenic]).     
 












































The title compound (32) was prepared and purified according to the procedure of 
the bis-alkene (31) using the primary amine (33b) (0.5 g, 0.001 mol), dry DIPEA 
(0.6 mL, 0.003 mol) and ethyl bromoacetate (0.12 mL, 0.001 mol) to give the bis-
ester (32) as a white solid. (0.12 g, 17.8 %); mp 145 °C; Rf = 0.36 (ethyl acetate : 
petroleum ether, 4 : 6); (HRMS found: [MNa
+] 640.1775.  Calc. for 
C29H35N3O8S2Na: [MNa
+], 640.1752); νmax (KBr) / cm
-1 1736 (C=O); 1157 (S=O); 
δH (CDCl3, 300 MHz) 7.51 (4H, d, J = 7.8, H2’ / H6’ and H2’’ / H6’’), 7.14 (4H, d, J = 
7.8, H3’ / H5’ and H3’’ / H5’’), 6.94 (3H, m, H2, H5, H6), 4.09 (4H, q, Jc, d = 6.9, Hc), 
3.71 (2H, s, Ha), 3.36 (4H, s, Hb), 2.31 (6H, s, 2 × CH3 [tosyl]), 1.19 (6H, t, Jd, c = 
6.9, Hd); δC (CDCl3, 75 MHz) 170.4 (CO), 144.1 (C4’, C4’’), 135.6 (C3 or C4), 135.4 
(C1’, C1’’), 130.8 (C4 or C3), 130.1 (C1), 129.6 (C3’ / C5’ and C3’’ C5’’), 127.9 (C2 or 
C5 or C6), 127.7 (C2’ / C6’ or C2’’ / C6’’), 127.6 (C2’ / C6’ or C2’’ / C6’’), 126.5 (C2 or 
C5 or C6), 126.0 (C2 or C5 or C6), 60.8 (Cc), 56.9 (Ca), 53.9 (Cb), 21.6 (2 × CH3 
[tosyl]), 14.3 (2 × Cd).   231


































Compound (33a) was prepared according to the procedure of (19a) using 4-nitro-
1,2-benzenediamine (33) (2.0 g, 0.013 mol) and p-toluenesulfonyl chloride (11) 
(5.48 g, 0.029 mol).  After work up, the crude product was recrystallised from 
ethyl acetate : methanol to afford the title compound as a yellow solid (5.45 g, 
82.3 %); mp 219 – 220 °C; Rf = 0.47 (DCM : methanol, 9 : 1); m/z 460.0 (M–H)
–; 
Analysis Calcd. for C20H19N3O6S2: C, 52.05; H, 4.15; N, 9.10 %. Found C, 51.84; 
H, 4.02; N, 9.15 %; νmax (KBr) / cm
-1 3237 (NH), 1519 (NO2), 1334 (NO2), 1148 
(S=O); δH (d6-DMSO, 300 MHz) 7.93 (1H, dd, J6, 5 = 9.0, J6, 2 = 2.7, H6), 7.83 (1H, 
d, J2, 6 = 2.7, H2), 7.72 (2H, d, J = 8.3, H2’ / H6’ or H2’’ / H6’’), 7.62 (2H, d, J = 8.3, 
H2’ / H6’ or H2’’ / H6’’), 7.40 (5H, m, H3’ / H5’ and H3’’ / H5’’ and H5), 2.37 (6H, s, 2 × 
CH3); δC (d6-DMSO, 75 MHz) 144.8 (C4’ or C4’’), 144.6 (C4’ or C4’’), 143.0 (C1), 
137.6 (C4), 136.3 (C1’ or C1’’), 136.2 (C1’ or C1’’), 130.5 (C3’ / C5’ or C3’’ / C5’’), 
130.4 (C3’ / C5’ or C3’’ / C5’’), 127.6 (C3), 127.5 (C2’ / C6’ or C2’’ / C6’’), 127.4 (C2’ / 
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The title compound was prepared according to the procedure of (19e) using (33a) 
(5.0 g, 0.011 mol) and 10 % Pd/C (0.5 g) to give the aniline bis-sulfonamide (33b) 
as a dark gray solid (4.4 g, 94 %); mp 223 – 225 °C; Rf = 0.33 (DCM : methanol, 
9 : 1); m/z 430.0 (M–H)
–; Analysis Calcd. for C20H21N3O4S2: C, 55.67; H, 4.91; N, 
9.74 %. Found C, 55.59; H, 4.84; N, 9.72 %; νmax (KBr) / cm
-1 3262 (NH), 1324 
(C-N), 1154 (S=O); δH (d6-DMSO, 300 MHz) 8.78 (2H, s, 2 × NH), 7.70 (2H, d, J  
= 8.4, H2’ / H6’ or H2’’ / H6’’), 7.53 (2H, d, J = 8.4, H2’ / H6’ or H2’’ / H6’’), 7.37 (4H, m, 
H3’ / H5’ and H3’’, H5’’), 6.48 (1H, d, J2, 6 = 2.4, H2), 6.36 (1H, d, J5, 6 = 8.6, H5), 6.07 
(1H, dd, J6, 5  = 8.6, J6, 2 = 2.4, H6), 5.27 (2H, s, NH2), 2.40 (6H, s, 2 × CH3); δC 
(d6-DMSO, 75 MHz) 148.7 (C1), 143.9 (C4’ or C4’’), 143.7 (C4’ or C4’’), 136.8 (C1’ or 
C1’’), 136.5 (C1’ or C1’’), 134.3 (C3), 130.1 (C3’ / C5’ or C3’’ / C5’’), 130.0 (C3’ / C5’ or 
C3’’ / C5’’), 128.5 (C5), 127.5 (C2’ / C2’’ and C6’ / C6’’), 115.5 (C4), 110.5 (C6), 106.1 
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Aniline bis-sulfonamide (33b) (0.50 g, 0.0012 mol) and sulfamide (0.13 g, 0.0014 
mol) were added to dry dioxane (30 mL) under argon.  The resulting solution was 
heated at reflux for 48 hours.  After this time, the solvent was removed in vacuo 
to afford a red sticky solid which was subjected to column chromatography 
eluting with DCM : methanol (95 : 5), to give sulfamide (33c) as a pink solid (0.43 
g, 72.7 %); mp 126 °C; Rf = 0.15 (ethyl acetate : petroleum ether, 9 : 1); m/z 
508.9 (M–H)
–; Analysis Calcd. for C20H22N4O6S3: C, 47.04; H, 4.34; N, 10.97 %. 
Found C, 46.92; H, 4.45; N, 10.63 %; νmax (KBr) / cm
-1 3269 (NH), 1597, 1513, 
1150 (S=O); δH (d6-DMSO, 300 MHz) 9.60 (1H, s, NH), 9.20 (1H, s, NH), 8.93 
(1H, s, NH), 7.71 (2H, d, J = 8.7, H2’ / H6’ or H2’’ / H6’’), 7.55 (2H, d, J  = 8.7, H2’ / 
H6’ or H2’’ / H6’’), 7.36 (4H, d, J  = 8.7, H3’ / H5  and H3’’, H5’’),  7.07 (1H, d, J2, 6 = 2.4, 
H2), 7.04 (2H, s, NH2), 6.77 (1H, dd, J6, 5 = 8.7, J6, 2 = 2.4, H6), 6.69 (1H, d, J5, 6 = 
8.7, H5), 2.38, (6H, s, 2 × CH3); δC (d6-DMSO, 75 MHz) 144.1 (C4’ or C4’’), 144.0 
(C4’ or C4’’), 138.7 (C1), 136.6 (C1’ and C1’’), 133.0 (C3), 130.1 (C3’ / C3’’ and C5’ / 
C5’’), 127.7 (C2’ / C6’ or C2’’ / C6’’), 126.6 (C5), 121.8 (C4), 114.1 (C6), 111.2 (C2), 
21.5 (2 × CH3).    
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A two necked, flame-dried round bottomed flask, was charged with the aniline 
bis-sulfonamide (33b) (0.3 g, 0.0007 mol), ethyl isocyanate (0.3 mL, 0.003 mol) 
and dry DCM (20 mL) under argon.  The resulting solution was heated at 45 °C 
for 18 hours.  After this time, the solvent was removed in vacuo and the resulting 
residue taken up in DCM (20 mL) and washed 2M HCl (3 × 30 mL).  The DCM 
was removed in vacuo to afford a cream coloured solid, which was recrystallised 
from DCM to afford the title compound (33d) as a white solid (0.28 g, 80 %); mp 
170 °C; Rf = 0.16 (DCM : methanol, 9.5 : 0.5); (HRMS found: [MNa
+] 525.1242.  
Calc. for C23H26N4O5S2Na: [MNa
+], 525.1237); νmax (KBr) / cm
-1 3376 (NH), 1690 
(C=O), 1151 (S=O); δH (d6-DMSO, 300 MHz), 9.12 (1H, s, NH), 8.83 (1H, s, NH), 
8.52 (1H, s, NH), 7.66 (2H, d, J = 8.1, H2’ / H6’ or H2’’ / H6’’), 7.50 (2H, d, J = 8.1, 
H2’ / H6’ or H2’’ / H6’’), 7.33 (6H, m, H3’ / H5’ and H3’’ / H5’’ and H2 and NH), 6.99 (1H, 
dd, J6, 5 = 8.7, J6, 2 = 2.4, H6), 6.63 (1H, d, J5, 6 = 8.7, H5), 3.06 (2H, q, J = 7.2, 
CH2), 2.35 (6H, s, 2 × CH3 [tosyl]), 1.02 (3H, t, J  = 7.2, CH3); δC (d6-DMSO, 75 
MHz) 155.2 (CO), 144.1 (C4’ or C4’’), 143.9 (C4’ or C4’’), 140.0 (C1 or C3 or C4), 
136.5 (C1’ or C1’’), 136.4 (C1’ or C1’’), 132.9 (C1 or C3 or C4), 130.1 (C3’ / C5’ and 
C3’’ / C5’’), 127.6 (C2’ / C6’ or C2’’ / C6’’), 127.4 (C2’ / C6’ or C2’’ / C6’’), 126.9 (C5),   235
120.9 (C1 or C3 or C4), 114.2 (C6), 110.7 (C2), 34.4 (CH2), 21.5 (2 × CH3 [tosyl]), 
15.9 (CH3). 
 













































The title compound was prepared according to the procedure of the ethyl urea 
(33d) using the aniline bis-sulfonamide (33b) (0.30 g, 0.0007 mol) and phenyl 
isocyanate (0.40 mL, 0.003 mol).  The crude product was recrystallised from 
DCM to afford the title compound (33e) as a white solid (0.33 g, 85 %); mp 154 – 
155 °C; Rf = 0.50 (DCM : methanol, 9.5 : 0.5); (HRMS found: [MNa
+] 573.1240. 
Calc. for C27H26N4O5S2Na: [MNa
+], 573.1231); νmax (KBr) / cm
-1 3380 (NH), 1689 
(C=O), 1597, 1497, 1156 (S=O); δH (d6-DMSO, 300 MHz) 9.11 (1H, s, NH), 8.90 
(1H, s, NH), 8.62 (1H, s, NH), 8.42 (1H, s, NH), 7.12 (16H, m, Ar – H), 2.42 (6H, 
s, 2 × CH3); δC (d6-DMSO, 75 MHz), 152.6 (CO), 144.2 (C4’ or C4’’), 144.0 (C4’ or 
C4’’), 139.9 (quat.), 138.9 (quat.), 136.5 (quat.), 136.5 (quat.), 132.7 (quat.), 130.1, 
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To a cooled solution of dry toluene (120 mL) was added benzotriazole (34a) 
(11.9 g, 0.1 mol) and methanesulfonyl chloride (9.3 mL, 0.12 mol) under argon.  
Dry pyridine (9.3 mL, 0.15 mol) was added dropwise and the resulting solution 
stirred at room temperature for 24 hours.  After this time, ethyl acetate (150 mL) 
and water (100 mL) were added.  The organic layer was separated, washed with 
water, and dried (MgSO4).  The solvent was removed in vacuo to give a white 
solid, which was recrystallised from toluene to afford 1-methanesulfonyl-1H-
benzotriazole (34b) as white crystals (15.5 g, 79 %); mp 112 °C [lit. 110 – 112 °C 
[2000JOC8210]; Rf = 0.44 (DCM : petroleum ether, 9 : 1); Analysis Calcd. for 
C7H7N3O2S: C, 42.63; H, 3.58; N, 21.31 %. Found C, 42.70; H, 3.43; N, 21.33 %; 
νmax / (KBr) cm
-1 3027 (NH), 1590, 1378, 1177 (S=O); δH (d6-DMSO, 300 MHz) 
8.29 (1H, ddd, J8,7 = 8.4, J8,6 = 1.8, J8,5 = 0.9, H8), 8.02 (1H, ddd, J5,6 = 8.4, J5,7 = 
1.8, J5,8 = 0.9, H5), 7.82 (1H, td, J6,5/7 = 8.4, J6,8 = 1.8, H6), 7.64 (1H, td, J7,8 = 8.4, 
J7,6 = 8.4, J7,5 = 1.8, H7), 3.85 (3H, s, CH3); δC (d6-DMSO, 75 MHz) 145.2 (C9), 
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A flame-dried, two necked, round bottomed flask was charged with 
methanesulfonyl benzotriazole (34b) (1.0 g, 0.005 mol), 2-furoic acid (0.57 g, 
0.005 mol), dry triethylamine (2 mL), and dry THF (20 mL) under argon.  The 
resulting solution was heated at reflux for 18 hours.  After this time, the THF was 
removed under reduced pressure to afford a cream coloured residue, which was 
taken up in ethyl acetate and washed with 1 M HCl (3 × 30 mL).  The ethyl 
acetate was dried (MgSO4) and removed in vacuo to afford a white solid which 
was recrystallised from toluene to give the title compound (34c) as fluffy white 
crystals (0.82 g, 77.0 %); mp 171 - 172 °C; [lit. 171 – 173 °C [2000JOC8210]]; Rf 
= 0.48 (DCM : petroleum ether, 5 : 5); Analysis Calcd. for C11H7N3O2: C, 61.97; H, 
3.31; N, 19.71 %. Found C, 61.73; H, 3.31; N, 19.71 %; νmax  (KBr) / cm
-1 3142 
(NH), 1681 (C=O), 1556, 1447; δH (d6-DMSO, 300 MHz) 8.30 (3H, m, H5, H8, H5’), 
8.08 (1H, dd, J3’, 4’ = 3.8, J3’, 5’ = 0.6, H3’), 7.82 (1H, td, J6, 5/ 7 = 7.2, J6, 8 = 1.2, H6), 
7.65 (1H, td, J7, 6/ 8 =7.2, J7, 5 = 1.2, H7), 6.94 (1H, dd, J4’, 3’ = 3.8, J4’, 5’ = 1.8, H4’); 
δC (d6-DMSO, 75 MHz) 155.0 (CO), 150.8 (C5’), 145.5 (C9), 144.4 (C2’) 132.1 (C4), 
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A flame-dried, two necked round bottomed flask was charged with aniline bis-
sulfonamide (33b) (0.30 g, 0.00069 mol), (34c) (0.14 g, 0.00069), DMAP (14) 
(0.02 g, 0.0002 mol) and dry THF (20 mL), under argon.  The resulting solution 
was heated at reflux for 72 hours.  After this time, the solvent was removed under 
reduced pressure to yield a red residue which was taken up in ethyl acetate and 
washed with 2.5 M HCl (3 × 30 mL).  The combined organic layers were dried 
(MgSO4) and the solvent removed in vacuo to afford (33f) as a deep red solid, 
which was recrystallised from ethyl acetate / petroleum ether (0.16 g, 44.0 %); 
mp 102 °C; Rf = 0.41 (DCM : methanol, 9.5 : 0.5); m/z 524.6 (M–H)
–; Analysis 
Calcd. for C25H23N3O6S2.
1/2EtOAc; C, 56.97; H, 4.70; N, 7.38 %. Found C, 56.63; 
H, 5.07; N, 7.13 %; νmax (KBr) / cm
-1 2923 (NH), 1656 (C=O), 1599 (NH [amide]), 
1155 (S=O); δH (d6-DMSO, 300 MHz) 10.20 (1H, s, NH, [amide]), 9.28 (1H, s, NH, 
[sulfonamide]), 9.06 (1H, s, NH, [sulfonamide]), 7.91 (1H, dd, J5’’’, 4’’’ = 1.5, J5’’’, 3’’’ = 
0.6, H5’’’), 7.80 (1H, d, J2, 6 = 2.1, H2), 7.70 (2H, d, J  = 8.4, H2’ / H6’ or H2’’ / H6’’), 
7.55 (2H, d, J = 8.4, H2’ / H6’ or H2’’ / H6’’), 7.33 (6H, m, H3’ / H5’ and H3’’ / H5’’ and 
H6 and H3’’’), 6.82 (1H, d, J5, 6 = 8.7, H5), 6.68 (1H, dd, J4’’’, 3’’’ = 3.3, J4’’’, 5’’’ = 1.5, 
H4’’’), 2.35 (6H, s, 2 × CH3); δC (d6-DMSO, 75 MHz) 156.6 (CO amide), 147.7 
(C2’’’), 146.3 (C5’’’), 144.2 (C4’ or C4’’), 144.0 (C4’ or C4’’), 137.5 (C1 or C3 or C4), 
136.5 (C1’ or C1’’), 136.4 (C1’ or C1’’), 132.0 (C1 or C3 or C4), 130.2 (C3’ / C5’ or C3’’   239
/ C5’’), 130.1 (C3’ / C5’ or C3’’ / C5’’), 127.6 (C2’ / C6’ or C2’’ / C6’’), 127.4 (C2’ / C6’ or 
C2’’ / C6’’), 125.8 (C5), 123.8 (C1 or C3 or C4), 117.2 (C6), 115.5 (C3’’’), 113.9 (C2), 
112.6 (C4’’’), 21.5 (2 × CH3).    
 

































To a stirred solution of  methyl 3,4-diamino-N,  N-bis-(toluene-4-
sulfonylamino)benzoate (12) (0.5g, 0.001 mol) in THF (30 mL) and water (10 mL) 
was added 1 M NaOH (2 mL, 0.002 mol).  The resulting solution was heated at 
reflux for six hours.  After this time, the solution was cooled to 0 °C and then 1 M 
HCl and ethyl acetate were added.  The aqueous layer was extracted with ethyl 
acetate (3 × 30 mL).  The combined organics were washed with water (3 × 30 
mL), brine (3 × 30 mL), and dried (MgSO4).  The organic solvent was removed in 
vacuo to afford a pink solid.  The crude solid was recrystallised from aqueous 
methanol to afford the title compound as a pink crystalline solid (0.33 g, 71.7 %); 
249 °C; Rf = 0.38 (DCM : methanol, 9.5 : 0.5); m/z 459.0 (M–H)
–; Analysis Calcd. 
for C21H20N2O6S2.
1/2 H2O; C, 53.72; H, 4.51; N, 5.96 %. Found C, 53.60; H, 4.34; 
N, 5.66 %; νmax (KBr) / cm
-1 3261 (OH), 1686 (C=O), 1159 (S=O); δH (d6-DMSO, 
300 MHz) 9.61 (2H, s, 2 × NH), 7.71 (2H, d, J = 8.4, H2’ / H6’ or H2’’ / H6’’), 7.61 
(4H, m, H2 and H6 and H2’ / H6’ or H2’’ / H6’’), 7.40 (4H, d, J = 8.4, H3’ / H5’ and H3’’ 
/ H5’’), 7.27 (1H, d, J5,6 = 9.0, H5), 2.39 (6H, s, 2 × CH3); (d6-DMSO, 75 MHz) 
166.5 (CO), 144.5 (C4’ or C4’’), 144.3 (C4’ or C4’’), 136.5 (C1’ or C1’’), 136.4 (C1’ or 
C1’’), 135.2 (C4), 130.3 (C3’ / C5’ or C3’’ / C5’’), 130.2 (C3’ / C5’ or C3’’ / C5’’), 127.9   240
(C3), 127.8 (C2 or C6), 127.4 (C2’ / C6’ or C2’’ / C6’’), 127.4 (C2’ / C6’ or C2’’ / C6’’), 
127.2 (C1), 125.9 (C2 or C6), 120.7 (C5), 21.5 (2 × CH3). 
 

































A flame dried three necked round bottomed flask was charged with dry THF (50 
mL) and methyl 3,4-diamino-N,  N-bis-(toluene-4-sulfonylamino)benzoate (12) 
(2.5 g, 0.005 mol) under argon. The resulting solution was cooled with an ice 
bath for twenty minutes. After this time, 1 M lithium aluminium hydride in THF (6 
mL, 0.006 mol) was added dropwise over five minutes.  The resulting solution 
was then stirred at room temperature under argon for six hours.  After this, the 
solution was cooled to 0 °C and quenched with ethyl acetate (50 mL).  Water (50 
mL) was then carefully added dropwise. The resulting organic layer was collected, 
washed with 1 M HCl (3 × 30 mL), brine (3 × 30 mL) and dried (MgSO4).  The 
organic solvent was removed under reduced pressure to afford a white residue 
which was recrystallised from toluene to afford (36) as white needles (1.97 g, 
88.2 %); mp 181 ° C; Rf = 0.11 (DCM : methanol, 9 : 1); m/z 445.0 (M–H)
–, 339.2; 
Analysis Calcd. for C21H22N2O5S2: C, 56.48; H, 4.96; N, 6.27 %. Found C, 56.22; 
H, 4.92; N, 6.18 %; νmax / cm
-1 3549 (OH), 3268 (NH), 1156 (S=O); δH (d6-DMSO, 
300 MHz) 9.27 (1H, s, NH), 9.16 (1H, s, NH), 7.62 (2H, d, J = 8.4, H2’ / H6’ or H2’’ / 
H6’’), 7.59 (2H d, J = 8.4, H2’ / H6’ or H2’’ / H6’’), 7.35 (4H, d, J = 8.4, H3’ / H5’ and 
H3’’ / H5’’), 7.10 (1H, br s, H2), 6.90 (2H, br s, H5, H6), 4.30 (2H, s, CH2), 2.35 (6H, 
s, 2 × CH3); δC  (d6-DMSO, 75 MHz) 144.1 (C4’ and C4’’), 141.2 (C1), 136.7 (C1’ or 
C1’’), 136.5 (C1’ or C1’’), 130.6 (C3 or C4), 130.2 (C3’ / C5’ and C3’’ / C5’’), 127.9 (C3   241
or C4), 127.4 (C2’ / C6’ and C2’’ / C6’’), 124.2 (C5 or C6), 124.0 (C5 or C6), 121.3 
(C2), 62.4 (CH2), 21.5 (2 × CH3). 
 



































A flame dried, three necked, round bottomed flask was charged with alcohol (36) 
(1.0 g, 0.002 mol) and dry DCM (40 mL) under argon.  PDC (2.1 g, 0.0056 mol) 
was slowly added and the resulting mixture was stirred under argon at room 
temperature for four hours.  After this time, the mixture was washed with 1 M HCl 
(3 × 30 mL), brine (3 × 30 mL) and dried (MgSO4).  The organic layer was 
removed under reduced pressure to give a white residue which was purified by 
column chromatography on silica, eluting with DCM : methanol (90 : 10), to afford 
the aldehyde (37) as a white crystalline solid (0.69 g, 77.6 %); mp 225 – 227 ° C; 
Rf = 0.22 (DCM : methanol, 9 : 1); m/z 442.9 (M–H)
–; Analysis Calcd. for 
C21H20N2O5S2: C, 56.74; H, 4.53; N, 6.30 %. Found C, 56.56; H, 4.51; N, 6.04 %; 
νmax (KBr) / cm
-1 3314 (NH), 1679 (CO), 1154 (S=O); δH (d6-DMSO, 300 MHz) 
9.74, (1H, s, CHO), 7.70 (2H, d, J = 8.4, H2’ / H6’ or H2’’ / H6’’), 7.60 (2H, d, J = 8.4, 
H2’ / H6’ or H2’’ / H6’’), 7.59 (1H, dd, J6, 5  = 8.4, J6, 2 = 1.8, H6), 7.51 (1H, d, J2, 6 = 
1.8, H2), 7.36 (5H, m, H3’ / H5’ and H3’’ / H5’’ and H5), 2.37 (6H, s, 2 × CH3); (d6-
DMSO, 75 MHz) 191.7 (CO), 144.6 (C4’ or C4’’), 144.3 (C4’ or C4’’), 136.7 (C4), 
136.4 (C1’ and C1’’), 132.4 (C3), 130.4 (C3’ / C5’ or C3’’ / C5’’), 130.3 (C3’ / C5’ or C3’’   242
/ C5’’), 129.0 (C6), 128.0 (C1), 127.5 (C2’ / C6’ or C2’’ / C6’’), 127.4 (C2’ / C6’ or C2’’ / 
C6’’), 124.7 (C2), 120.3 (C5) 21.5 (2 × CH3). 
 











































A 100 mL three necked flame dried round bottomed flask was charged with dry 
acetonitrile (10 mL), aniline bis-sulfonamide  (33b)  (0.5 g, 0.0011), and dry 
pyridine (0.18 mL, 0.0023 mol), under argon.  The resulting solution was cooled 
to 0 °C and acryloyl chloride (38) (0.11 mL, 0.0014 mol) was slowly added 
dropwise.  After this, the solution was stirred at 0 °C for twenty minutes.  The 
organic layer was then removed under reduced pressure and the resulting 
residue taken up in ethyl acetate (50 mL).  The organic layer was washed with 1 
M HCl (3 × 30 mL), brine (3 × 30 mL), and dried (MgSO4).  The organic layer was 
removed  in vacuo to afford a brown solid, which was purified by column 
chromatography on silica, eluting with DCM / methanol (10 : 1).  The resulting 
solid was recrystallised from ethanol to afford N-[3,4-bis-(toluene-4-
sulfonylamino)phenyl]acrylamide (39)  as pale brown needles (0.32 g, 59.9 %); 
mp 191 °C; Rf = 0.25 (DCM : methanol, 9 : 1); m/z 484.0 (M–H)
–; Analysis Calcd. 
for C23H23N3O5S2.
1/2EtOH: C, 56.73; H, 5.15; N, 8.26 %. Found C, 56.79; H, 4.81; 
N, 7.96 %; νmax (KBr) / cm
-1 3355 (NH), 1677 (C=O), 1598 (NH [amide]), 1162 
(S=O);  δH (d6-DMSO, 300 MHz) 9.27 (1H, s, NH [amide]), 8.58 (2H, s, NH   243
[sulfonamide]), 7.68 (2H, d, J = 8.1, H2’ / H6’ or H2’’ / H6’’), 7.64 (1H, d, J2, 6 = 2.4, 
H2), 7.54 (2H, d, J = 8.1, H2’ / H6’ or H2’’ / H6’’), 7.35 (4H, m, H3’ / H5’ and H3’’ / H5’’), 
7.29 (1H, dd, J6, 5  = 8.4, J6, 2 = 2.4, H6), 6.82 (1H, d, J5, 6 = 8.4, H5), 6.37 (1H, dd, 
Ja, b2 = 16.8, Ja, b1 = 9.9, Ha), 6.23 (1H, dd, Jb2, a = 16.8, Jb2, b1 = 2.4, Hb2), 5.74 (1H, 
dd, Jb1, a = 9.9, Jb1, b2 = 2.4, Hb1), 2.27 (6H, s, 2 × CH3); δC (d6-DMSO, 75 MHz) 
163.6 (CO), 144.2 (C4’ or C4’’), 144.0 (C4’ or C4’’), 137.9 (C1 or C3 or C4), 136.5 
(C1’ or C1’’), 136.4 (C1’ or C1’’), 132.2 (C1 or C3 or C4), 132.1 (Ca), 130.1 (C3’ / C5’ 
and C3’’ / C5’’), 127.6 (Cb), 127.5 (C2’ / C6’ or C2’’ / C6’’), 127.4 (C2’ / C6’ or C2’’ / C6’’), 
126.1 (C5), 123.5 (C1 or C3 or C4), 116.2 (C6), 112.8 (C2), 21.5 (2 × CH3).   
 
















To a stirred solution of uracil (3.36 g, 0.03 mol) and potassium hydroxide (6.45 g, 
0.115 mol) in water (20 mL) was added dropwise, over 30 minutes, bromoacetic 
acid (6.25 g, 0.045 mol).  The solution was then stirred at room temperature for 2 
hours.  After this time, the pH was adjusted to 5 using 12 M HCl.  The solution 
was cooled and resulting precipitate was collected by filtration, which was then 
discarded.  The pH of the filtrate was adjusted to 2 and cooled.  The resulting 
white precipitate was collected by filtration and dried under reduced pressure to 
give 2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetic acid (40a)  as a white solid 
(3.58 g, 67 %); 285 – 288 °C [lit. 287 °C [1973T2293]]; Rf = 0.35 (ethyl acetate : 
methanol, 7 : 3); m/z 169.1 (M–H)
–; νmax / cm
-1 3097 (OH), 1682 (C=O), 1603 
(NH), 1474, 1200; δH (d6-DMSO, 300 MHz) 11.31 (1H, s, OH), 7.61 (1H, d, J6, 5  = 
8.1, H6), 5.59 (1H, dd, J5, 6  = 8.1, J5, NH  = 1.8, H5), 4.44 (2H, s, CH2); δC (d6-  244
DMSO, 75 MHz) 170.0 (CO [carboxylic acid]), 164.3 (C4), 151.5 (C2), 146.5 (C6), 
101.3 (C5), 49.1 (CH2).       
 










































To a stirred solution of aniline bis-sulfonamide (33b) (0.5 g, 0.0012 mol) in dry 
DMF (10 mL) was added HBTU (0.44 g, 0.0012 mol) and (2,4-dioxo-3,4-dihydro-
2H-pyrimidin-1-yl)acetic acid (40a)  (0.19 g, 0.0012 mol), under argon.  To the 
resulting solution was added slowly, dropwise, over 30 minutes, dry DIPEA (0.6 
mL, 0.0034 mol), which caused the solution to change colour from light brown to 
deep red.  The resultant red solution was stirred at room temperature for 48 
hours.  After this, the reaction mixture was added to water (300 mL) and 
extracted with ethyl acetate (3 × 30 mL).  The combined organic layers were 
washed with water (3 × 30 mL), brine (3 × 30 mL) and dried (MgSO4). The 
organic layer was removed under reduced pressure to afford a red solid which 
was purified using a gradient column eluting initially with DCM, and then DCM / 
methanol (1 : 1) to give a red residue. The resulting residue was recrystallised 
from DCM to afford (42) as a deep red crystalline solid (0.37 g, 52.8 %); mp 184 
– 187 °C; Rf = 0.15 (DCM : methanol, 8 : 2); m/z 582.1 (M–H)
–; Analysis Calcd.   245
for C26H25N5O7S2.
1/2DCM: C, 50.87; H, 4.19; N, 11.19 %.  Found C, 50.52; H, 
4.29; N, 11.05 %; νmax (KBr) / cm
-1 3252 (NH), 1673 (C=O), 1600 (NH [amide]) 
1155 (S=O); δH (d6-DMSO, 300 MHz) 10.89 (1H, s, NH), 10.29 (1H, s, NH), 9.22 
(2H, s, 2 × NH), 7.65 (2H, d, J = 8.4, H2’ / H6’ or H2’’ / H6’’), 7.58 (1H, d, Ja, b = 7.8, 
Ha), 7.51 (3H, m, H2’ / H6’ or H2’’ / H6’’ and H2), 7.33 (4H, overlapping doublet, J = 
8.4, H3’ / H5’ and H3’’ / H5’’), 7.22 (1H, dd, J6, 5  = 8.4, J6, 2 = 2.4, H6), 6.78 (1H, d, J5, 
6 = 8.4, H5), 5.60 (1H, d, Jb, a = 7.8, Hb), 4.48 (2H, s, CH2), 2.35 (6H, s, 2 × CH3); 
δC  (d6-DMSO, 75 MHz) 166.1 (CO), 164.3 (CO), 151.6 (CO), 147.1 (Ca), 144.2 
(C4’ or C4’’), 144.1 (C4’ or C4’’), 137.5 (C1 or C3 or C4), 136.4 (C1’ or C1’’), 136.2 (C1’ 
or C1’’), 132.4 (C1 or C3 or C4), 130.2 (C3’ / C5’ and C3’’ / C5’’), 127.5 (C2’ / C6’ or 
C2’’ / C6’’), 127.4 (C2’ / C6’ or C2’’ / C6’’), 126.3 (C5), 123.6 (C1 or C3 or C4), 115.9 
(C6), 112.6 (C2), 101.1 (Cb), 50.6 (CH2), 21.5 (2 × CH3).   
 


































The title compound (43a) was prepared according to the procedure of (19a) 
using 4-bromo-1,2-benzenediamine (43) (2.0 g, 0.010 mol) and p-toluenesulfonyl 
chloride  (11)  (4.48 g, 0.023 mol).  After work up, the crude product was 
recrystallised from ethyl acetate : petroleum ether to afford the title compound as 
red crystals (4.90 g, 93.4 %); mp 212 °C; Rf = 0.53 (DCM; Analysis Calcd. for 
C20H19BrN2O4S2: C, 48.49; H, 3.87; N, 5.65 %. Found C, 48.49; H, 3.79; N, 5.72 
%; νmax (KBr) / cm
-1 3287 (NH), 1595, 1491, 1388, 1161 (S=O), 585 (C–Br); δH   246
(d6-DMSO, 300 MHz).9.28 (2H, s, 2 × NH), 7.43 (4H, m, H2’ /  H6’ and H2’’ /  H6’’), 
7.19 (4H, m, H3’ /  H5’ and H3’’ / H5’’), 7.01 (1H, dd, J6, 5 = 8.7, J6, 2 = 2.3, H6), 6.98 
(1H, d, J2, 6 = 2.3, H2), 6.77 (1H, d, J5, 6 = 8.6, H5), 2.19 (6H, s, 2 × CH3); δC (d6-
DMSO, 75 MHz) 144.5 (C4’ or C4’’), 144.3 (C4’ or C4’’), 136.4 (C1’ or C1’’), 136.3 
(C1’ or C1’’), 131.8 (C3), 130.3 (C3’ / C5’ or C3’’ / C5’’), 130.3 (C3’ / C5’ or C3’’ / C5’’), 
129.2 (C4), 128.8 (C6), 127.4 (C2’ / C6’ and C2’’ / C6’’), 125.5 (C2), 125.5 (C5), 
117.9 (C1), 21.5 (2 × CH3).   
 




















To a stirred solution of 4-bromo-1,2-benzenediamine (43) (2 g, 0.01 mol) in dry 
THF (30 mL), under argon, was slowly added di-tert-butyl dicarbonate (4.90 g, 
0.022 mol) and DMAP (0.05 g, 0.0004 mol) .  The resulting solution was heated 
at reflux for 18 hours.  After this time, the solution was cooled and ethyl acetate 
(50 mL) was added.  The organic layer was washed with 10 % citric acid solution 
(3 × 30 mL), water (3 × 30 mL), brine (3 × 30 mL), and then dried (MgSO4).  The 
organic layer was removed in vacuo to afford a dark sticky solid, which was 
purified using column chromatography on silica, eluting with DCM, to give 3,4-
diamino-N,N-bis-(tert-butoxycarbonyl)-1-bromobenzene  (43b)  as a pale pink 
solid (3.18 g, 82.1 %); mp 150 °C; Rf = 0.48 (DCM); νmax (KBr) / cm
-1 2985 (NH), 
1796 (C=O), 1736 (C=O), 1476, 1143 (C–O), 680 (C–Br); δH (d6-DMSO, 300 
MHz) 8.00 (1H, d, J2, 6  = 2.1, H2), 7.67 (1H, d, J5, 6  = 8.7, H5), 7.27 (1H, dd, J6, 5  = 
8.7, J6, 2  = 2.1, H6), 1.59 (9H, s, C(CH3)3), 1.58 (9H, s, C(CH3)3); (d6-DMSO, 75   247
MHz) 148.3 (CO), 148.2 (CO), 146.8 (C3), 127.2 (C6), 127.2 (C4), 125.3 (C1), 
117.3 (C2), 115.3 (C5), 85.9 (C(CH3)3), 85.8 (C(CH3)3), 28.1 (C(CH3)3). 
 
7.43. Synthesis of 2-nitro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-














A 100 mL three necked flamed dried round bottomed flask was charged with 30 
mL of dry DMF (30 mL) under argon.  The flask was then degassed with argon 
for 30 minutes using a gas dispersion tube.  Once this was achieved, 4-bromo-2-
nitrophenylamine  (44)  (1 g, 0.0046 mol), pinacolborane dimer (45)  (1.28 g, 
0.0051 mol), and potassium acetate (1.35 g, 0.0138 mol) were added.  The 
resulting mixture was stirred at room temperature under argon for five minutes.  
After this time, 1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.37 g, 
0.00046 mol) was added, upon which the mixture turned black.  The mixture was 
then heated at 80 °C for 24 hours under argon.  After this time, the reaction 
mixture was added to water (300 mL) and extracted with ethyl acetate (3 × 30 
mL).  The combined organics were washed with water (3 × 30 mL), brine (3 × 30 
mL), and dried (MgSO4). The organic layer was removed under reduced pressure 
to afford a yellow solid, which was purified by column chromatography on silica, 
eluting with ethyl acetate / petroleum ether (1 : 1), to afford the title compound 
(46) as a deep yellow solid. (0.68 g, 56 %); mp 172 °C; Rf = 0.45 (ethyl acetate : 
petroleum ether, 1 : 1; νmax (KBr) / cm
-1 3471 (NH2), 3329 (NH2), 2980 (CH), 1553 
(NO2), 1342 (NO2); δH (d6-DMSO, 300 MHz) 8.28 (1H, d, J3, 5  = 1.2, H3), 7.67 (2H,   248
s, NH2), 7.57 (1H, dd, J5, 6  = 8.4, J5, 3  = 1.2, H5), 7.00 (1H, d, J6, 5  = 8.4, H6), 1.29 
(12H, s, 4 × CH3); (d6-DMSO, 75 MHz) 148.5 (C1), 140.6 (C5), 133.2 (C3), 130.7 
(C2), 119.2 (C6), 84.1 (2 × C(CH3)2), 25.1 (4 × CH3).    
 
7.44.  Synthesis of 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzene-















To a solution of  2-nitro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-
yl)phenylamine  (46) (1.0 g, 0.0038 mol) in methanol (50 mL) was added, 
carefully, 10 % Pd/C (0.1 g).  The resulting mixture was hydrogenated (3 atm) at 
room temperature for 18 hours.  After this time, the catalyst was removed by 
filtration through a bed of Celite.  The filtrate was concentrated in vacuo to afford 
(47) as a dark sticky gum (0.76 g, 85.4 %); mp 96 °C;  Rf = 0.11 (DCM : methanol, 
9 : 1); mp 152 – 156 °C; m/z 233.1 (M–H)
–; νmax (KBr) / cm
-1 3323 (NH2), 2978 
(CH), 1620, 1430, 1352; δH (CDCl3, 300 MHz) 7.17 (2H, m, H3, H5), 6.62 (1H, d, 
J6, 5  = 7.5, H6), 3.89 (4H, s, 2 × NH2), 1.24 (12H, s, 4 × CH3); δC (CDCl3, 75 MHz) 
138.8 (C1), 131.5 (C2), 129.0 (C5), 124.9 (C3), 118.9 (C4), 115.9 (C6), 83.4 (2 × 
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4'-Amino-4-fluoro-3'-nitrobiphenyl-3-carbonitrile  (50)  was prepared according to 
the procedure of  2-nitro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-
yl)phenylamine  (46)  using dry DMF (30 mL), 1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.31 g, 0.00038 mol),  2-
nitro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (46), (1 g, 
0.0038 mol),  2-fluoro-5-iodobenzonitrile (49) (0.46 mL, 0.0038 mol)  and dry 
sodium carbonate (0.40 g, 0.0114 mol).  After work up, the product was 
recrystallised from ethyl acetate / petroleum ether to afford the title compound 
(50) as an orange crystalline solid (0.84 g, 85.9 %); mp 216 °C; Rf = 0.45 (DCM : 
methanol, 9.5 : 0.5); m/z 256.2 (M–H)
–; Analysis Calcd. for C13H8FN3O2: C, 60.65; 
H, 3.13; N, 16.34 %. Found C, 60.19; H, 3.09; N, 16.03 %; νmax (KBr) / cm
-1 3478 
(NH2), 3377 (NH2), 2230 (CN), 1558 (NO2), 1356 (NO2); δH (d6-DMSO, 300 MHz) 
8.28 (1H, d, J2’, 6’  = 2.1, H2’), 8.21 (1H, dd, J2, F  = 6.0, J2, 6  = 2.4, H2), 8.04 (1H, 
ddd, J6, 5  = 8.7, J6, F  = 5.4, J6, 2  = 2.4, H6), 7.80 (1H, dd, J6’, 5’  = 8.7, J6’,  2’  = 2.1, 
H6’), 7.58 (2H, s, NH2), 7.55 (1H, t, J = 8.7, H5), 7.13 (1H, d, J5’, 6’  = 8.7, H5’); (d6-
DMSO, 75 MHz) 162.0 (J4, F = 255.5, C4), 146.3 (C4’), 136.3 (J1, F = 3.4, C1), 
134.5 (C6’), 133.6 (J6, F = 8.5, C6), 131.4 (C2), 131.0 (C3’), 124.7 (C1’), 123.7 (C2’), 
120.5 (C5’), 117.5 (J5, F = 19.7, C5), 114.4 (CN), 101.2 (J3, F = 15.5, C3). 
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3',4'-Diamino-4-fluorobiphenyl-3-carbonitrile (51) was prepared according to the 
procedure of (19e) using 4'-amino-4-fluoro-3'-nitro-biphenyl-3-carbonitrile (50) (1 
g, 0.004 mol) and 5 % Pd/C (0.1 g) to give 3',4'-diamino-4-fluorobiphenyl-3-
carbonitrile (51) as a pale brown solid (0.88 g, 96.8 %); Rf = 0.33 (DCM : 
methanol, 9.5 : 0.5); νmax (KBr) / cm
-1 3413 (NH2), 3343 (NH2), 2230 (CN), 1388 
(C–F); δH (d6-DMSO, 300 MHz) 7.93 (1H, dd, J2, F  = 6.0, J2, 6  = 2.4, H2), 7.84 (1H, 
ddd, J6, 5  = 8.9, J6, F  = 5.4, J6, 2  = 2.4, H6), 7.48 (1H, t, J5, F/6  = 8.9, H5), 6.87 (1H, 
d, J2’, 6’  = 2.1, H2’), 6.78 (1H, dd, J6’, 5’  = 8.1, J6’,  2’  = 2.1, H6’), 6.59 (1H, d, J5’, 6’  = 
8.1, H5’), 4.73 (4H, s, 2 × NH2); (d6-DMSO, 75 MHz) 161.2 (J4, F = 253.6, C4), 
139.4 (J1, F = 3.4, C1), 136.4 (C3’ or C4’), 135.8 (C3’ or C4’), 133.0 (J6, F = 8.2, C6), 
130.3 (C2), 126.1 (C1’), 117.2 (J5, F = 19.4, C5), 116.5 (C6’), 115.1 (C5’), 114.8 
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3',4'-Bis-(toluene-4-sulfonylamino)-4-fluorobiphenyl-3-carbonitrile (53) was 
prepared according to the procedure of methyl 3,5-diamino-N,N-bis-(toluene4-
sulfonylamino)benzoate (18) using 3',4'-diamino-4-fluorobiphenyl-3-carbonitrile 
(51)  (0.15 g, 0.0006 mol),  p-toluenesulfonyl chloride (0.27 g, 0.0014 mol), dry 
pyridine (0.3 mL, 0.004 mol) and dry acetonitrile (20 mL).  After work up, 
purification was achieved by column chromatography on silica, eluting with ethyl 
acetate / petroleum ether (1 : 1) to afford the title compound as a pale brown 
solid (0.22 g, 68.5 %); mp 171 – 173 °C; Rf = 0.42 (DCM : methanol, 9.5 : 0.5); 
(HRMS found: [MNa
+] 558.0935.  Calc. for C27H22FN3O4S2Na: [MNa
+], 558.0922); 
νmax (KBr) / cm
-1 3269 (NH), 2238 (CN), 1157 (S=O); δH (d6-DMSO, 300 MHz) 
7.57 (4H, overlapping doublet, H2’’ / H6’’ and H2’’’ / H6’’’), 7.48 (1H, ddd, J6, 5  = 8.7, 
J6, F  = 5.4, J6, 2  = 2.4, H6), 7.31 (1H, dd, J2, F  = 6.0, J2, 6  = 2.4, H2), 7.17 (7H, m, 2 
× NH and H3’’ / H5’’ and H3’’’ / H5’’’ and H5), 7.09 (1H, d, J5’, 6’  = 8.4, H5’), 7.03 (1H, 
dd, J6’, 5’  = 8.4, J6’,  2’  = 2.1, H6’),  6.96 (1H, d, J2’, 6’  = 2.1, H2’), 2.36 (3H, s, CH3), 
2.32 (3H, s, CH3); δC  (d6-DMSO, 75 MHz) 162.7 (J4, F = 260.6, C4), 144.7 (C4’’ or 
C4’’’), 144.5 (C4’’ or C4’’’), 136.5 (J1, F = 3.8, C1), 136.4 (C1’ or C3’ or C4’), 135.5 (C1’’ 
or C1’’’), 135.3 (C1’’ or C1’’’), 133.4 (J6, F = 8.4, C6), 131.6 (C2), 131.3 (C1’ or C3’ or   252
C4’), 130.8 (C1’ or C3’ or C4’), 129.8 (C3’’ / C5’’ and C3’’’ / C5’’’), 127.8 (C2’’ / C6’’ or 
C2’’’ / C6’’’), 127.6 (C2’’ / C6’’ or C2’’’ / C6’’’), 125.6 (C5’), 125.6 (C6’), 124.5 (C2’), 117.1 
(J5, F = 19.8, C5), 113.7 (CN), 102.0 (J3, F = 15.8, C3), 21.7 (2 × CH3). 
 










































A 250 mL three necked flame dried round bottomed flask was charged with 
aniline bis-sulfonamide (33b) (0.5 g, 0.001 mol), dry acetonitrile (20 mL) and dry 
pyridine (0.18 mL, 0.002 mol) under nitrogen.  2-Thiophenecarbonyl chloride (54) 
(0.15 mL, 0.0014 mol) was then added dropwise over five minutes.  The resulting 
solution was heated at reflux for 18 hours.  After this, the acetonitrile was 
removed under reduced pressure to give a brown oil, which was taken up into 
DCM (30 mL), washed with 0.5 M HCl (3 × 30 mL), brine (3 × 30 mL), and dried 
(MgSO4).  The organic layer was removed in vacuo to afford a brown solid which 
was recrystallised from methanol to give the title compound as white needles 
(0.43 g, 79.4 %); mp 224 – 226 °C; Rf = 0.43 (DCM : methanol, 9.5 : 0.5); m/z 
540.0 (M–H)
– ; Analysis Calc. for C25H23N3O5S3.
1/2MeOH; C, 54.92; H, 4.33; N, 
7.55 %. Found C, 54.75; H, 4.25; N, 7.49 %; νmax (KBr) / cm
-1 3353 (NH), 1648 
(C=O), 1597 (NH [amide]), 1163 (S=O); δH (d6-DMSO, 300 MHz) 10.17 (1H, s, 
NH [amide]), 9.17 (2H, s, 2 × NH [sulfonamide]), 7.97 (1H, d, J3’’’, 4’’’  = 3.0, H3’’’), 
7.85 (1H, d, J5’’’, 4’’’  = 4.8, H5’’’), 7.69 (3H, m, H2’ / H6’ or H2’’ / H6’’ and H2), 7.55 (2H, 
d, J = 8.4, H2’ / H6’ or H2’’ / H6’’), 7.30 (5H, m, H3’ / H5’ and H3’’ / H5’’ and H6), 7.21   253
(1H, m, H4’’’), 6.86 (1H, d, J5, 6 = 9.0, H5), 2.36 (3H, s, CH3), 2.35 (3H, s, CH3); δC 
(d6-DMSO, 75 MHz) 160.2 (CO), 143.8 (C4’ and C4’’), 140.3 (C2’’’), 136.9 (C1’ and 
C1’’), 136.8 (C1 or C3 or C4), 132.5 (C1 or C3 or C4), 132.4 (C5’’’), 130.1 (C3’ / C5’ or 
C3’’ / C5’’), 130.0 (C3’ / C5’ or C3’’ / C5’’), 129.7 (C3’’’), 128.5 (C4’’’), 127.5 (C2’ / C6’ or 
C2’’ / C6’’), 127.4 (C2’ / C6’ or C2’’ / C6’’), 124.7 (C1 or C3 or C4), 124.6 (C5), 116.6 
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Appendix 1 
Derivative  LigScore1  Ligscore2 -PLP1  -PLP2  JAIN  -PMF  Ludi 1  Ludi 2 
RDP00060 (12) 3.320  5.610 84.120  77.490  2.180 87.740  539  440 
(18)  3.060 5.598  78.290  75.528  1.759 90.783  478  443 
 (19a)  3.560 6.120  87.090  72.970  6.780 113.580  454  400 
 (19b)  3.690 6.100  89.480  74.430  1.110 75.660  453  430 
 (19c)   3.320 6.130  78.860  72.450  2.460 97.030  540  470 
(19d)  4.490 6.380  72.500  63.030  1.510 86.800  564  471 
(19e)  3.130 5.710  91.520  83.150  3.310 109.480  520  437 
(20a)  4.790 6.310  90.440  79.800  2.160 108.100  522  448 
(20b)  4.290 6.680  80.160  73.520  1.540 83.510  462  449 
(20c)  3.930 5.840  76.550  70.460  2.510 95.180  577  501 
(20d)  4.780 6.280  87.660  76.270  1.810 103.450  575  450 
(20e)  3.310 5.630  82.820  82.160  3.770 112.200  594  461 
(21b)  2.480 5.580  74.950  67.750  2.560 80.100  391  361 
(21c)  3.400 5.310  68.200  71.270  1.290 86.880  407  363 
(21d)  2.660 5.710  77.070  75.410  0.885 89.770  664  536 
(23)  2.330 5.620  70.840  61.000  0.410 78.190  444  439 
(25)  2.960 6.260  73.600  60.700  0.770 56.200  448  368 
(27)  3.610 5.967  59.320  55.670  0.560 58.380  469  420 
(28)  3.390 5.380  66.450  60.360  2.660 92.770  615  501 
(29)  1.770 4.770  72.220  64.190  1.840 77.080  349  340 
(30)  3.580 6.070  81.060  76.110  1.600 68.780  402  346 
(31)  2.280 4.930  75.780  74.180  0.920 95.640  493  446 
(32)  1.940 2.480  79.060  87.050  3.700 87.410  592  512 
(33a)  2.670 5.320  65.830  53.820  0.630 91.470  326  314 
(33b)  2.130 4.820  74.610  71.860  1.830 128.720  435  399 
(33c)  2.380 4.850  61.520  52.890  2.070 87.810  301  298 
(33d)  4.460 5.720  77.070  68.360  0.780 79.190  530  418 
(33e)  2.710 5.350  79.960  61.400  2.210 89.980  585  474 
(33f)  3.350 5.490  62.990  50.900  1.620 93.720  457  387 
(35)  3.630 5.670  69.810  62.020  0.530 100.720  294  281 
(36)  3.550 5.450  48.270  54.350  1.610 94.650  438  384 
(37)  2.960 4.960  55.250  49.410  1.610 111.110  394  331 
(39)  3.740 5.380  62.460  57.290  1.650 77.720  493  411   255
(42)  5.120 5.420  70.010  57.760  2.200 127.210  479  412 
(53)  2.290 5.580  78.250  75.200  2.800 58.510  487  487 
(55)  2.400 4.460  79.570  84.550  3.300 50.090  652  575 
 
Appendix 1. The values obtained from eight scoring functions used to evaluate the ligand – 
protein interaction for each analogue made during the current work.  A high scoring function 
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